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Abstract
iii
The human gut microbiota is altered by numerous factors, not least
antibiotic exposure. This thesis sets out to investigate the effects of
antibiotics on gut microbiota composition and its role as a reservoir for
antibiotic resistance genes and, in doing so, highlight how new
sequencing and molecular approaches can greatly enhance our
knowledge in these areas.
Currently, there is a paucity of studies applying high-throughput
sequencing technologies to assess the effects of antibiotics on the infant
gut microbiota. Thus, our aim was to investigate the effects of ampicillin
and gentamicin treatment on these populations, compared to those in
healthy controls, 4 and 8 weeks after antibiotic therapy ceased. DNA
extracted from faecal samples was amplified using 16S rRNA and rpoB
primers and was sequenced using 454-pyrosequencing. Four weeks post
antibiotic therapy there was a significant increase in Proteobacteria and a
significant decrease in Bifidobacterium in the gut microbiota of antibiotic
treated infants, compared to the no antibiotic controls. By week 8 the
levels of Actinobacteria had recovered, though Proteobacteria remained
dominant in the treated infants. This is the first high-throughput
sequencing study to demonstrate the significant short-term effects of
antibiotics on infant gut microbiota.
It is notable that it has recently been proposed that the human gut
microbiota acts as a reservoir for antibiotic resistance genes. Our second
goal was to investigate the presence of aminoglycoside and β-lactam
iv
resistance genes in the gut microbiota of healthy adult males. To facilitate
this, metagenomic DNA was extracted from faecal samples of adult
males without antibiotic exposure and degenerate primers were used to
screen for the presence of β-lactam (blaTEM, blaOXA, blaSHV, blaROB,
and blaCTX-M) and aminoglycoside resistance genes (acetylation,
adenylation and phosphorylation genes). PCR successfully detected
resistance genes, without the need for prior screening for resistant
isolates. Moreover, the results indicate that the adult microbiota is a
significant reservoir for β-lactam and aminoglycoside resistance genes,
with members of the Proteobacteria being significant sources of these
genes. This was the first study to use direct PCR analysis on
metagenomic DNA thereby eliminating the need for initial screening for
resistant isolates from complex environments.
Following on from this, and to determine if Bifidobacterium sp. contain
aminoglycoside or β-lactam resistance genes, we conducted an in silico
based screen of Bifidobacterium using the NCBI Protein database. A high
prevalence of putative aminoglycoside and β-lactam resistance proteins
in Bifidobacterium was observed. Laboratory investigations found no β-
lactam resistance phenotype in any of the bifidobacteria containing these
putative β-lactam resistance proteins. We concluded that such sequences
have been mis-annotated. In contrast, when we disrupted, through
insertional inactivation, the 2 genes responsible for aminoglycoside
resistance proteins in B. breve UCC2003, a reduction in aminoglycoside
vresistance resulted. This was the first study to identify genes contributing
to the innate aminoglycoside resistance of Bifidobacterium species.
In our 4th study, the expertise gained with respect to working with
metagenomic DNA, infant samples and screening for antibiotic resistance
and associated genes was combined. More, specifically we constructed a
fosmid metagenomic bank using infant faecal microbiota from healthy 6
month old infants who had no antibiotic exposure, and screened for
ampicillin and gentamicin resistant clones. Resistant isolates underwent
PCR and sequencing analysis. Additional PCRs were also completed
directly on metagenomic DNA from the infant faecal samples to
determine if additional genes would be detected, which had not been
captured or were not expressed in the E. coli host. The results
demonstrate that the gut microbiota of healthy 6 month old infants is a
sizable reservoir of β-lactam and aminoglycoside resistance genes and
that a metagenomic fosmid bank enables the detection of such genes
from diverse sources.
Although this thesis focuses primarily on investigating antibiotics,
antibiotic resistance and the gut microbiota, other factors that impact on
the gut microbiota, i.e. surgery/short bowel syndrome, the microbes
present in the appendix and conjugated linoleic acid, were also
investigated. Short bowel syndrome is a condition characterized by a
significant reduction in the length of the bowel, which culture-based
studies have suggested results in a significant increase in Lactobacillus in
vi
the gut microbiota. The aim of our study was to use a porcine model of
the infant gut to investigate the effects of surgical resection on gut
microbiota and inflammation. A significant increase in Firmicutes
occurred, while Veillonellaceae were dominant at family level. Bacterial
diversity was also reduced following resection, which was associated with
increased inflammation. No increased Lactobacillus levels occurred
following short bowel resection.
The human appendix has generally been regarded as an evolutionary
vestige. Recently however, it was proposed that the appendix could act
as a microbial safe house and could potentially replenish the gut with
commensals following perturbations to the normal gut microbiota, e.g.
following antibiotic therapy. Our aim was to investigate this microbiota
using high-throughput DNA sequencing techniques. Seven appendices
were sequenced, with significant inter-individual differences observed
between their diverse and complex microbiota. Some trends did emerge,
with Firmicutes being the dominant phylum and Ruminoccoccaceae,
Fusobacterium and Bacteroides comprising the majority of family and
genus sequences. Given the location at the distal colon and the
complexity and individual nature of the appendix microbiota demonstrated
in our study, it is highly probable that the human appendix has an
important role to play in the human body, one which has yet to be
elucidated.
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Finally, given the importance of gut microbes in health and daily
functioning, extensive research has been conducted to investigate ways
to manipulate this environment in a positive manner. Bifidobacterium
have received significant attention as potential probiotics. In this study, 2
conjugated linoleic acid producing probiotic B. breve strains (DPC 6330
and NCIMB 702258) were administered to mice for 8 weeks and the
effects on gut microbiota, fat distribution and composition were
investigated. The results indicated that the 2 strains exerted different
effects on gut microbiota, with DPC 6330 supplementation resulting in
increased proportions of Clostridiaceae and decreased Eubacterium,
compared to mice receiving the NCIMB 702258 strain. The results also
demonstrated that fatty acid metabolism is dependent on the probiotic
strain administered.
Thus, the data presented in this thesis highlights the negative
consequences of antibiotic therapy and surgery on gut microbiota
composition, while also identifying the infant and adult gut microbiota as
reservoirs of antibiotic resistance genes. Furthermore, we have
demonstrated ways in which the gut may be repopulated, via the
appendix, or beneficially manipulated.
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Chapter 1
Literature review:
Composition of the early intestinal microbiota:
knowledge, knowledge gaps and the use of high-
throughput sequencing to address these gaps
Published in Gut Microbes, Volume 3, Issue 3, May-June 2012,
Pages 203-220
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1.1 Abstract
The colonization, development and maturation of the newborn
gastrointestinal tract that begins immediately at birth and continues for 2
years, is modulated by numerous factors including mode of delivery,
feeding regime, maternal diet/weight, probiotic and prebiotic use and
antibiotic exposure pre-, peri- and post-natally. While in the past, culture-
based approaches were used to assess the impact of these factors on
the gut microbiota, these have now largely been replaced by culture-
independent DNA-based approaches and most recently, high-throughput
sequencing-based forms thereof. The aim of this review is to summarise
recent research into the modulatory factors that impact on the acquisition
and development of the infant gut microbiota, to outline the knowledge
recently gained through the use of culture-independent techniques and, in
particular, highlight advances in high-throughput sequencing and how
these technologies have, and will continue to, fill gaps in our knowledge
with respect to the human intestinal microbiota.
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1.2 Introduction
Following birth, the gut microbial composition undergoes remarkable
alterations during the first two years of life. More specifically, the human
gastrointestinal tract (GIT) changes from being initially sterile, to
possessing an adult-like stable microbiome by the time the infant reaches
2 years of age (Adlerberth and Wold, 2009). Despite being home to more
than 1014 bacterial cells (outnumbering the total amount of human cells in
the body (1013)) (Vaishampayan et al., 2010), which contribute up to 60%
of faecal mass, the human gut contains a surprisingly limited number of
dominant phyla (i.e. Firmicutes and Bacteroidetes). A diverse number of
factors contribute to the development of the gut microbiota and impact on
the unique composition that each individual develops (Figure 1).
The infant gut is initially an aerobic environment. However, through
colonization the environment is altered, resulting in a reduction in oxygen
levels thereby creating an environment suitable for the growth of
anaerobes. The initial gut composition is simple, dynamic and very
unstable and undergoes marked fluctuations (Palmer et al., 2007).
Nonetheless, evidence exists that the initial colonization influences
subsequent immune system development by influencing intestinal
morphology and gut associated lymphoid tissue (GALT) function.
Furthermore, more recently it has also been suggested that the gut
microbiota play a significant role in the regulation of the immune system
(something which will be returned to later) (Fagerås et al., 2011). Thus,
an altered gut microbiota composition can potentially predispose the
- 4 -
infant to more frequent infections and allergic disease risk (Conroy et al.,
2009).
Given the enormity of the bacterial population present in the gut, it has
been proposed that the gut bacterial microbiome be considered a “super
organism” (O' Hara and Shanahan, 2006). While the composition of the
species present within this microbiome is of great significance, the overall
diversity of this population can also be of critical importance. In the
majority of cases, the interaction between the bacteria and the human
host can be regarded as mutualistic, in that both the bacteria and the host
benefit from a mutual relationship. The vast array of functions which
these bacteria are capable of are still being elucidated but many benefits
have been well documented (Guarner and Malagelada, 2003), and these
functions can be divided into those which are metabolic, trophic or
protective (Guarner and Malagelada, 2003). The mechanisms by which
these functions occur are outside the scope of this review, but examples
of some of these diverse functions have been summarised in Figure 2.
1.3 Advances in techniques to study gut microbiota
In the past, investigations into the infant gut microbiome were culture-
based and therefore the insight provided was limited by a lack of
knowledge with respect to the growth requirements of the majority of
microbes present in the gut. Selection of the correct media, temperature,
oxygen content and time for growth all impacted on the ability to generate
accurate culture-based results. It has since been estimated that as little
- 5 -
as 10-50% of the entire gut bacteria are easily cultured (Eckburg et al.,
2005). With our increasing knowledge of the growth requirements of a
vast number of microbes, as well as the availability of specialised
culturing media, we can now successfully culture increasing numbers of
different microbes, as recently demonstrated by Goodman et al.
(Goodman et al., 2011). Culture-based approaches are still being
employed in some studies (despite the availability of much more
sophisticated and complex technologies, some of which will be outlined
below; Table 1), though most often in combination with culture-
independent techniques such as fluorescent in situ hybridization (FISH)
or flow cytometry. Despite these advances in culturing capabilities, this
approach is still unsuitable for characterising the microbiota as a whole,
especially in complex environments such as the human gut.
Another approach that has been taken has involved the study of
differences in the composition or presence/absence of microbiota
associated characteristics (MACs) between different subject groups. The
concept of MACs was first proposed in 1978 (Midtvedt et al., 1985) and
some examples include mucin degradation, conversion of cholesterol to
coprostanol and inactivation of tryptic activity. One of the most commonly
studied MACs are short chain fatty acids (SCFAs). These are a sub-
group of fatty acids that contain 6 or less carbons on their aliphatic side
chain. They include acetic, butyric and propionic acids and are produced
as a result of fermentation of dietary fibre by bacteria in the large
intestine. Differences in bacteria populations could result in alterations in
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the type and amount of faecal SCFAs present. The comparison of MACs
has been a major component of studies investigating the contribution of
the microbiome in, for example, coeliacs relative to controls (Tjellström et
al., 2005, Tjellström et al., 2007), probiotic or antibiotic treated
infants/children compared to controls (Bezirtzoglou and Stavropoulou,
2011, Cardona, 2002) and even to identify changes in gut microbiota-
related functionality due to allergic disease (Böttcher et al., 2000,
Thompson-Chagoyan et al., 2011). While MACs are useful as a tool for
screening large populations, such as in epidemiological studies, they are
most useful when supplemented with detailed insights into gut microbial
composition.
Due to the limitations associated with culture-based approaches,
researchers began to develop and utilize culture-independent, DNA-
based approaches to gain such detailed insights. There are a variety of
such DNA-based approaches available. Among the most popular of those
employed initially were temperature gradient gel electrophoresis (TGGE)
and denaturing gradient gel electrophoresis (DGGE) (Cani et al., 2008).
These systems work by the separation of amplicons (often of the 16S
ribosomal RNA gene (rRNA)) based on their GC content, to reveal
distinctive patterns. The 16S gene allows phylogenetic identification of
the bacteria present, as this gene is present in all prokaryotes and
contains conserved and variable regions which facilitates amplicon
generation and differentiation (O' Toole and Claesson, 2010). These
techniques are rapid and provide an overview of the composition of
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microbial populations. Downstream analysis to identify specific
components of the population can be facilitated by band excision and
sequencing, however, despite this, these approaches usually only provide
limited phylogenetic information and, as with all PCR based strategies,
can be subject to PCR bias. Dot-blot hybridization technologies have also
been utilized to investigate the infant gut microbiota (Malinen et al.,
2003). In this case, RNA is isolated, immobilised and assessed
qualitatively and quantitatively using oligonucleotide-labelled probes. This
approach is not subject to PCR bias, but the resolution of results can be
limited, and it is focussed on specific populations rather than the
microbiota as a whole. Furthermore, results depend on the ability to firstly
generate reference sequences to facilitate the design of probes. Similarly,
FISH approaches have been used and have also provided valuable
information, but, as with dot-blot hybridization, the results are again
focussed on specific populations and reference sequence generation is
again required (Duncan et al., 2008, Manichanh et al., 2006). Quantitative
PCR (qPCR) is now also frequently used, which measures the
accumulation of products through measurement of fluorescently labelled
primers or probes (Overturf, 2009). Studies have also employed several
techniques in combination, such as dot-blot hybridization together with
qPCR to allow for the quantification of bacterial numbers as well as
identification of the different species present (Zwielehner et al., 2009).
Other studies have used qPCR and FISH in combination, yielding
significantly more detailed and enlightening results (Collado et al., 2010).
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The next step in the evolution of culture-independent technologies
involved the use of phylogenetic microarrays (Palmer et al., 2007).
Microarrays are similar to the previously described approaches, but are
more advantageous in that they allow hybridisation of greater numbers of
sequences to the one slide, thus allowing extensive data generation from
the one read. Briefly, the sequences are attached to the glass slide, using
a robotic arrayer. These sequences are fluorescently labelled and their
expression can be measured using a fluorescence assay (Brown and
Botstein, 1999). Thus it is clear that a shift in gut microbiota research has
occurred in recent decades, to focussing more specifically on the
bacterial 16S ribosomal RNA (rRNA) gene (Frank and Pace, 2008,
Mardis, 2008b).
As highlighted by an extensive review in 2008 (Frank and Pace, 2008),
the investigation into the gastrointestinal microbiota has moved into the
“metagenomic era”, with increasing numbers of studies employing DNA
sequencing-based techniques. Sequencing of the 16S rRNA gene has
the advantage of providing the gene sequence itself (and, thus, valuable
information regarding the identity of microbes present) rather than the
indirect, and less accurate, information provided by DGGE and TGGE.
When carried out on a larger scale, DNA sequencing can reveal detailed
information relating to the overall microbial population in a particular
environment e.g. the human gut which contrasts with targeted
approaches such as dot-blotting, FISH, qPCR and, to a lesser extent,
phylogenetic microarrays. The earliest sequencing-based approaches
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were based on cloning of full length 16S rRNA genes into a plasmid, its
introduction into a host (most often Escherichia coli, E. coli), followed by
conventional, capillary-based, Sanger sequencing thereof. While this
technique allows the identification of bacterial species, it is slow and
expensive. This process can take up to 3 weeks from the generation of
purified DNA to the generation of results (Strausberg et al., 2008). Today
the focus has shifted to high-throughput sequencing which, because of
the scale at which sequence data is generated, provides a greater insight
into the precise composition of the microbiota present (Mardis, 2008b).
High-throughput sequencing technologies (also known as next generation
sequencing), such as those supplied by Roche/454 and Illumina, have
been used extensively for gut microbiota-related studies. The Roche/454
pyrosequencing approach is based on sequencing by synthesis. For 16S
sequencing, purified DNA is used to generate an amplicon library which
then undergoes an emulsion based clonal PCR. This PCR uses beads
coated in oligonucleotides, which are specific to adaptor sequences
attached to the amplicons. Following bead recovery and enrichment, the
amplicon coated beads are added to a picotitre plate and sequencing
ensues. Sequencing involves an enzymatic reaction and, as each
nucleotide is sequentially added, pyrophosphate is released and ATP is
subsequently generated. This then enables the conversion of luciferin
and the emission and detection of photons of light (Strausberg et al.,
2008). For Illumina sequencing, single stranded DNA fragments are
generated with oligo-ligated adaptors attached. These are then attached
- 10 -
to a glass flow cell, onto which oligonucleotides complementary to the
adaptor region of the amplicons are attached. Heating and cooling cycles
follow, after which incubation with reagents and a polymerase to hybridise
the DNA fragments to the oligonucleotides occurs. The flow cell, when
placed into a cassette, is then sequenced and the incorporation of the
nucleotides (each of which is fluorescently labelled) is measured using
imaging technologies (Mardis, 2008a). However, these techniques also
have their own inherent limitations. In the case of amplicons, they are
prone to PCR bias. One also requires extensive bioinformatic capabilities
to handle the vast amount of bioinformatic data generated and the
associated platforms are expensive to purchase and run. In addition to
this, while these technologies provide valuable information with respect to
the proportions of different populations present, qPCR is often required to
generate absolute quantification data.
While amplicon-based 16S compositional sequencing has been most
frequently used for human studies, another option is shotgun sequencing
whereby the metagenomic DNA (i.e. all of the DNA from the microbial
population) is first fragmented into short lengths and sequenced randomly
(Weber and Myers, 1997, Hattori and Taylor, 2009). This approach
involves the sequencing of random fragments of DNA rather than
specifically targeted regions and provides valuable information regarding
the functional potential and, to some degree, the identity of the microbes
present in a particular niche and, if carried out on a sufficiently large
enough scale, entire genomic sequences can be generated (Kurokawa et
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al., 2007, Venter et al., 2001). As with target-specific approaches,
shotgun sequencing has also benefited enormously from the availability
of high-throughput sequencing technologies (Turnbaugh et al., 2008,
Turnbaugh et al., 2009, Claesson et al., 2011, Vaishampayan et al.,
2010).
Other high-throughput sequencing technologies have, or will shortly,
emerge. Examples include the Ion torrent (Schadt et al., 2010), SOLid
(Applied Biosystems) (Shendure et al., 2005), SMRT (Pacific Biosystems)
(Levene et al., 2003) and nano pore sequencers (Branton et al., 1996,
Clarke et al., 2009). These techniques aim to provide longer, or greater
numbers of reads, more rapidly and/or at a lower cost. While the exact
mechanisms, advantages, disadvantages and differences between these
new culture-independent techniques are outside the scope of this review
(and are covered extensively in other reviews cited herein), it is worth
noting that these technologies will undoubtedly revolutionise the way in
which we study the human gut microbiota in the future. Indeed, in the
past few years alone, these high-throughput sequencing technologies
have already been employed to study the gut microbiota associated with
different diseases including, but not limited to, diabetes (Roesch et al.,
2009), Crohn’s disease (Gophna et al., 2006), irritable bowel syndrome
(Kassinen et al., 2007), cancer (Maitra et al., 2004, Thomas et al., 2007)
and obesity (Ley, 2010, Ley et al., 2005, Turnbaugh et al., 2008) and to
investigate the effects of diet (De Filippo et al., 2010, Turnbaugh et al.,
2009) and antibiotics (Dethlefsen et al., 2008) on the gut microbiota.
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Thus, it is clear that in the past 15 years researchers have progressed
from relying heavily on culture-based approaches to utilizing
sophisticated high-throughput sequencing technologies to investigate the
microbial world within us. Before proceeding, it should also be noted that
while there has been enormous progress made, one limitation that still
remains with respect to studying the gut microbiota, is accessing a
representative bacterial sample to study. Most frequently, the composition
of the gut microbiota of infants is assessed following the collection of
stool samples and the extraction of DNA. However, there are limitations
to this approach, as faecal samples are most representative of the
bacteria present in the lower colon but less representative of the bacteria
of the stomach and upper intestine. However, despite this limitation,
faecal samples are very useful with respect to identifying the majority of
bacteria present in the colon, which is where the preponderance of
intestinal bacteria reside (due to transit time, pH, nutrient availability etc.)
and, in the absence of other alternatives, faecal-based assessments
remain the approach of choice. This review will focus on the infant gut
microbiota development, based on results generated using culture-
independent approaches and will highlight how the results generated
using these different technologies compare to those generated using
older approaches.
1.4 Shaping the early intestinal microbiota: Effect of mode
of delivery
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Infants undergo rapid colonization during delivery and in the first few
hours following birth. Initially the infant is colonized by aerobes, followed
by facultative anaerobes and, as the oxygen level is diminished, strict
anaerobes predominate (Grölund et al., 1999, Edwards and Parrett,
2002, Salminen et al., 2004). Some of the earliest colonizers include E.
coli and enterococci and, once the oxygen has been consumed, they are
followed by strict anaerobes including bifidobacteria, Bacteroides and
Clostridium spp. (Stark and Lee, 1982, Adlerberth and Wold, 2009).
However, while these general patterns of colonization occur, colonization
of the infant’s gut is altered by birth mode. Infants born vaginally are
colonized with vaginal and faecal microbes from their mother and this has
been shown to result in a strong maternal signature, which contrasts with
the microbiota of Caesarean born infants (Adlerberth and Wold, 2009). It
is generally accepted that infants born by Caesarean section have no
access to the mother’s microbiota, although there have been suggestions
that the swallowing of amniotic fluid allows some colonization of the
infant’s gut in utero (Mshvildadze and Neu, 2010). Caesarean delivered
infants are instead colonized by microbes from the environment, such as
those from healthcare staff, wards and other infants. A recent study of 9
women and their 10 infants (i.e. including one set of twins) was
completed using high-throughput sequencing (Roche/454) of the variable
2 (V2) region of the bacterial 16S rRNA gene (Dominguez-Bello et al.,
2010). The authors sequenced 34 samples from the mother and 46 from
their infants, resulting in 157,915 partial 16S sequences. The study found
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that there was a strong vertical transmission of vaginal microbes from the
mother to the infant when birth was by vaginal delivery, resulting in a
dominant number of lactobacilli within hours of birth. In contrast, in the gut
of Caesarean delivered infants there was a strong presence of maternal
skin microbes, with staphylococci being dominant in these infants
(Dominguez-Bello et al., 2010). This study advances our understanding of
the relationship between the mother’s microbiota and that of her infant
and highlights the benefits of employing high-throughput sequencing for
such purposes.
Other DNA-based studies have also been completed that support the
aforementioned results. A study of over 1000 infants in the Netherlands
examined, using qPCR, the potential of over 16 factors to alter the
composition of the infant gut microbiota at age 1 month (Penders et al.,
2006). When the gut microbiota of infants that were vaginally born was
compared with those born by Caesarean section, it was apparent that the
latter group had 100 fold lower bifidobacteria and Bacteroides fragilis
numbers. In addition, birth by Caesarean delivery was also associated
with a 100 fold increased colonization with Clostridium difficile. C. difficile
is a Gram positive spore-forming anaerobic pathogen, which has been
shown to be capable of producing toxins and is frequently a cause of
diarrhoea and colitis (Fitzpatrick et al., 2008, Gerding et al., 1995,
Thomas et al., 2003). Notably, a follow-on study by the same group found
a positive association between mode of delivery, the gut microbiota and
atopy risk (Van Nimwegen et al., 2011). Another such study focussed on
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the microbial composition of even younger infants (i.e. 3 days old) (n=46)
(Biasucci et al., 2010). The TGGE- and DGGE-based approaches
employed again highlighted the strong impact of delivery mode on the
microbial composition, with vaginally born, exclusively breastfed infants,
having the highest bifidobacteria levels and lowest C. difficile counts of all
infants (Biasucci et al., 2010). Surprisingly, although subject to bias and
the inherent limitations outlined previously, culture-based approaches
have revealed similar trends in that, when Adlerberth et al. examined over
300 infants across 3 European cohorts, they found that Caesarean
delivered infants are colonized with greater numbers of clostridia and
Klebsiella and decreased E. coli, bifidobacteria and Bacteroides
compared to vaginally delivered infants (Adlerberth et al., 2007).
A FISH-based study of 168 one month old Finnish infants provided a
somewhat different set of results in that the Clostridium, Bacteroides and
Lactobacillus populations in the gut were found to be similar in both
vaginally and Caesarean born infants (Huurre et al., 2008). Notably,
however, it was again apparent that bifidobacteria were greatly impacted
upon by delivery mode, with a 1300 fold higher level observed in infants
born vaginally. This is significant as bifidobacteria, along with lactobacilli,
are the microorganisms most frequently employed as probiotics.
Bifidobacteria were first characterised in the period 1899-1900 and, since
then, have been shown to predominate in vaginally delivered, breastfed
infants. The health promoting properties of specific lactobacilli and
bifidobacteria have been reported and include the combat of diarrhoea,
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increasing resistance to pathogenic microorganisms, decreased
occurrence of urinary, gastrointestinal and respiratory infections,
alleviating lactose intolerance symptoms, reducing constipation and
boosting immune functioning (Leahy et al., 2005, Picard et al., 2005,
Liepke et al., 2002). However, as has been highlighted recently by EFSA
(European Food Safety Authority), it is critical that the health claims
pertaining to each specific strain are rigorously tested (Efsa, 2007).
Nonetheless, research to date does suggest that a delivery-mode
mediated variation in the numbers and diversity of both lactobacilli and
bifidobacteria occurs and considerable research has been carried out
with a view to determining the significance of these differences. Moving
forward this area of research will benefit from more detailed investigations
to determine precisely which populations are influenced by delivery
modes and to establish which of these populations can be specifically
associated with subsequent health-related impacts.
Culture-based studies have shown that the influence of delivery mode on
the gut microbiota can persist for some time and thus may impact on the
subsequent health of the infant (Grölund et al., 1999). Recent culture-
independent approaches have also shown this to be the case, once more
showing the ability to verify the results of culture-based approaches using
new culture-independent and high-throughput sequencing based
technologies. More specifically, a FISH-based study of 60 children at age
7 years, in which 31 had been born by Caesarean section and 29
vaginally (Salminen et al., 2004), revealed that vaginally born infants had
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increased levels of clostridia compared to those delivered by Caesarean
section. The authors reported that lower clostridia levels appear in those
infants being treated for asthma at age 7, while healthy children had
higher numbers of clostridia, thereby highlighting a potential long-term
consequence of the impact of delivery mode on the gut microbiota. A
recent birth cohort supports these gut microbiota findings of a long-term
consequence on health due to delivery mode (Goldani et al., 2011). The
study examined the association between Caesarean delivery and the
subsequent risk of being obese at age 23-25 years. After controlling for
sex, birth weight, activity, income, smoking and maternal factors
(schooling and smoking during the pregnancy), it was revealed that those
born by Caesarean section had a 58% increased risk of obesity
compared to vaginally born infants, thus highlighting the long-term effects
of a factor that impacts on the infant’s gut microbiota (Goldani et al.,
2011). This topic has also been the focus of a recent review (Neu and
Rushing, 2011).
1.5 Effect of early feeding regime
The impact of feeding choice, i.e. breastfeeding versus formula feeding,
and weaning on the infant gut microbiota has also been investigated. The
World Health Organisation (WHO) recommends exclusive breastfeeding
of all infants up to 6 months of age and continued supplemented
breastfeeding up to 12 months of age (Who, 2003). Despite this, there
are large variations in the rates of breastfeeding from one country to
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another. Presently, Scandinavian countries have some of the highest
levels of breastfeeding with, for example, recent data for Norway
suggesting that 96% of infants are breastfed at birth, of which 84% are
exclusively breastfed (Kristiansen et al., 2010). In comparison to these
high levels, many developed countries have much lower rates of
breastfeeding, with recent Irish data suggesting that rates of exclusive
breastfeeding currently stand at just 47% at hospital discharge and drop
to between 6.5 and 9.4% of women partially breastfeeding during the first
6 months of the infant’s life (Tarrant et al., 2010). In the USA, the 2007
National Immunisation Survey found that at 3 months of age, just 33% of
infants were exclusively breastfed, and that this level falls further at 6
months to just 13% being exclusively breastfed (Survey, 2007).
Breastfeeding is accepted as being highly beneficial to both mothers and
infants (Allen and Hector, 2005). Breastmilk is a nutritious food for the
newborn, the composition of which varies in response to the infant’s
changing nutritional requirements and age. In addition to containing the
appropriate nutrients for the growing infant, breastmilk can have a
significant impact on the gut microbial composition by virtue of being a
source of prebiotics (non digestible food ingredients that beneficially
effect the host by selectively stimulating the growth of one or a limited
number of bacteria in the colon), lactoferrin (an antimicrobial protein) and
lysozyme (an enzyme found naturally in milk, tears and sweat that is
capable of digesting the cell walls of bacteria) (Fox and Kelly, 2006).
Thus, the constituents of milk may play a determining role in the gut
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microbial composition and development. Significantly, there are
considerable differences in the oligosaccharide composition of human
breastmilk and cows’ milk although it has been revealed that the addition
of prebiotics to cows’ milk based infant formulas can reduce these
differences somewhat (Manning and Gibson, 2004). The ability of
prebiotics to modulate the infant gut microbiota in a manner similar to that
associated with breastmilk will be discussed in greater depth later in this
review.
Thirty years ago, Stark and Lee pioneered the research into the influence
of different approaches to feeding on the infant gut microbiota (Stark and
Lee, 1982). This culture-based study paved the way for the more recent
investigations and was notable in that it revealed that bifidobacteria levels
varied greatly depending on feeding method, with breastfed infants
having higher bifidobacteria levels compared to formula fed controls.
Although it is now apparent that the feeding regime is not the sole
determinant of the levels of bifidobacteria and lactobacilli in the infant gut
(Adlerberth and Wold, 2009), it is clear that feeding does have a crucial
impact. The findings of this initial culture-based study by Stark and Lee
(Stark and Lee, 1982), have been corroborated by several more recent
culture-independent studies and reviews, which confirm that
bifidobacteria are more dominant (and, in at least some cases, more
diverse) in the gut of breastfed infants (Bezirtzoglou et al., 2011, Fallani
et al., 2010, Le Huërou-Luron et al., 2010, Roger et al., 2010, Penders et
al., 2006). These studies have also revealed that E. coli and clostridia
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counts, including C. difficile, are lower in breastfed infants than those fed
infant formula. Notably, when formula was supplemented with
oligosaccharides it resulted in greater bifidobacteria counts in the faecal
samples of the associated infants than was present in samples provided
by the unsupplemented control group (Penders et al., 2006). Thus, in this
case and as is often the case, the use of culture-independent techniques
has resulted in the validation of earlier culture-dependent studies but has
also significantly advanced our understanding of the broader
consequences of feeding method choice with respect to the infant gut
microbiota. Thus, while culture-based approaches are rapid and relatively
straight forward and therefore are useful as preliminary investigations, the
more advanced techniques provide us with the greatest insight into the
complex interaction between feeding method and gut microbiota.
Other patterns have also been noted in that a review by Adlerberth and
Wold (2009) noted trends towards higher levels of Lactobacillus
rhamnosus in partially breastfed infants compared to weaned infants,
observed that staphylococci are also more common in breastfed infants,
while also establishing that higher levels of Klebsiella and Nitrobacteria
are seen in formula fed infants (Adlerberth and Wold, 2009). Fallani et al.
have reported that Bacteroides were dominant in the gut microbial
population of 6 week old formula fed infants (Fallani et al., 2010) and it
has also been noted that the microbiota of formula fed infants is, in
general, more diverse than that of their breastfed counterparts
(Bezirtzoglou et al., 2011). Perhaps most notably of all, it has also been
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established that the consumption of breastmilk can significantly reduce
the risk of necrotizing enterocolitis (NEC) (by 3-10 fold) in infants relative
to those who are formula fed (Lin and Stoll, 2006).
In addition to the fact that the composition of milk consumed influences
infant gut microbial composition, it has also been claimed that breastmilk
contains microbes such as staphylococci, streptococci, lactobacilli,
micrococci and bifidobacteria (Martín et al., 2003) and thus may be a
direct source of the lactobacilli and bifidobacteria that become
established in the infant gut (Martín et al., 2007, Sinkiewicz and
Ljunggren, 2008). These earlier studies have been supported by a 2010
study which provided further evidence of the role of breastmilk-associated
microbes in the establishment of lactic acid bacteria (LAB; which includes
the lactobacilli) and bifidobacteria in the immature infant gut (Solís et al.,
2010). In addition to the benefits of nutrients, oligosaccharides and,
perhaps, microbes present in breastmilk on the infant gut microbiota, the
antimicrobial impact of lactoferrin, as alluded to earlier, may be beneficial.
In 2009, a review found that oral treatment with lactoferrin reduced the
incidence of sepsis and NEC in very low birth weight (VLBW) infants
(usually including infants 1-1.5 kg in weight). Significant reductions in
sepsis and NEC were apparent when lactoferrin was supplemented along
with the probiotic L. rhamnosus GG (Mohan and Abrams, 2009).
The introduction of solid foods (recommended by the European Society
for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) to
occur not before 17 weeks of age and no later than 26 weeks) (Agostoni
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et al., 2008) is also known to induce alterations in the gut composition of
infants (Edwards and Parrett, 2002, Koenig et al., 2011). Koenig and
colleagues performed high-throughput sequencing of faecal DNA from
one infant over a 2.5 year period (Koenig et al., 2011). The study
employed 454-pyrosequencing to generate 318,620 16S rRNA gene
sequences from sixty samples and over 500,000 metagenomic
sequences from 12 samples. The study identified so called “steps” at
which dramatic alterations occurred in the infant’s GIT microbiota which
they found could be attributed to a significant life event (Koenig et al.,
2011). An example of this was “Step 3”, which took place around days
170-290, when the introduction of formula and peas to the diet of the
previously exclusively breastfed infant resulted in a significant increase in
Bacteroidetes. Overall, the study found that the introduction of solid foods
was associated with an increase in Bacteroidetes and Firmicutes. It was
also again suggested that by 2.5 years the gut microbiota closely
resembled that of an adult. The impact of weaning has also been
investigated by others. In one case, this involved a study of 605 children
from 5 European countries (Fallani et al., 2011). The infants were
examined 4 weeks after weaning commenced and were compared to the
same infants prior to weaning, with results being generated using FISH
and flow cytometry. The study found Bifidobacterium, the Clostridium
coccoides group and Bacteroides to predominate after weaning but it was
noted that the relative proportions of these were affected by the approach
to pre-weaning feeding i.e. infants who had been breastfed had higher
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levels of bifidobacteria and decreased Bacteroides compared to infants
who had been formula fed prior to weaning. The authors noted that
despite weaning having a noticeable modifying effect on the gut
microbiota of infants, other modulating factors such as mode of delivery,
continued to exert measurable effects during the weaning period (Fallani
et al., 2011). Roger and colleagues have also reported an increase in the
diversity of bifidobacteria corresponding to the introduction of solid foods
(Roger et al., 2010).
Finally, an alternative approach to the investigation of the impact of diet
was demonstrated by De Filippo et al. in a study which compared diet,
and its effects on the gut microbiota, of children (aged 1-6 years) from
Europe (n=15) compared to those from rural Africa (n=14) (De Filippo et
al., 2010). The African diet was low in fat and protein from animal sources
and was high in fibre and starch and these children also differed in that
they were breastfed up to 2 years of age. The authors performed
pyrosequencing of the V5 and V6 hyper-variable regions of the bacterial
16S rRNA gene and generated 438,219 gene sequences, corresponding
to 15,111 sequences per sample. The study found that the lack of
diversity in the Western diet, and its over-reliance on nutrient dense,
processed and refined foods, appears to have an effect on the gut
microbial composition. More specifically, the Western diet was associated
with a reduced microbial diversity, with the European gut microbiota
containing higher proportions of Firmicutes and Proteobacteria and lower
proportions of Bacteroidetes and Actinobacteria (De Filippo et al., 2010).
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Despite the increased knowledge gained in recent years, it is clear that
there is a need to more closely investigate the gut microbial composition
of breast and formula fed infants as well as the effects of weaning and
other diet-related issues. Investigations are also required to determine the
duration of such effects and the short- and long-term impact that they
have on infant health. It is anticipated that high-throughput sequencing
technologies will provide significant clarity in this regard.
1.6 Impact of family structure
Though studied to a lesser extent, a factor that is emerging as a possible
contributor to the composition of an infant’s gut microbiota is family
structure. One relevant concept is known as the ‘sibling effect’ which is an
adjunct to the hygiene hypothesis and postulates that allergic disease is
lower in children from larger families (Strachan, 1989). However, this
theory remains controversial, particularly as the studies which have been
performed to test this theory have been carried out in a myriad of different
ways. Thus, to date, definitive evidence of the effects of family size,
structure and birth order has yet to be established. Nonetheless, as part
of the ALLERGYFLORA study (Adlerberth et al., 2007), it was found
(using culture-based approaches) that infants without older siblings had
increased proportions of non-E. coli enterobacteria as well as clostridia in
the gut, but also had a lower anaerobe to facultative anaerobe ratio,
resembling that of Caesarean delivered infants (Adlerberth et al., 2007).
In 2006, Penders et al. had reported the presence of greater
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bifidobacteria concentrations in infants with older siblings than those
without. While family order and the environment have been implicated in
allergic disease development (Mckeever et al., 2002, Strachan, 2000),
the link between these effects and the composition of the intestinal
microbiota requires further investigation. Further culture-independent
studies are needed, for example, to identify if the gut microbiota of infants
without older siblings is significantly different from that of other infants
and if this predisposes them to later health risks. By providing answers to
such questions, it will then become possible to address problems, that
might previously have been overlooked, by positively influencing the gut
microbiota (e.g. through probiotics use). As has been shown in the
previous sections, the results of culture-based approaches are often
verified by newer approaches, though these new technologies are
advantageous as they provide a more detailed and less biased insight
into such complex interactions between environmental factors and the gut
microbiota of infants. Thus, there is an obvious opportunity to employ
sequencing approaches to identify the gut microbiota of these infants and
its relationship to health outcomes.
1.7 Effect of maternal weight/diet
The WHO released startling figures in 2010, which were updated in 2011,
relating to the state of the world’s obesity crisis (Who, 2011). The
statistics showed that obesity levels have doubled since 1980 and that,
as of 2008, 200 million men and 300 million women were obese.
- 26 -
Childhood obesity was also highlighted, with 43 million children under 5
years being obese in 2010. Surprisingly, 65% of the world’s populations
now live in countries where more deaths occur due to obesity rather than
being underweight (Who, 2011). Obesity appears to be a vicious cycle, as
an obese mother is more likely to have an obese infant, who in turn has
an increased risk of becoming an obese adult (Lawlor et al., 2007). Work
by Gordon, Cani and others have shown that obesity is influenced by the
microbial composition of the gut (Cani et al., 2008, Ley et al., 2005). The
effects of childhood obesity on the composition of the child’s gut
microbiota have recently been studied (Kalliomaki et al., 2008). This
culture-independent study (comparing FISH and flow cytometry in
combination, to results from microscopic detection and qRT-PCR)
examined participants (n=25) and controls (n=24) at birth, at 3, 6, 12, 18
and 24 months and again when aged 4 and 7 years (at which time BMI
was calculated). The controls (i.e. normal weight children) were matched
for birth mode, gestational age, probiotic treatment, breastfeeding
duration, antibiotic treatment, atopic disease prevalence and cohort at
age 7 years. Faecal samples were analysed and it was shown that
children who were classified as being of normal weight had, and
continued to have, higher levels of bifidobacteria than those who were, or
who became, obese. They also noted lower Staphylococcus aureus
levels in normal weight infants. This therefore provides a further indicator
for the role of gut microbiota in obesity development and highlights the
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possibility of modulating disease risk through the alteration of the gut
microbiota.
A recent study has taken the alternative approach of investigating if a
mother’s weight before or during pregnancy could impact on her infant’s
gut microbiota (Collado et al., 2010). The results from this 2010 study
showed that infants of overweight mothers tended to be overweight or
heavier at birth than those of normal weight mothers, while also revealing
that overweight mothers had infants with decreased numbers of gut
bacteria from the Bacteroides-Prevotella group at age 1 month, but had
higher levels of Clostridium histolyticum in their gut at age 6 months.
Similar results were observed among infants whose mothers underwent
significant weight gain during pregnancy. The gut microbiota of the
offspring of overweight mothers contained higher Clostridium leptum,
lower Clostridium perfringens and higher S. aureus levels than that of the
infants of normal weight mothers. In contrast, at 6 months bifidobacteria
counts were higher in the infants of normal weight mothers than in those
of overweight mothers. While this culture-independent study provides
intriguing evidence of the effect that obese mothers have on their infant’s
gut microbiota, research in this area still remains limited and additional
culture-independent studies are required. There is an opportunity to apply
high-throughput sequencing approaches to this area of research to
compare the microbial profile of the mother at birth, and at later time
points, with that of her infant and to track the changes in gut microbiota
and the weight profile of both. There is a clear opportunity to exploit these
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technologies to considerably advance our knowledge of this complex
interaction between gut microbiota and weight. Finally, it has also been
shown that a mother can modulate her infant’s gut microbiota through the
consumption of probiotics (Gueimonde et al., 2006) or the use of
antibiotics during pregnancy (Mangin et al., 2010). The impact of
probiotics and antibiotics on the infant’s gut microbial population will be
addressed later in this review.
1.8 Probiotics
The word probiotic is derived from the Latin “pro” meaning for and from
the Greek “biotic” meaning living. Having undergone numerous
alterations (Parker, 1974, Fuller, 1989, Salminen et al., 1999) since the
first proposed definition in 1965 (Lilly and Stillwell, 1965), today the most
generally accepted, and most widely used definition, is that provided by
the Food and Agricultural Organization (FAO) who define probiotics as
“live microorganisms which, when consumed in adequate amounts as
part of food, confer a health benefit on the host” (Fao/Who, 2001).
Additionally, criteria have been proposed to allow for a more systematic
identification of probiotics and these have been outlined by a review in
2007 (Parracho et al., 2007). To date, representatives of the lactobacilli
have been most extensively studied with a view to their use as probiotics
(Holzapfel and Schillinger, 2002).
- 29 -
The issue of the health benefits associated with the consumption of a
probiotic has been the focus of great attention in recent years. Since
2006, EFSA has implemented regulations pertaining to nutrition and
health claims, including claims relating to probiotics. They have outlined
that with respect to health claims relating to the ability of a probiotic to
modulate the gut microbiota positively, they expect that the changes
induced should have a specific health benefit, such as a reduction in
specific (potentially) pathogenic microorganisms within the gut, which is
clearly related to the consumption of the product under investigation
(Efsa, 2010). They do not, however, support the claim that increased
levels of bifidobacteria or lactobacilli are beneficial to overall health per
se, due to a lack of specific scientific evidence to support such a claim.
Thus, in many cases, further evidence is needed to prove the role of
specific probiotic strains in the gut and thus allow health claims relating to
them. EFSA also require all scientific documents presented in the dossier
supporting the health claim to specifically relate to the species and strain
of probiotic microorganisms being examined. Thus, while there is
considerable evidence supporting the role of some probiotics in gut
microbiota modulation (as discussed below), care needs to be taken
when making associated health claims.
Given the recent EFSA rulings, it is not surprising that the specific
mechanisms by which probiotics exert beneficial health effects on the
host continues to be the focus of much attention (Aureli et al., 2011,
Preidis and Versalovic, 2009, Rastall et al., 2005). There are several
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proposed modes of action including the production of bacteriocins and
other antimicrobials which inhibit other bacteria or the alteration of
immune function, possibly through altered GALT function or through a
physical enhancement of the mucosal barrier function (O' Hara and
Shanahan, 2006). Indeed, the specific mechanism(s) involved will vary
depending on the specific strain administered, further highlighting the
importance of assessing each probiotic strain individually. Regardless of
the precise mechanism(s) involved, a vast array of data exists relating to
the beneficial impact of probiotics on host health (Fuller, 1989, Holzapfel
and Schillinger, 2002, Wallace et al., 2011). However, for the purpose of
this review, the focus will be confined to the benefits to infant gut
microbiota and subsequent health. With respect to healthy, full term
infants, this review has previously outlined the transition that the infant
gut undergoes from being initially sterile to having a composition that is
relatively stable and resembles that of an adult by 2 years of age. It is
during this initial transition phase that probiotics may be most beneficial. It
is also notable, however, that in many cases the proposed benefit has
related to increasing levels of lactobacilli and bifidobacteria in the gut,
which, as highlighted above, is not accepted as a health claim by EFSA.
Given the ongoing debate regarding the significance of the ability of a
probiotic to alter the composition of the gut microbiota (other than
alterations in levels of specific pathogens), we have presented just a few
examples to highlight the considerable degree to which some probiotics
can bring about change. In one instance, a RCT examining the effects of
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supplementing the diet of infants with Bifidobacterium breve Bb12 for the
first 28 days of life showed, using culturing techniques, that gut
colonization patterns were altered compared to those of infants in the
placebo group (Kitajima et al., 1997). As one might expect, B. breve
colonization commenced more quickly in these infants but, in addition,
after 6 weeks Lactobacilllus colonization rapidly increased. In contrast,
Enterobacteriaceae decreased over the supplementation period in treated
infants compared to controls (Kitajima et al., 1997). Investigations have
also taken place to determine if probiotic administration to pregnant
mothers affects the gut microbiota of their infants. In 2006 a study
investigated (using qPCR) the impact of probiotic administration of L.
rhamnosus GG to pregnant mothers on the gut microbiota of their infants
(Gueimonde et al., 2006). The probiotic was fed to 29 mothers 2-4 weeks
prior to delivery and up to 3 weeks after delivery, while the control group
consisted of the infants of 24 mothers not in receipt of probiotics. Results
showed that supplementation of the mother’s diet with the probiotic had a
significant impact on the infants’ gut microbial composition, i.e.
significantly increased bifidobacteria numbers and diversity in these
infants at day 5 and a trend towards increased B. breve levels at age 3
weeks, relative to the controls. Thus, probiotics have the potential to have
a significant impact regardless of whether they are administered to the
mother during pregnancy or directly to the infant, via supplemented
formula after birth. A recent study was conducted using qPCR and flow
cytometry coupled with FISH (FCM-FISH) to analyze the faecal
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microbiota of infants in Finland and Germany who received perinatal
probiotic treatment (Grześkowiak et al., 2011). This study of over 150
infants found that the perinatal administration of probiotics did impact on
the gut microbiota of the infants, but also found that the consequences
depended on the feeding method employed (either breastfed or formula
fed) as well as the microbiota present in the infant’s gut prior to probiotic
administration. This area of research lends itself perfectly to further
investigation through high-throughput sequencing, which will provide
information with respect to the impact of these probiotics on gut microbes
other than bifidobacteria and lactobacilli.
In recent years there has been an increase in allergies and atopic
diseases, which have paralleled a corresponding decrease in infectious
diseases. In 1976 John Gerrard first proposed the hygiene hypothesis
(Gerrard et al., 1976), although it was not until 1989, when David P
Strachen published his paper in the BMJ which focussed on hay fever,
hygiene and household size that the hygiene hypothesis really began to
gain scientific interest (Strachan, 1989). Strachen’s paper suggested that
decreased exposure to environmental challenges in early life, due to
improved sanitation and hygiene practices, resulted in the reduced
exposure of the immature immune system to the challenges necessary to
develop tolerance and resistance to everyday environmental challenges
e.g. dust, pollen etc. Additionally, in 1997, the hygiene hypothesis was
extended to incorporate the relationship between gut microbiota and
immune regulation (Sepp et al., 1997). This hypothesis is still being
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debated and studied today. However, given the knowledge we have of
the influential role that gut microorganisms play in the establishment,
maturation and regulation of the infant immune system, studies have
once more returned to the hygiene hypothesis to determine if alterations
in the gut microbial composition could result in alterations in the
development of the immune system, which result in an altered allergy
risk. In 2003, Bourlioux et al. reviewed the evidence up to that point which
related to the role of the intestinal microbiota in immune function
(Bourlioux et al., 2003). The authors reminded us that alterations in the
ratio of T helper 1/T helper 2 cells can have adverse consequences for
the host i.e. increased Th2 levels result in an increased risk of allergy,
while increased Th1 levels increases autoimmune disease risk e.g.
diabetes mellitus. Studies have shown that having lower counts of
bifidobacteria and atopy risk are associated and it has been proposed
that bifidobacteria alter the level of Th2 development and inhibit the Th2
type response (Saavedra, 2007). Similarly, it has also been revealed that,
in children with allergic parents, higher levels of lactobacilli in early life did
reduce the risk of allergy development at age 5 years (Johansson et al.,
2011). It has also been suggested that the beneficial roles of specific
commensal bacteria in allergic disease prevention may be due to
alterations in the immune regulation process. The regulatory role that gut
microbes play in the immune system has been convincingly
demonstrated through studies involving gnotobiotic mice as well as
human trials and, most recently, it was also shown to influence secretory
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IgA levels and subsequent allergic symptom development (Fagerås et al.,
2011). Such a role of gut microbes in the regulation of the immune
system would help explain why it is not only Th2 mediated allergic
diseases, but also Th1 associated illnesses such as Type 1 diabetes,
which are increasing globally (Bach, 2002).
Following on from findings such as these, scientists have investigated the
potential to favourably alter the infant gut microbiota in early life to
decrease allergic disease risk. Notably, several studies have shown
benefits in treating atopic children with probiotics and thus, modulation of
the infant gut could potentially reduce the risk of them becoming allergic
to environmental stimuli. The proposed regulatory role of gut microbes
would occur predominantly during infancy and this may also explain why
the effects of probiotics are more clearly observed in infants than in
adults. This review will now summarise a number of relevant studies that
address this topic.
In a study published in 2002, L. rhamnosus GG was provided to
pregnant women who had a family history of atopic diseases (Rautava et
al., 2002). The supplement was consumed for the last 4 weeks of
pregnancy and throughout the breastfeeding period, until 3 months after
the birth of the infant. The study found that the risk of the infant
developing eczema was significantly reduced, i.e. 15% compared to 47%
incidence in the control group up to 2 years of age. A subsequent study
again involved supplementation with L. rhamnosus GG but, on this
occasion, L. rhamnosus LC705 (DSM 7061), B. breve Bb99 (DSM 13692)
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and Propionibacterium freudenreichii ssp. shermanii JS (DSM 7076) were
also provided to expectant mothers who had a family history of atopy
(Kukkonen et al., 2007). Once born, these infants also received this
combination of probiotics, plus galactooligosaccharides (prebiotics). The
authors found that compared to controls, probiotic treatment reduced the
frequency of IgE associated (atopic) diseases, with an odds ratio (OR) of
0.71; 95% CI 0.5-1.00, though not significantly. Probiotic treatment did
significantly reduced the risk of eczema with an OR of 0.74 CI 0.55-0.98,
p<0.035. The authors also noted the frequent colonization of
bifidobacteria and lactobacilli in the gut of supplemented infants. In 2005,
a study of 230 infants (aged 1.4-11.9 months) investigated the use of
probiotics in the reduction in the symptoms of atopic eczema/dermatitis
(Viljanen et al., 2005). Unlike the previous studies in which mothers
received probiotics, this study specifically investigated the effect of
directly treating the infants with probiotics. Treatment was either with
Lactobacillus GG (LGG), LGG in combination with 3 other probiotics or a
placebo. Participants were randomised into the 3 groups and treated for 4
weeks. Although the authors noted that symptoms improved, they did so
in all three groups and only a non-significant improvement was observed
when the probiotic treated group was compared with the control groups.
The study found there to be potential for probiotics with respect to
decreasing symptoms in IgE sensitised individuals but showed little
benefit in non-IgE sensitised infants.
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Despite the fact that, as noted above, some positive outcomes have been
reported, a 2007 review of this topic concluded that the studies to date
are conflicting and inconclusive (Prescott and Björkstén, 2007) and a
Cochrane meta-analysis of the effects of probiotics in the treatment of
eczema found no significant benefit of probiotic treatment (Boyle et al.,
2009). In a recent paper on this topic evidence of the benefits of providing
probiotics in order to prevent atopic eczema was quite convincing.
However, the authors did agree that weaker associations have been
shown between probiotics and other atopic diseases (Kalliomäki et al.,
2010). The inconsistent findings to date most likely reflect differences with
respect to the probiotic strains employed in the studies reviewed. It is
apparent that large RCTs involving infants are needed to investigate fully
and to specifically determine the benefits of treatment with specific
probiotics in the context of allergy and atopic diseases. Use of high-
throughput sequencing of faecal samples from affected versus unaffected
individuals could be employed to determine if differences in symptoms
are due to altered gut microbial compositions. Given that the hypothesis
is that probiotic treatment alters gut microbiota, thus reducing allergy risk,
one would presume that it is only a matter of time before culture-
independent strategies are employed to investigate the link between
probiotic use, alterations to the gut microbiota and subsequent impacts
on allergy. It is also notable that the studies to date have often been
limited to the use of lactobacilli as probiotics and thus the inclusion of
other genera or the use of strains in combination may also be beneficial.
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While there has been a focus on the impact of specific strains, a
consistent observation across many studies is the reduced microbial
diversity in the gut of allergic infants (Wang et al., 2008). This reduction in
diversity and allergic status relates well to the research on the association
between early antibiotic exposure, the accompanying reduction in gut
microbiota diversity and subsequent allergic disease risk (Jernberg et al.,
2010, Jernberg et al., 2007).
While debate continues as to the specific beneficial health effects of
many probiotics, one area where more convincing evidence exists is with
respect to NEC. NEC, though first characterised over 100 years ago, still
remains a poorly understood disease. The condition is characterised by
abdominal distension, bleeding of the intestines and ulcer formation
(Claud and Walker, 2001, Lin and Stoll, 2006). There has been
considerable interest in the use of probiotics to prevent NEC by
normalising the intestinal microbiota of preterm infants, i.e. trying to
change its composition to resemble that of healthy, full term infants
(Deshpande et al., 2007, Braga et al., 2011). Notably, trials using animal
models of NEC have shown the benefits of introducing probiotic
supplemented diets (Caplan et al., 1997, Caplan et al., 1999). In one
instance the animals, which were fed 109 organisms/animal/day, had
significantly reduced cases of NEC with just 7/24 in the treatment group
suffering from NEC, compared to 19/27 in the control group.
Corresponding human studies have also been completed (Lin et al.,
2005). In one case, the benefits of feeding Lactobacillus acidophilus in
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combination with B. infantis (no strain details provided) to infants was
tested (Hoyos, 1999). This large, year long, study of over 1000 infants
revealed that the cases of NEC, as well as the mortality rates in the
treated group, were reduced compared to the controls. In 2005, a trial
was conducted to examine the effects of some probiotics and NEC
prevention but in low birth weight infants (Bin-Nun et al., 2005). The study
found that a reduction in NEC cases in treated infants occurred with a
reduction in the incidence of NEC from 17% in controls to 4% in the
treated group. They noted that levels of clinically significant NEC
(classified as Bell Stage 2 or 3) in the treated group (1/72 i.e. 1%) were
statistically significantly reduced compared to the control group (10/73 i.e.
14%). Several meta-analysis and systematic reviews have been
conducted on this topic to date (Alfaleh and Bassler, 2010, Barclay et al.,
2007, Deshpande et al., 2010) and they have provided support for the
use of probiotics in preterm infants to prevent NEC. Despite this,
questions relating to what changes occur in the gut microbiota
composition of NEC affected infants as well as the changes that occur
following probiotic treatment remain unanswered and this is one
knowledge gap that lends itself to the utilization of modern DNA based
approaches. It is anticipated that in the future, in addition to assessing the
ability of different strains to prevent NEC, attention will also begin to focus
on unravelling the specific mechanism(s) via which probiotics can prevent
this disease.
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Some studies have also been carried out to investigate the potential
benefits of using probiotics to prevent or treat antibiotic associated
diarrhoea (AAD). The concept is that probiotics could temporarily colonize
the gut, to compensate for the collateral damage to the gut microbiota
resulting from antibiotic use, thus reducing the risk of diarrhoea due to
altered digestion and absorption. It is estimated that between 8 and 30%
of children suffer from AAD (Gooch, 1996, Hoberman et al., 1997). Two
systematic reviews on this topic concluded that when probiotics and
antibiotics were co-administered, AAD risk was reduced (Cremonini et al.,
2002, D'souza et al., 2002). However, these reviews were based mainly
on studies in adults. Cremonini and colleagues also highlighted the lack
of RCTs, especially with respect to infants and noted that generalisations
could not be made about probiotic effects, as different strains exerted
different effects (Cremonini et al., 2002). The studies which have taken
place which relate to children have provided conflicting outcomes. In
1990, a small study on children treated with L. acidophilus and
Lactobacillus helveticus (administered prophylactically as Lactinex) found
that they did not have a significant effect with respect to the prevention of
AAD (Tankanow et al., 1990). In contrast in 2004, ESPGHAN concluded
that there is promising evidence to suggest that some probiotics can
contribute to the prevention of AAD (Agostoni et al., 2004a). In a 2007
review, it was concluded that (based on 6 RCTs at the time), co-treatment
with probiotics did result in a reduced risk of AAD compared to those who
received antibiotics alone (28.5% to 11.9% reduction in risk) (Saavedra,
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2007). This meta-analysis found that the most significant beneficial
effects occurred when Lactobacillus GG, Saccharomyces boulardii and
Bifidobacterium lactis and Streptococcus thermophilus were
administered. They did not however, see any significant beneficial effect
from administering Lactobacillus acidophilus/Bifidobacterium infantis or L.
acidophilus/Lactobacillus bulgaricus. This again further emphasises the
species and strain specific effects of probiotics and the need for rigorous
testing of each proposed probiotic rather than making generalisations that
all probiotics are beneficial to health. A recent Cochrane review on this
topic, which also looked at the above mentioned species, again found
evidence of a protective effect from concomitant treatment with probiotics
during antibiotic therapy. However, once again the authors emphasised
the species and strain specific effects that occurred and the need for
further high quality studies on this topic before routine administration of
probiotics to infants/children could be recommended. Thus, there is still a
considerable gap in our knowledge in this area with respect to the specific
impact of probiotic administration on the composition of the gut microbiota
of infants in receipt of antibiotics. Further research is required to establish
if temporary colonization by probiotics occurs, to identify which microbial
populations are impacted on by antibiotic administration and probiotic
supplementation, to assess the duration of microbiota-related changes
and to definitively establish the merits of probiotic administration in such
circumstances. Finally, there is a strong need to carry out further studies
to assess the success with which probiotics can prevent C. difficile
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associated diarrhoea (CDAD) in infants and children. This was also the
conclusion of a meta-analysis on this topic (Segarra-Newnham, 2007).
1.9 Prebiotics
In 1995, Gibson and Roberfroid defined a prebiotic as “a non digestible
food ingredient that beneficially affects the host by selectively stimulating
the growth and/or activity of one or a limited number of bacteria in the
colon and thus improves health” (Gibson and Roberfroid, 1995). Based
on this definition a substance must escape digestion or degradation in the
stomach and small intestine and reach the colon intact, where it must
only act as a stimulant for the growth of beneficial bacteria, which must
then result in a measurable benefit to the host. The substances that have
received the greatest attention to date have been oligosaccharides.
Oligosaccharides are composed of repeating sugar units (2-20 units
generally) and they exist naturally in breastmilk at a level of 10-12g/l
(Veereman-Wauters, 2005). It is notable however that the human milk
oligosaccharides present in human breastmilk have yet to be produced
commercially, and instead it has been fructooligosaccharides (FOS) and
galactooligosaccharides (GOS) which have been the most studied as
potential prebiotics. In the past, lactulose was investigated with a view to
its use as a potential prebiotic, however such investigations have become
more limited due to associated laxative effects at high doses. Although
FOS and GOS are naturally present in foods such as bananas, celery,
chicory and artichoke (Manning and Gibson, 2004), the amount present is
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too small to be beneficial and thus there is considerable interest in
incorporating prebiotics into functional foods following their extraction
from plant sources or synthesis thereof (Playne and Crittenden, 1996).
This review will focus on the studies relating to the effect of prebiotics on
infant health, through modulation of their gut microbiota.
Oligosaccharides are unusual in that they consist of a β-glycosidic bond
which is resistant to degradation in the human GIT, due to a lack of
appropriate enzymes to digest this bond. They remain intact until they
reach the colon where they are fermented by a subset of bacteria which
are capable of degrading this bond. This fermentation results in short
chain fatty acids, primarily acetate, butyrate and propionate. On the basis
of culture-based studies, it has been known for quite some time now that
the gut microbes which benefit from supplementation with prebiotics,
such as bifidobacteria, proliferate at the expense of other gut microbes
including Bacteroides, clostridia or coliforms, thus resulting in what is
being suggested as being a more favourable gut microbial composition
(Wang and Gibson, 1993). Indeed, most research to date has focused on
the ability of prebiotics to increase bifidobacteria and, to a lesser extent,
lactobacilli numbers. However, it has been suggested that moving
forward the increase in the numbers of other bacteria such as Roseburia
and Eubacterium needs consideration also (Roberfroid et al., 2010).
Furthermore, as highlighted previously in this review, details on the actual
benefit to health from increased levels of specific populations of
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microorganisms are needed i.e. simply targeting an increase in the
numbers of specific microbes cannot be employed as a health claim.
Interest in prebiotics has increased as a consequence of evidence of
several potential benefits, including the possibility of decreased colon
cancer risk (Reddy, 1999), improved host resistance to pathogens,
improved calcium absorption, altered blood lipids and altered
immunological responses (Arslanoglu et al., 2007, Gibson et al., 2004),
the majority of which still require further testing before EFSA will fully
approve these claims. However extensive investigations have occurred
and have been of considerable value (Macfarlane et al., 2006). To date
GOS and FOS have been the most extensively studied as prebiotics for
supplementation to infant formula. ESPGHAN have concluded that the
inclusion of 0.8g/100ml of oligosaccharide (combination of 90%
oligogalactosyl-lactose and 10% high molecular weight oligofructosyl-
saccharose) in infant formulas poses no major risk to the infant (Agostoni
et al., 2004b). The review also showed evidence that 0.4g/dL, 0.8g/dL or
1g/dL mix of 90:10 GOS:FOS ratio brought about a significant increase in
faecal bifidobacteria levels. It appears that a combination of long chain
and short chain FOS/GOS and the ratio they appear in plays an important
role in the efficiency of the prebiotic and its ability to exert beneficial
effects. Extensive studies have repeatedly shown that prebiotics increase
bifidobacteria and lactobacilli levels (Ben et al., 2004, Waligora-Dupriet et
al., 2007) and examples of these studies will be described below. Before
proceeding, it should again be noted that lactobacilli and bifidobacteria
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constitute only a small proportion of the overall gut microbiota and future
studies will need to investigate the global impact of prebiotics on the
infant gut microbiota. Furthermore, as noted before, an increase in
bifidobacteria and lactobacilli levels is not regarded as a valid health
claim by EFSA.
In 2008, a review of studies investigating the impact of prebiotics on
infant health was completed (Boehm and Moro, 2008). The authors
highlighted the benefits of consuming human milk oligosaccharides
(HMOS) with respect to infant health. These included decreased
incidence of gastroenteritis and respiratory infections (Howie et al., 1990).
It was also noted that specific combinations of prebiotics, including short
chain (sc) GOS/ long chain (lc) FOS, increased bifidobacteria and
lactobacilli levels to the extent that, in some cases, levels of these genera
were comparable to those observed in the gut of breastfed infants
(Boehm et al., 2005, Haarman and Knol, 2005, Parracho et al., 2007,
Rinne et al., 2005, Salvini et al., 2011). This impact was apparent despite
the fact that these prebiotics had structures which differed from those of
HMOS. In one such study qPCR and FISH were used in combination to
identify and quantify the bifidobacteria in faecal samples from infants fed
GOS and FOS supplemented feeds (Haarman and Knol, 2005). This
study revealed significant increases in faecal bifidobacteria in treated
infants compared to controls and once again highlighted the ability of
prebiotic supplemented formula to mimic breastfeeding effects on the gut
microbiota, thus corroborating the results from earlier culture-based
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studies. As this review has shown, newer studies are now employing
culture-independent methods (e.g. FISH and qPCR in combination or
separately) to investigate more specifically the effects of prebiotics on the
gut microbiota of infants, which may lead to greater insights compared to
those provided by earlier culture-based approaches. There is also
however, an opportunity to use sequencing technologies to more
accurately assess the effects of prebiotics on the gut microbiota (and not
just the effects on bifidobacteria and lactobacilli levels).
1.10 Antibiotics
While probiotics and prebiotics can potentially modulate the infant’s gut
microbiota in a positive manner, antibiotics can exert a detrimental effect
on the infant’s commensal microbiota. The use of antibiotics has
increased dramatically and consequently the effects of specific antibiotics
on the gut microbiota of infants are a significant concern. A culture-based
study in 1970 was one of the first to examine the effects of various
antimicrobials on the gut microbial composition (Finegold, 1970). The
study suggested that the intestinal microbiota was altered to different
degrees depending on the spectrum of specificity of the antimicrobial
administered, the duration of treatment and the route of administration.
Interestingly in this early study, and also in some infant related studies
since, it has been shown that penicillin exerts a less significant effect (and
in some cases no significant effect) on the gut microbiota (Bennet et al.,
2002) relative to other antibiotics, once more stressing the need to
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investigate the effect of the different antimicrobials commonly prescribed
during childhood in turn in order to determine the specific impact that they
have on the gut microbiota. Since the initial Finegold et al. study
highlighted the effects of antibiotics on the gut microbiota, several other
culture-based studies have also supported these findings (Bennet et al.,
2002, Sakata et al., 1985). Following on from these culture-based
approaches, culture-independent approaches were completed and, in the
majority of cases, they corroborated the results of the earlier studies while
also providing an even greater insight (Mangin et al., 2010). In 2009, a
culture-independent study examining the effects of antibiotics on the
infant gut microbiota in the early postnatal period was published (Tanaka
et al., 2009). This study involved 26 infants, 5 of whom had been treated
with antibiotics. Faecal samples were analysed for the first 5 days of life
and then monthly for 2 months. The impact on the gut microbiota was
assessed using qPCR targeting the V1-V3 regions of the 16S rRNA gene.
The study found that antibiotic treated infants (treated with cefalexin
50mg/kg four times daily, for the first four days of life) had significantly
lower bifidobacteria until 1 month of age and had increased Enterococcus
levels compared to antibiotic free controls. The impact of antibiotic
administration on colonization patterns has also been the subject of
attention. In one instance this involved a study which focussed on an
infant in receipt of clavulanic acid and amoxicillin (Augmentin®) for 13
days, followed by trimethoprim and sulfamethoxazol (Bactrimel®) for 12
days (Favier et al., 2003). This study employed both culture-based and
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culture-independent techniques to examine the effects of antibiotics on
gut microbial composition. The antibiotic treated infant had an extremely
unstable microbiota up to the age of 1 month, with E. coli being dominant
in the early colonization period. However, the most significant difference
between the antibiotic treated infant and the controls was the apparent
absence of gut bifidobacteria. Indeed, up to 5 months of age no
bifidobacteria were detected, highlighting the prolonged effects of
antibiotic treatment on some commensal bacteria (Favier et al., 2003).
Following on from the previously outlined negative effect of antibiotic
treatment on bifidobacteria populations, another study in 2010 showed
that treatment of infants with parenteral antibiotics (a combination of
ampicillin and gentamicin), administered within 48 hours of birth, reduced,
but did not completely eliminate bifidobacteria, i.e. some bifidobacteria
such as B. bifidum survived antibiotic treatment (Hussey et al., 2011). At
8 weeks of age those who had been treated with antibiotics continued to
have a less diverse population of bifidobacteria relative to controls.
Recent reviews have indicated that the recovery of microorganisms after
antibiotic administration can be delayed (Jernberg et al., 2010) and that in
some cases some bacteria (namely Bacteroides) may not re-establish
(Penders et al., 2006). In a recent longitudinal study of 28,354 mother-
child pairs in the Danish national birth cohort it was found that antibiotics
administered in the first 6 months of life were positively associated with
an increased obesity risk in children of normal weight mothers by the time
the children reached age 7 (Ajslev et al., 2011). Thus, the changes to the
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infant’s gut microbiota in the initial months of life could predispose the
infant to chronic illness in later life.
The impact of administering antibiotics to expectant mothers with respect
to the gut microbiota and/or health of their infants has also been
investigated (J Drychowski et al., 2006). Furthermore, in 2002, McKeever
and colleagues examined the effect of maternal antibiotic use on the risk
of allergic disease in their infants (Mckeever et al., 2002). The study was
part of the general practice research database in the UK and included
24,690 children. The authors noted that 3 or more exposures to
antibiotics during pregnancy was associated with an increased hazard
ratio for asthma (1.36; 95% CI 1.16-1.60), eczema (1.19; 95% CI 1.02-
1.39) and hay fever (1.33; 95% CI 1.0-1.77) in the infant. The positive
association between antibiotic use in the first year of the child’s life and
subsequent asthma and allergy risk was also demonstrated in a 2009
study, when it was established among 193,412 children that such
antibiotic use was associated with an increased risk of asthma and
allergies at age 6 or 7 (Foliaki et al., 2009). Previous studies have also
supported this association between early life exposure to antibiotics and
increased asthma and allergy risk (Kozyrskyj et al., 2007, Marra et al.,
2009). Russell and Murch have also reviewed the impact of peripartum
antibiotics on the gut microbiota of infants and in turn, their health effects
and have suggested that administration of peripartum antibiotics could
alter the initial colonization of the infant gut, resulting in an alteration to
the GALT and a shift towards Th2 differentiation. Such a shift is known to
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result in an increased risk of atopy (Russell and Murch, 2006).
Furthermore, as highlighted previously in this review, changes to the gut
microbiota in early life could affect the regulation of the immune system,
which in turn could cause health effects. A complication in studying the
effects of antibiotics and atopic disease is called “reverse causation”. The
concept is that antibiotics may have preceded the atopic disease or may
have been prescribed in response to symptoms. Thus, it is difficult to
separate these to identify cause and effect.
While these studies demonstrate the negative effects of antibiotics on the
gut microbiota, there is considerable merit in carrying out further
investigations using the newer technologies available to us. Thus, by not
having to select for specific microorganisms, as is the case when culture-
or hybridisation-based approaches are employed, one could generate an
overall profile of the impact of antibiotics on infant gut microbiota. While
the studies to date are significant, and it is notable that a recent meta-
analysis of 18 studies also found a weak positive association between
antibiotic use in infancy and asthma and wheeze risk (OR 1.27 95% CI
1.12-1.43) (Penders et al., 2011), there are a number of other studies,
such as that by Celedon et al. (Celedon et al., 2004), that failed to reveal
the existence of an association. Similarly in 2007, the Koala Birth Cohort
Study of over 2,700 families, once more failed to demonstrate any
association between antibiotic use and eczema or asthma risk
(Kummeling et al., 2007). In contrast, the most recent publication on this
topic found that the limited diversity in the gut microbiota of infants arising
- 50 -
through antibiotic exposure before 1 month of age, was positively
associated with atopic eczema risk by the age of 2 years (Abrahamsson
et al., 2011). This again provides support for the theory that it may be
reductions in the diversity of the gut microbiota (rather than in any
particular species of bacteria) which results in an altered development
and regulation of the immune system and subsequently results in long-
term health consequences. Antibiotics by their very nature cause
alterations to the microbiota present in the individual. However, the extent
of the effects on beneficial microbiota, during and after the treatment
period, needs to be examined further. As a consequence of the research
on the concomitant use of probiotics and antibiotics and the observed
benefits (such as decreased antibiotic associated diarrhoea risk), the use
of specific probiotics in conjunction with antibiotics to benefit the host by
minimising the negative effects on gut microbiota composition, may
become even more prevalent in the future. New technologies such as
high-throughput sequencing will also improve our ability to more
accurately study the gut microbiota of antibiotic treated subjects in a less
biased manner, than culture-dependent techniques. In particular, the
impact of antibiotics on the GIT of preterm infants requires greater
attention. Knowing the impact of different antibiotics on fullterm and
preterm infant’s gut microbiota acquisition and development could lead to
the selection of particular antibiotics on the basis of their efficiency in
dealing with the illness, while having a minimal impact on the infant’s
microbiota.
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1.11 Conclusions
The infant’s gut microbiota undergoes rapid and radical changes during
the first 2 years of life. During this period, changes at both the phylum
and species levels occur. The changes which occur are determined by
the factors that have been outlined in this review. Some of the most
influential factors appear to be mode of delivery, feeding practices and
the use of probiotics and prebiotics to potentially modulate the infant gut
in what appears to be a positive manner (though there is a need for
further research to determine what constitutes a ‘normal healthy’ gut
microbiota). However, in contrast, antibiotics have clearly been shown to
have detrimental and often prolonged effects. Thus, the first 2 years of
the infant’s life may pose a unique window of opportunity, during which
time the gut microbial composition can be positively modulated through
diet and lifestyle factors. However, a number of questions remain. As
scientists we must question what is the ideal composition of the infant gut
microbiota? Do we know what core gut microbes will lead to the most
favourable health outcomes? Does the core gut microbiome depend on
the age of the infant (i.e. should we have milestones of colonization to
aim for), and should this change depending on other factors such as
ethnicity? Notably, breastmilk has been shown to be the optimum
nutrition source for infants, thus investigating the composition of the
breastfed infant’s gut microbiota at different time points may provide
targets to aim for. If we know the benefits of breastfeeding should we try
to prolong these effects and mimic them in the weaning period? While
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this review has outlined the significant advances in our understanding of
the acquisition and development of the infant gut microbiota, it is evident
that large knowledge gaps still exist. Most notably we still struggle to
define what constitutes a beneficial or normal gut microbiota. In the
future, additional research of the long-term impacts on health arising from
an altered infant gut microbiota and, of the duration of the effects of
different factors (such as breastfeeding or antibiotic use) on these
populations is needed. To date, high-throughput sequencing technologies
have been relatively under-utilized with respect to investigations of the
infant gut microbiota, despite their widespread use in other fields of
microbial ecology, or even the gut microbiota of adults. Where these
technologies have been utilized, in many cases the results correlate
closely with those from culture-based approaches, thus showing the
ability to corroborate and supplement the culture-based results with those
generated using newer technologies. Additionally, it is evident the
significantly more comprehensive insights that can be achieved by using
the new technologies available. Accordingly, it is anticipated that our
movement into the metagenomic era will provide us with detailed insights
into the gut microbiota of infants, and the factors which influence this
microbiota, in the very near future. The value of such research has the
potential to be immense.
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Table 1 Techniques used to investigate the human gut microbiota; advantages, disadvantages and examples of use
Microflora associated characteristics Culture-dependent techniques Culture-independent techniques High-throughput sequencing
Technique
description
The use of characteristics associated with
microbes e.g. SCFA production to identify
if differences exist in the gut microbial
populations between different subject
groups
Use of selective media to culture specific
microorganisms or species of
microorganisms e.g. Man Rogosa Sharpe
(MRS) media for lactobacilli growth
Identify bacteria through isolation and
amplification of bacterial DNA e.g. 16S
rRNA gene.
Includes: PCR, DGGE, TGGE, qPCR,
dot blot hybridization, FISH, flow
cytometry
Sequencing based approaches used to
rapidly identify bacteria using bacterial
DNA as template e.g. 454, Illumina,
SoLID, Ion torrent
History of use In the past has been predominantly used
as an initial population screen or in
epidemiological studies
Historically, the most frequently used
approach to identify bacteria present in
various environments
Increasingly popular in past 2 decades
with increasing availability of computer
based technologies and software
programs
Became commercially available at the
beginning of the 21st century and
becoming increasingly popular ever
since
Advantages  Simple
 Inexpensive
 Suitable as initial screen
to test a novel
hypothesis
 Useful for large
population screens e.g.
in epidemiology studies
 Quick
 Inexpensive
 Limited skill required
 Limited equipment
needed
 Useful as the initial
screen before more
detailed investigations
 Relatively inexpensive
 Relatively simple
 More detailed results
achievable
 Less biased results
 Very detailed
information
 Bacterial profile in
complex environments
e.g. gut microbiota can
be identified
 Huge phylogenetic
information provided
 Relatively quick
Disadvantages  Provides limited
information
 No bacterial species
identification possible
 Up to 90% of bacteria
non-culturable
 Provides limited
information
 Need prior knowledge of
bacteria to screen for
 Requires further tests for
species identification
 Prone to PCR bias
 Requires more
sophisticated
equipment and
training on their use
 May need several
methods in
combination to get
appropriate level of
details in results
 Extremely expensive
 Data handling
requirements are
significant
 Requires training on
sample preparation
and machine use and
experience of
interpreting results
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Examples of
studies using
this technique
References (Böttcher et al., 2000,
Cardona, 2002, Tjellström et al., 2007)
References (Bennet et al., 2002, Hascoët
et al., 2011)
Reference (Fallani et al., 2011) References (De Filippo et al., 2010,
Vaishampayan et al., 2010)
Future use
in infant gut
microbiota
research
Most likely to be used to test novel
hypotheses and to be followed up with
more detailed techniques
Likely to become infrequently used and to
be mainly used in combination with and
verified by newer technologies
Likely to remain popular in the coming
decade, but decrease thereafter as
increased availability and use of
sequencing approaches occurs
Increased use since 2000 as cost is
decreasing and likely to become the
main approach used in the future
- 76 -
Figure 1 Factors contributing to changes in gut microbiota composition in
the first 2 years of life
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Figure 2 Location, concentrations and functions of human gut microbiota
Chapter 2
High-throughput sequencing reveals the
incomplete, short-term, recovery of the infant gut
microbiota following parenteral antibiotic treatment
with ampicillin and gentamicin
Published in Antimicrobial Agents & Chemotherapy, Volume
56, Issue 11, November 2012, Pages 5811-5820
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2.1 Abstract
The infant gut microbiota undergoes dramatic changes during the first two
years of life. The acquisition and development of this population can be
influenced by numerous factors, with antibiotic treatment being suggested
as being among the most significant. Despite this, however, there have
been relatively few studies which have investigated the short-term
recovery of the infant gut microbiota following antibiotic treatment. The
aim of this study was to use high-throughput sequencing (employing both
16S rRNA and rpoB specific primers) and quantitative PCR to compare
the gut microbiota of 9 infants who underwent parenteral antibiotic
treatment with ampicillin and gentamicin (within 48 hours of birth), 4 and 8
weeks after the conclusion of treatment, relative to that of 9 matched
healthy controls. The investigation revealed that the gut microbiota of the
antibiotic-treated infants had significantly higher proportions of
Proteobacteria (p=0.0049) and significantly lower Actinobacteria
(p=0.00001), (and the associated genus Bifidobacterium (p=0.0132)) as
well as the genus Lactobacillus (p=0.0182) compared with the untreated
controls 4 weeks after the cessation of treatment. By week 8, the
Proteobacteria remained significantly higher in the treated infants
(p=0.0049) but the Actinobacteria, Bifidobacterium and Lactobacillus
levels had recovered and were similar to the control samples. Despite this
recovery in total Bifidobacterium numbers, rpoB-targeted pyrosequencing
revealed that the number of different Bifidobacterium species present in
the antibiotic-treated infants was reduced. It is thus apparent that the
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combined use of ampicillin and gentamicin in early life can have
significant effects on the evolution of the infant gut microbiota, the long-
term health implications of which remain unknown.
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2.2 Introduction
It is becoming increasingly evident that the composition of the human gut
microbiota can have a significant impact on health and disease (Sekirov
et al., 2010, Mai and Draganov, 2009, Turnbaugh and Gordon, 2009,
Zoetendal et al., 2008). Indeed, several studies have highlighted the role
gut microbes play in diverse and important functions in the body
including, for example, vitamin synthesis, immune system development
and toxin metabolism (Guarner and Malagelada, 2003, Fujimura et al.,
2010). Furthermore, there have been a number of studies which have
suggested associations between an altered gut microbial composition
and Crohn’s disease (Gophna et al., 2006), irritable bowel syndrome
(Kassinen et al., 2007), obesity (Ley, 2010, Murphy et al., 2010) and
other diseases/syndromes. These studies have highlighted the
importance of developing and maintaining a ‘healthy’ gut microbiota.
Indeed, it has recently been established that the fact that the immune
system of germ free mice is not exposed to commensal microbes in early
life can lead to increased numbers of invariant natural killer T cells, which
in turn caused inflammation on exposure to particular microbes, resulting
in an increased risk of both colitis and asthma (Olszak T, 2012). The
infant gut microbiota is established early in life such that, although the
infant gut is sterile in utero, by the time the infant reaches the age of two
years, this microbiota resembles that of an adult (Adlerberth and Wold,
2009). Consequently, this period of the infant’s life represents a unique
window of opportunity during which time the gut microbiota may be
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modified with implications for health outcomes (Penders et al., 2006). A
myriad of factors that affect this composition have been investigated and
include mode of delivery (Penders et al., 2006), feeding choice (i.e.
breast versus formula feeding) (Bezirtzoglou et al., 2011, Le Huërou-
Luron et al., 2010), prematurity (Schwiertz et al., 2003, Westerbeek et al.,
2006), and the administration of probiotics (Bourlioux et al., 2003,
Cremonini et al., 2002, Parracho et al., 2007, Sazawal et al., 2010) and
prebiotics (Boehm et al., 2005, Haarman and Knol, 2005, Sherman et al.,
2009). It is also thought that exposure to antibiotics can have a significant
negative influence on the composition and development of the gut
microbiota in early life (Bennet et al., 2002, Favier et al., 2003, Hussey et
al., 2011). Antibiotics by their very nature are designed to target and
inhibit microorganisms in a variety of ways. The majority of those used
clinically have a broad spectrum of activity and, as a consequence, in
addition to controlling pathogenic bacteria, have the potential to inflict
collateral damage on commensal gut bacteria (Blaser, 2011), including
genera that can often have health-promoting roles, such as the
bifidobacteria and lactobacilli. Thus far, the most in-depth investigations
into the nature and extent of this collateral damage have relied on the use
of denaturing gradient gel electrophoresis (DGGE) (Favier et al., 2003)
and have revealed that antibiotic exposure in infancy results in significant
decreases in bifidobacteria, lactobacilli and Bacteroides levels compared
to control infants.
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More recently, the impact of antibiotic administration on the gut
microbiota has been revealed in even greater depth as a consequence of
the use of high-throughput sequencing technologies in both animal and
human trials (Antonopoulos et al., 2009, Dethlefsen et al., 2008,
Dethlefsen and Relman, 2011, Murphy et al., 2010, Rea et al., 2011,
Suchodolski et al., 2009). These studies have shown that antibiotics can
dramatically alter the gut microbiota, with the effects depending on factors
such as the specific antibiotic administered, the spectrum of inhibition and
the duration of treatment (Sullivan et al., 2001). While antibiotic
administration in adults can have a number of gut microbiota-mediated
consequences, such as an increased susceptibility to Clostridium difficile
associated diarrhoea (Cramer et al., 2008) there is also evidence to
suggest that perturbation of the infant gut microbiota during its rapid
developmental phase can have even more significant consequences.
Indeed, for example, an association between antibiotic administration in
early life and an increased risk of asthma and allergies, such as atopic
eczema, in later life has been noted previously (Kozyrskyj et al., 2007,
Robinson and Young, 2010, Abrahamsson et al., 2011). Thus, developing
a detailed understanding of the impact of specific antibiotics on the infant
gut microbiota is vital in order to begin to understand the mechanism(s)
by which these changes could increase the risk of disease. It is thus
notable, that the impact of antibiotics on the composition of the infant gut
microbiota has yet to be assessed through high-throughput sequencing
technologies. Here we address this issue, by using 454-pyrosequencing
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technology together with quantitative PCR (qPCR), to reveal the short-
term (4-8 weeks) consequences of the treatment of infants with a
combination of ampicillin and gentamicin within the first 48 hours of birth.
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2.3 Materials and Methods
2.3.1 Participants
Approval for this trial was received from the Clinical Research Ethics
Committee of the Cork Teaching Hospitals, Cork, Ireland. Details on
inclusion criteria, sample collection and storage have been outlined
previously (Hussey et al., 2011). Briefly, 18 infants were recruited, 9 of
whom had received parenteral antibiotic treatment with a combination of
ampicillin and gentamicin within 48 hours of birth, and 9 untreated
controls. Exclusion criteria included premature birth, requiring oral
antibiotics, being on nil by mouth, infants who required surgery or those
with congenital abnormalities. Faecal samples were collected 4 and 8
weeks after the cessation of antibiotic treatment. Of the 18 infants, 8 had
been breastfed and 10 formula fed, while 13 were born vaginally and 5 by
Caesarean section (Table 1).
2.3.2 Generation of 16S rRNA amplicons for high-throughput
sequencing
The generation of 16S rRNA amplicons was performed as described
previously (Murphy et al., 2010). Total bacterial DNA was extracted from
the faecal samples using the QIAamp DNA Stool Mini Kit (Qiagen, West
Sussex, UK) (Hussey et al., 2011). DNA was frozen at -80°C prior to PCR
amplification. 16S rRNA bacterial gene amplicons (V4) were generated
with a view to high-throughput sequencing using the Roche Genome
Sequencer FLX platform. These amplicons, 239 nucleotides in length,
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were generated using one forward, i.e. F1 (5’ AYTGGGYDTAAAGNG),
and a combination of 4 reverse primers, R1 (5’
TACCRGGGTHTCTAATCC), R2 (5’ TACCAGAGTATCTAATTC), R3 (5’
CTACDSRGGTMTCTAATC) and R4 (5’ TACNVGGGTATCTAATC).
These primers also contained an A (F primer) or B (R primers) adapter
and different versions of the F primer (each containing a distinct multiple
identifier (MID)) were employed for each sample. PCRs were completed
on a G-storm PCR machine under the following conditions: heated lid
110°C, 94°C for 2 min followed by 35 cycles of 94°C for 1 min, 52°C for 1
min and 72°C for 1 min followed by a temperature step of 72°C for 2 min
and held at 4°C. PCRs had a final volume of 50µl made up of 25 µl of
Biomix Red (MyBio, Ireland), 1 µl forward primer (0.15µM), 1 µl reverse
primer (0.15µM) (mix of 4), template DNA and sterile PCR grade water.
All samples were completed in duplicate. PCR products were analysed by
agarose gel electrophoresis (1.5% in 1x TAE buffer). Following this, PCR
products were cleaned using Agentcourt AMPure kit (Beckman Coulter
Genomics, UK) as per manufacturer’s protocol. Samples were then
quantified using the Quant-iT Picogreen quantification kit (Biosciences,
Ireland) and the Nanodrop 3300 (Thermo Scientific, Ireland). Equimolar
solutions of samples were then pooled for sequencing. These pooled
samples were then cleaned and re-quantified (as before). Emulsion
based clonal amplification was completed as part of the 454-
pyrosequencing process. Sequencing took place at the Teagasc 454
Sequencing facility on a Genome Sequencer FLX platform (Roche
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Diagnostics Ltd, West Sussex, UK) according to the manufacturer’s
protocols.
2.3.3 Generation of Bifidobacterium-derived rpoB amplicons for
high-throughput sequencing
A set of PCR primers, which have been used previously to facilitate the
identification of bifidobacteria (Kim et al., 2010), and which amplify a 351
bp region from the Bifidobacterium RNA polymerase β-subunit gene,
rpoB, were also utilized in this study. Twelve week 4 and twelve week 8
samples were selected and amplified using these primers which had MID
tags and 454 adapters attached, allowing pooling of the samples for
sequencing while also enabling downstream separation of individual
results for analysis (Table S1). PCRs were completed on a G-storm PCR
machine under the following conditions: heated lid 110°C, 94°C for 2 min
followed by 35 cycles of 94°C for 1 min, 60°C for 1 min and 72°C for 1
min followed by a temperature step of 72°C for 2 min and held at 4°C.
PCRs had a final volume of 50µl containing 25 µl of Biomix Red (MyBio,
Ireland), 1 µl forward primer (0.15µM) (BC1 5’-
TCGATCGGGCACATACGG), 1 µl reverse primer (0.15µM) (Rev 1 5’-
CGACCACTTCGGCAACCG), template DNA and sterile PCR grade water.
All samples were completed in duplicate. All other steps for sequencing
(cleaning, quantifying, pooling etc.) were completed as outlined above.
2.3.4 Bioinformatic analysis
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Raw 16S rRNA sequencing reads were quality-trimmed using a locally
installed version of the Ribosomal Database Project (RDP)
Pyrosequencing Pipeline applying the criteria as previously described (O’
Sullivan et al., 2011). Trimmed FASTA sequences were then BLASTed
(Altschul et al., 1997) against a previously published 16S-specific
database (Urich et al., 2008) using default parameters. The BLAST
output was then parsed using MEGAN software (version 4.6) (Huson et
al., 2007), which assigns reads to NCBI taxonomies by employing the
Lowest Common Ancestor algorithm. Bit scores from within MEGAN were
used to filter the results prior to tree construction and summarization. A
bit-score of 86 was selected, as previously used for 16S ribosomal
sequence data (Urich et al., 2008). Phylum, family and genus counts for
each subject were extracted from MEGAN. Clustering and diversity
analysis of the sequence data was performed using the MOTHUR
software package (Schloss and Handelsman, 2008, Schloss et al., 2009).
For Bifidobacterium analysis, raw rpoB sequencing reads were quality
trimmed as above, with read-lengths for the rpoB amplicon above 300 bp
being used. Trimmed FASTA sequences were then BLASTed (Altschul et
al., 1997) against the NCBI non-redundant database using default
parameters. The resulting BLAST output was parsed through MEGAN
using default parameters (Huson et al., 2007).
2.3.5 qPCR-based determination of total bacteria and total
bifidobacteria numbers
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Absolute quantification of total bacterial numbers (from 8 representative
infants, infants B, F, G, H, K-N) and total bifidobacteria numbers (from 9
representative infants, infants B, F, G, H, K-O) was carried out by qPCR
using the Roche 480 Lightcycler platform. To determine total
bifidobacteria counts, the primers g-Bifid-F (5’-
CTCCTGGAAACGGGTGG) and g-Bifid-R (5’-
GGTGTTCTTCCCGATATCTACA) were used (Matsuki et al., 2004).
Bifidobacterium longum ATCC 8809 was used as a reference strain to
generate a standard curve for total bifidobacteria quantification (Echarri et
al., 2011). B. longum was grown overnight anaerobically at 37°C in
modified MRS broth (Difco) (0.05% cysteine) (Sigma Aldrich). Total
bacterial DNA was then isolated using High Pure PCR template
preparation kit (Roche Diagnostics, West Sussex, United Kingdom) as
per manufacturer’s instructions, and used to establish a standard curve
on the Lightcycler 480 platform (Roche Diagnostics, West Sussex, United
Kingdom). Total bifidobacteria numbers were quantified using the
following programme: 95°C for 5 min followed by 50 cycles of 95°C for
10s, 60°C for 20s and 72°C for 20s followed by melting curve analysis of
95°C for 5s, 65°C for 1 min and 97°C continuously, followed by cooling at
40°C for 10s. Reactions took place in a 20 µl volume made up of 3 µl
PCR grade water, 1 µl g-Bifid-F (0.15 µM), 1 µl g-Bifid-R (0.15 µM), 5 µl
DNA template and 10 µl SYBR green (Roche Diagnostics, West Sussex,
United Kingdom). To quantify total 16S rRNA bacterial counts, a standard
curve was established using copy numbers of 16S rRNA/µl from 109-102
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copies 16S rRNA/µl. Values were then converted to copies 16S rRNA/g
wet stool using a previously outlined calculation (Zhang et al., 2009). The
following programme was used to quantify total bacterial numbers: 95˚C
for 5 minutes followed by 35 cycles of 95˚C for 20s, 51˚C for 20s and
72˚C for 20s followed by melting curve analysis of 95˚C for 5s, 46˚C for 1
min and 97˚C continuously and a final cooling at 40˚C for 10s. Samples
contained 2 µl of PCR grade water, 1 µl of forward primer F1 (5’-
AYTGGGYDTAAAGNG) (0.15 µM), 1 µl of the reverse primer R1 (5’-
TACCRGGGTHTCTAATCC) (0.15 µM), 1 µl template DNA and 5 µl of
SYBR green (Roche Diagnostics, West Sussex United Kingdom), giving a
final reaction volume of 10 µl. Samples were run in quadruplicate, while
negative controls (where template DNA was replaced with PCR grade
water) and standards were run in triplicate.
2.3.6 Statistical Analysis
Minitab Release 15.1.1.0 (Minitab Inc. 2007) was used to perform non-
parametric statistical analysis (Mann Whitney test) when comparing 2
specific subject groups to determine the impact of antibiotic treatment on
the microbiota. Statistical significance was accepted at p<0.05.
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2.4 Results
2.4.1 High-throughput sequencing of 16S rRNA amplicons from the
faecal samples of antibiotic-treated and control infants
Eighteen infants, 9 of whom had been treated with a combination of
parenteral ampicillin and gentamicin within 48 hours of birth, and 9
controls who had received no antibiotic treatment, were recruited (Hussey
et al., 2011). Faecal samples were collected 4 and 8 weeks after the
cessation of antibiotic treatment and faecal DNA was extracted and used
as a template to generate 16S rRNA amplicons, with a view to
determining the composition of the gut microbiota through next
generation sequencing. Diversity, richness, coverage and evenness
estimations were calculated for all data sets (Table 2). The Chao 1
calculation is an estimator of phylotype richness in a dataset and the
Shannon index of diversity reflects both the richness and the community
evenness (i.e. proportional phylotype abundance). The diversity index
was above 3.6 in all samples, indicating an overall high level of
biodiversity (Table 2). The Good’s coverage, a measure of sampling
completeness, at the 97% similarity level ranged between 88.6-96.1% for
the datasets. The lowest value was obtained for the control samples at
week 8 and is a reflection of the more diverse nature of the microbiota
present (Table 2).
2.4.2 Composition of the gut microbiota of antibiotic-treated and
control infants 4 weeks after the conclusion of treatment
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Bioinformatic analysis of 16S rRNA sequence data revealed that there
were significant differences in the gut microbiota of antibiotic-treated
infants compared with untreated controls 4 weeks following the cessation
of antibiotic treatment. Statistically higher proportions of reads
corresponding to the phylum Proteobacteria were detected in the
antibiotic-treated samples compared with the control samples (p=0.0049)
(Figure 1). Indeed, the gut microbiota of the antibiotic-treated infants was
dominated by Proteobacteria, accounting for 54% of all bacteria present,
compared to just 37% in the untreated controls (Figure 1). While
Proteobacteria, Firmicutes and Actinobacteria were found in all antibiotic-
treated infants at week 4, Bacteroidetes were detected in less than half of
these infants and, in those where they were detected, levels were notably
low (Figure 1 & SI Figure 1). Actinobacteria were also significantly lower
in the antibiotic-treated samples than in the controls (3% vs. 24%;
p=0.00001).
At the family level, the antibiotic-treated samples had significantly higher
numbers of Enterobacteriaceae (55% vs. 37%; p=0.0073) and
Peptostreptococcaceae (23% vs. 2%; p=0.0381) compared to the control
infants at week 4 (Figure 2). Significantly lower numbers of
Bifidobacteriaceae (3% vs. 24%; p=0.0132) were also evident in the
antibiotic-treated samples at week 4. In addition antibiotic treatment also
resulted in significant differences at genus level relative to the controls at
this time (Figure 3). Significantly higher levels of Bifidobacterium (25% vs.
5%; p=0.0132) and Lactobacillus (4% vs. 1% p=0.0088) were present in
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the untreated controls compared to the antibiotic-treated infants.
Additionally, the gut microbiota of the antibiotic-treated infants displayed
limited diversity, as they were dominated by genera within the
Enterobacteriaceae family, with levels of these bacteria being statistically
significantly higher in the antibiotic-treated infants compared to the
controls (p=0.0073). This pattern was also apparent with respect to
proportions of the Firmicutes-associated genus Clostridium (p=0.0033).
Additionally, there was a significantly higher level of enterococci in the
treated infants compared to the controls at week 4 (p=0.0172). Despite
the fact that the diversity of antibiotic-treated and control samples did not
differ significantly (p=0.5752) (Table 2), the overall numbers of genera
detected in the antibiotic-treated samples was notably lower than in the
controls, reflecting the restriction in diversity and the dominance of the
members of the Proteobacteria and the persistent effects of antibiotic
treatment 4 weeks after administration ceased.
2.4.3 Composition of the gut microbiota of antibiotic-treated and
control infants 8 weeks after the conclusion of treatment
Bioinformatic analysis of the 16S rRNA sequence data revealed that, the
week 8 samples from the antibiotic-treated infants contained significantly
higher proportions of Proteobacteria (44%) compared to controls (23%)
(p=0.0049). Eight weeks after the cessation of antibiotic treatment
Proteobacteria continued to be the dominant phylum present in antibiotic-
treated infant samples despite the fact that the proportions of
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Proteobacteria reads decreased significantly between week 4 and week 8
(p=0.0136). During the same period the proportion of Actinobacteria
reads increased significantly (p=0.0055) in the antibiotic-treated infant
samples, to the extent that they no longer differed significantly from those
in the control samples (p=0.1164). Nonetheless, a more diverse gut
microbe population was observed in the controls relative to the antibiotic-
treated samples 8 weeks after antibiotic treatment (Shannon’s index for
diversity was 3.8 and 4.6 in the treated and control infants, respectively)
(Figure 1 & Table 2). Analysis of data from individual infants also
revealed that the recovery of the infant gut microbiota to one more
comparable to that of the controls was also dependent on the duration of
treatment (data not shown). For example, the gut microbiota of the infant
who underwent the longest antibiotic treatment period (infant A, treated
for 9 days) displayed the most limited recovery of all treated infants. This
infant’s gut microbiota was populated predominantly by Proteobacteria,
and this phylum remained dominant at week 8, at which time it accounted
for 67% of all of the bacteria detected (Figure S1).
At the family level at week 8, the Enterobacteriaceae remained dominant
in the antibiotic-treated infants (45%), despite having significantly
decreased in proportion relative to week 4 (p=0.0136) (Figure 2). During
the same interval, proportions of Enterobacteriaceae decreased in the
control infants (37% at week 4 vs. 24% at week 8). In the antibiotic-
treated group, there was also a significant decrease in levels of
Peptostreptococcaceae between week 4 and week 8 (p=0.0014) whereas
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a significant increase (p=0.0182) in the Bifidobacteriaceae levels
occurred during this 4 week interval, to the extent that the proportions of
this family in the antibiotic-treated and control samples no longer differed
significantly by week 8 (p=0.3927).
At genus level, the gut microbiota of the antibiotic-treated infants
remained predominantly populated with members of the
Enterobacteriaceae family, which accounted for half of all of the genera
detected at week 8. The numbers of these bacteria were significantly
higher in the antibiotic-treated infants than in the control samples at week
8 (p=0.0061). In contrast, Bifidobacterium numbers were similar in the
controls and antibiotic-treated samples at this time (19% vs. 15%,
p=0.3927). This was as a consequence of the fact that the proportions of
Bifidobacterium had increased significantly in the antibiotic-treated
samples during this 4 week interval (p=0.0182). Significant differences in
the levels of Lactobacillus no longer existed at week 8 between the 2
groups (p=0.3253) (Figure 3), due to a trend towards a significant
recovery in Lactobacillus proportions in the antibiotic-treated samples
(p=0.059) during this interval. In addition, Clostridium proportions
remained higher in the treated infants compared to the controls at week 8
(7% vs. 2%; p=0.0345), as a consequence of the fact that there was no
significant change in the levels of Clostridium in the antibiotic-treated
infants between weeks 4 and 8 (p=0.6132). By week 8 there was no
longer a significant difference in the proportions of enterococci seen in
the treated infants compared to the controls (p=0.1105).
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2.4.4 qPCR-based determination of total bacteria and total
bifidobacteria numbers
To determine the impact of antibiotic treatment on the total number of
bacteria and of bifidobacteria, absolute quantification was completed
using qPCR, with a representative subset of samples. The qPCR results
revealed that all infants, i.e. both treated and controls, had 107-108 copies
of the 16S rRNA gene/g wet stool (Table 3) and established that no
significant differences existed between total 16S rRNA gene copies
(which is representative of total bacteria numbers) when values for
antibiotic-treated infant samples were compared to those for controls at
week 4 (p=0.7667) or week 8 (p=0.7918). However, a statistically
significant increase in total 16S rRNA values did occur in the antibiotic
associated samples (p=0.0005) between weeks 4 and 8. With respect to
total bifidobacteria numbers, it was established that counts in both the
treated and control samples ranged from 106-107 CFU/g wet stool (Table
4). There was no significant difference in the average bifidobacteria
numbers of the antibiotic-treated infants relative to the controls at week 4
(p=0.4273) or at week 8 (p=0.1548). Furthermore, in the majority of
individual infants, the total bifidobacteria numbers did not differ
significantly between the two time points (Table 4).
2.4.5 Specific assessment of the composition of the gut
Bifidobacterium population in antibiotic-treated and control infants
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Given the health benefits that have been attributed to many strains of
Bifidobacterium, a strategy was implemented to specifically assess the
impact of antibiotic treatment on gut bifidobacteria. This again relied on
the use of high-throughput sequencing but in this instance focused on the
sequencing of amplicons corresponding to a region of the Bifidobacterium
sp. RNA polymerase β-subunit gene, rpoB, using a set of primers which
have been used previously for bifidobacterial species identification (Kim
et al., 2010) but, in this instance, contain adapters and MIDs to facilitate
the sequencing process. These primers demonstrated excellent
specificity with 99% of the reads at phylum level being assigned to the
Actinobacteria. The total number of reads for the antibiotic-treated infants
at week 4 was 80,034, averaging at 6670 reads per subject and for week
8 was 36,557, averaging at 3046 reads per subject. While the 16S rRNA
data presented above showed that antibiotic treatment decreased the
proportion of bifidobacteria present in the gut microbiota of infants, the
rpoB data provides further, more detailed insights. More specifically, this
analysis revealed that only 2 species were detected in the majority of
cases in the antibiotic-treated infants, namely B. longum and
Bifidobacterium breve. In contrast, the controls showed a more
considerable variation in the composition of individual samples, and even
between samples from the same individuals at different time points
(Figure 4).
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2.5 Discussion
Antibiotics are of fundamental importance to modern medicine and their
use has been pivotal to the prolongation of human life. Despite this, there
are ever increasing concerns with respect to the negative consequences
of antibiotic utilization, including issues revolving around the collateral
damage inflicted on the commensal microbiota and the implications
thereof (Blaser, 2011). Short-term health effects include antibiotic
associated diarrhoea, gastrointestinal discomfort, gastritis and glossitis
(Finegold, 1970) as well as the possible development of antibiotic
resistant bacteria populations in the gut (Jernberg et al., 2010).
Furthermore, it has been suggested that a number of long-term health
effects are influenced by the development of the gut microbiota
(Jakobsson et al., 2010) and, in turn, the immune system in early life (Hill
and Artis, 2009, Hill et al., 2010, Ivanov et al., 2008, Sekirov et al., 2010),
with data suggesting that antibiotic administration contributes to the risk
of developing asthma and allergy (Celedon et al., 2004, Foliaki et al.,
2009, Johnson et al., 2005) in addition to heightened risk of obesity
(Ajslev et al., 2011) later in life. The risks associated with disrupting the
gut microbiota may be especially great in young infants, as antibiotic
administration can impact on the commensal microbiota at a time when
this population is in rapid flux and can easily be unbalanced. Despite this
concern, there have been no studies to date which have used powerful
next generation sequencing technologies to assess the microbiota of
infants who have been administered antibiotics. This study was
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performed with a view to addressing this issue by employing 454-
pyrosequencing, together with qPCR analysis. The results of this
relatively small study are important and highlight the apparently major
impact that treatment with a combination of ampicillin and gentamicin can
have on the gut microbiota of infants. It is evident that the treated infants
suffered significant reductions in potentially beneficial bacteria belonging
to the phylum Actinobacteria, including Bifidobacterium, as well as some
members of the Firmicutes phylum, including Lactobacillus. These
appeared to be replaced by members of the Proteobacteria, including
members of the Enterobacteriaceae family, thereby resembling trends
previously noted in a terminal restriction fragment length polymorphism-
based study of antibiotic-treated infants (Tanaka et al., 2009). The
dominance of the Proteobacteria, and an overall reduced microbial
diversity, continued to be evident even 8 weeks after antibiotic treatment,
despite the fact that populations of potentially beneficial bacteria
(including Bifidobacterium) recovered somewhat. Given the fact that
sequencing data provides results revealing the proportions of different
populations present, rather than their absolute number, the question as to
whether the dominance of Proteobacteria is reflective of an outgrowth of
this population, or its numbers remaining stable among a total bacterial
population which is diminished in number, exists and some of the more
recent sequencing based studies have begun to address this issue
(Murphy et al., 2010, Rea et al., 2011). It is thus important that in this
instance qPCR data establishes that there is no significant difference
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between the total 16S rRNA counts in the treated infants compared to the
controls, thereby implying Proteobacteria outgrowth, presumably as a
consequence of reduced competition from other more antibiotic-sensitive
gut microbes. Others have also documented a corresponding
phenomenon of Proteobacteria outgrowth as a consequence of antibiotic
administration (Rea et al., 2011, Fallani et al., 2010, Murphy et al., 2010).
Notably, the frequency of β-lactam antibiotic resistance among
Enterobacteriaceae, as a consequence of the production of β-
lactamases, has been well established (Bush, 2010, Nordmann, 1998,
Penders et al., 2006, Qin et al., 2009). The presence of significantly
higher levels of enterococci in the antibiotic-treated samples 4 weeks
after treatment ended is also consistent with the fact that ampicillin
(Jureen et al., 2003, Weisser et al., 2012) and gentamicin (Donabedian et
al., 2003, Huycke et al., 1991) resistant Enterococcus have been
identified on numerous occasions. The ability of the administered
antibiotics, and especially ampicillin, to significantly alter the gut
microbiota is also reflective of their activity profile. Following parenteral
administration, ampicillin is rapidly and widely distributed throughout the
body resulting in high levels in bile (Acred et al., 1962) and, once
excreted, in the gut.
It was notable that while the 16S rRNA sequencing data and the total
bacteria qPCR data correlated well, the assessment of the impact of
antibiotic administration on relative or total bifidobacteria numbers, as
determined by sequencing and qPCR respectively, was not consistent.
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More specifically, qPCR analysis at week 4 revealed no significant
difference between total bifidobacteria values in the antibiotic-treated
infants compared to the controls, while the 16S sequencing data detected
significantly lower proportions in infants that had undergone antibiotic
treatment. These differences may be accounted for by the fact that only a
subset of the 18 infants were included in the rpoB-based qPCR analysis
and, as outlined earlier, individual variations occur in response to
antibiotic treatment. Furthermore, differences regarding primer specificity
between those used for qPCR and for total bacterial 16S rRNA
sequencing may also have contributed to this result.
The altered gut microbial composition of antibiotic-treated infants is a
concern given that several members of the Bifidobacterium and
Lactobacillus genera have been found to possess health-promoting
properties, to the extent that they are frequently employed as probiotic
cultures, whereas many Proteobacteria have the potential to become
pathogenic given a suitable environment. This study also demonstrated
that the collateral damage inflicted on the gut microbiota through the use
of broad spectrum antibiotics is not rapidly repaired, as significant
differences between the composition of antibiotic-treated and control
populations were apparent at 4 and 8 weeks post treatment. Previous
studies, employing temperature gradient gel electrophoresis or DGGE,
have also shown that antibiotic treatment causes short- to medium-term
effects, in some cases with no bifidobacteria being detected 28 days after
treatment ceased (Favier et al., 2003, De La Cochetiere et al., 2005).
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However, the fact that some recovery was evident in this and previous
trials (Hussey et al., 2011, De La Cochetiere et al., 2005) indicates that
the infant microbiota, despite being much less stable than that of an adult,
is somewhat resilient. Indeed, on average, bifidobacteria populations
recovered to the extent that both sequencing- and qPCR-based analysis
revealed that their levels were no longer significantly reduced in the
antibiotic-treated samples, relative to the controls, at week 8. Critically,
however, it was apparent that the composition of these Bifidobacterium
populations differed from one another. This is consistent with previous
studies highlighting the differing susceptibilities of species of
bifidobacteria to antibiotics (Fallani et al., 2010, Favier et al., 2003,
Mangin et al., 2010). More specifically, in agreement with previous
DGGE-based analysis (Hussey et al., 2011), B. longum was found to be
more dominant in samples from antibiotic-treated infants. This may be
due to the fact that while all bifidobacteria have previously been found to
display comparably high levels of sensitivity to gentamicin, strains of B.
longum have been found to be more ampicillin resistant than other
bifidobacteria (Mättö et al., 2007). The significant impact of antibiotic
administration on the Bifidobacterium population at the species level
suggests that many other species are similarly impacted upon by
antibiotic administration, something which warrants further investigation.
It is important to note that factors other than antibiotic administration may
also contribute to the differences in the gut microbial composition of the
cohort of infants that were the focus of this investigation. From this
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perspective, it is notable that the majority of antibiotic-treated infants were
delivered by Caesarean section, while the controls were all delivered
vaginally. This is particularly relevant as numerous studies have noted
the presence of an altered gut microbiota profile in Caesarean delivered
infants (Adlerberth and Wold, 2009, Dominguez-Bello et al., 2010, Fouhy
et al., 2012). Caesarean delivered infants have significantly altered
profiles compared to vaginally delivered infants, due to a lack of
colonization with their mother’s vaginal microbiota during delivery and are
instead colonized by skin microbiota (predominantly Staphylococcus and
Corynebacterium (Dominguez-Bello et al., 2010)). However, it has also
been previously demonstrated that while levels of Bifidobacterium were
significantly lower in Caesarean delivered infants compared to vaginally
delivered infants, Bifidobacterium levels were comparable by 1 month of
age (Grölund et al., 1999). This was not the case in our study, in that all
antibiotic-treated infants (regardless of delivery mode) had significantly
lower levels of Bifidobacterium at 1 month of age and, even at 2 months
of age, possessed a gut microbiota which was altered relative to the
control group. It is also worth noting that although our microbiota-related
data is presented as an average, we also possessed the microbiota-
related data (both high-throughput sequencing and qPCR derived) from
each infant. Analysis of this data failed to reveal significant differences
between the microbial populations of the vaginally delivered and
Caesarean delivered infants subgroups of the antibiotic treated infants
(data not shown). Thus, while we acknowledge that delivery mode may
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influence the microbial composition of the infants studied, it would seem
not to be as significant a factor as antibiotic administration.
Another factor that merits consideration relates to breastfeeding. While
there are a considerable numbers of publications regarding the benefits
of breastfeeding with respect to the development of the infant gut
microbiota (Bezirtzoglou et al., 2011, Penders et al., 2006), in this study
breastfeeding did not provide any additional protection to the infant gut
microbiota against the impact of antibiotic treatment. A failure to observe
protection could well be due to the relatively small subgroup of our infants
who were breastfed. Regardless, this is a topic which warrants further
investigation.
Regardless of the extent to which factors other than antibiotic
administration influence these results, there is a concern that these short-
term changes to the microbiota may in turn have long-term health
consequences in the form of allergies, asthma etc. later in life (Celedon et
al., 2004, Foliaki et al., 2009). While follow up analysis of these infants
was outside the scope of this short-term study, we hope to return to this
topic in future studies.
In conclusion, this study has shown the altered microbiota, over 8 weeks,
of a group of infants who were in receipt of parenteral antibiotic treatment
within the first 48 hours of life. To our knowledge, this is the first study to
use high-throughput sequencing of 16S rRNA and/or rpoB amplicons to
accurately assess these impacts. While the results may reflect a
combination of several environmental effects in early life, it would appear
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that antibiotic administration is the most influential factor. It would thus
seem that, where available, the use of narrow spectrum antibiotics
coupled with the use of pre and probiotics should be considered with a
view to minimizing the risk of long-term health effects. While it is evident
that the study of the composition of the infant gut microbiota and the
consequence of antibiotic treatment on this population requires further
investigation, it is anticipated that the further application of high-
throughput sequencing technologies (including those used in long-term
follow up trials) will shed additional light as to the optimal strategies to
employ to control infection, while minimising the risks to commensal
microbes.
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Table 1 Details of the infants in the trial
Infant Sex* Mode of delivery Feeding method Duration of
antibiotic
treatment
(days)
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
M
M
M
M
F
F
F
M
M
M
M
F
F
M
F
M
M
F
Caesarean section
Caesarean section
Caesarean section
Vaginal delivery
Caesarean section
Vaginal delivery
Vaginal delivery
Caesarean section
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Vaginal delivery
Breastfed
Breasfed+Formula
Breastfed
Formula
Formula
Breastfed
Breastfed
Formula
Formula
Formula
Formula
Formula
Formula
Breastfed
Breastfed
Breastfed
Formula
Formula
9
5
2
2
5
2
2
2
2
-
-
-
-
-
-
-
-
-
* M, male; F, female. Table adapted with permission from Hussey et al. 2011
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Table 2 Estimation of diversity within the treated and control groups at
week 4 and week 8
Data set Treated
week 4
Control
week 4
Treated
week 8
Control
week 8
Similarity
Chao 1 richness estimation
Shannon’s index for diversity
Good’s coverage
97%
243
3.6
96.1
97%
364
3.8
94.3
97%
334
3.8
93.2
97%
490
4.6
88.6
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Table 3 Total bacteria numbers given as copies of 16S rRNA/g wet stool
in treated and control samples at week 4 and week 8
P values based on Mann Whitney analysis, with statistical significance
determined as p< 0.05. P values are indicating if statistically significant
differences exist between total bacterial numbers in each infant between
week 4 and week 8.
Treated Wk 4 Wk 8 P Controls Wk 4 Wk 8 P
B
F
G
H
Average
9.79x107
5.89x107
3.28x107
3.52x107
4.78x107
6.57x107
3.53x108
7.79x107
6.43x108
2.48x108
0.7728
0.0809
0.0518
0.1489
0.0005
K
L
M
N
6.23x107
2.19x107
2.37x107
9.05x107
4.96x107
7.35x107
3.61x108
2.18x108
5.75x106
1.91x108
0.1489
0.0809
0.0518
0.0765
0.0289
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Table 4 Total bifidobacteria numbers as CFU/g infant stool in the treated
and control samples at week 4 and week 8
Treated Wk 4 Wk 8 P Controls Wk 4 Wk 8 P
B
F
G
H
Average
1.49x104
7.32x106
2.51x105
5.55x107
1.58x107
1.76x107
1.10x109
1.93x105
4.57x108
3.94x108
0.0814
0.0809
0.2472
0.0304
0.4273
K
L
M
N
O
6.62x107
7.95x106
1.48x106
4.75x106
5.05x107
2.62x107
5.98x105
5.11x104
2.39x108
5.47x106
1.14x108
7.18x107
0.0809
0.0809
0.0809
0.7728
0.0369
0.1548
P values based on Mann Whitney analysis, with statistical significance
determined as p< 0.05. P values are calculated with respect to
differences in total bifidobacteria numbers within individual infants
between week 4 and week 8.
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Figure 1 Microbial distributions at phylum level in the treated and control
samples at week 4 and week 8. Statistically significant differences between
treated samples and controls at week 4 are denoted by * (where p< 0.05).
Statistically significant differences between treated samples and controls at
week 8 are denoted by *. A statistically significant difference between treated
samples at week 4 and at week 8 (i.e. the recovery of the treated samples)
is denoted by ♦. Percentages are based on proportion of assignable tags.
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Figure 2 Microbial distributions at the family level in the treated and
control samples at week 4 and week 8. Statistically significant differences
between treated samples and controls at week 4 are denoted by * (where
p<0.05). Statistically significant differences between treated samples and
controls at week 8 are denoted by *. A statistically significant difference
between treated samples at week 4 and at week 8 (i.e. the recovery of
the treated samples) is denoted by ♦. Percentages are based on 
proportion of assignable reads.
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Figure 3 Microbial distributions at the genus level in the treated and control
samples at week 4 and week 8. Statistically significant differences between treated
samples and controls at week 4 are denoted by * (where p<0.05). Statistically
significant differences between treated samples and controls at week 8 are
denoted by *. A statistically significant difference between treated samples at week
4 and at week 8 (i.e. the recovery of the treated samples) is denoted by ♦. 
Percentages are based on proportion of assignable reads.
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Figure 4 Individual distributions of bifidobacteria in the treated (B1-H1; B2-H2) and
control samples (J1-R1; J2-R2) as detected using rpoB amplicons for 454-
pyrosequencing. Values show the percentage of the different bifidobacteria species
present in the individual samples. Treated samples show far less variability both
between treated samples and also between week 4 and week 8 compared to the
controls. X-axis indicates the individual infants; y-axis percentage of total bifidobacteria
assigned to each species.
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TABLE S1 rpoB primer sequences for 454-pyrosequencing of
bifidobacteria populations
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Figure S1 Distribution of microbiota at phylum level in the antibiotic-
treated (A1-I1) and control infants (J1-R1) at week 4 and week 8,
showing the limited number of phyla detected in the antibiotic-treated
infants compared to the controls and also showing the individual
variability that exists between samples, particularly in the controls.
Chapter 3
A degenerate PCR-based strategy as a means of
identifying homologues of aminoglycoside and β-
lactam resistance genes in the gut microbiota
Published in BMC Microbiology BMC Microbiology Feb 2014;
14 (25) doi:10.1186/1471-2180-14-25
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3.1 Abstract
The potential for the human gut microbiota to serve as a reservoir for
antibiotic resistance genes has been the subject of recent discussion.
However, this has yet to be investigated using a rapid PCR-based
approach. In light of this, here we aim to determine if degenerate PCR
primers can detect aminoglycoside and β-lactam resistance genes in the
gut microbiota of healthy adults, without the need for an initial culture-
based screen for resistant isolates. In doing so, we would determine if the
gut microbiota of healthy adults, lacking recent antibiotic exposure, is a
reservoir for resistance genes.
Degenerate PCR primers were used to detect and amplify
aminoglycoside and β-lactam resistance genes from human gut
microbiota samples. Cloning and Sanger sequencing of the PCR
amplicons was also conducted to assess levels of homology to known
resistance genes.
The strategy employed resulted in the identification of numerous
aminoglycoside (acetylation, adenylation and phosphorylation) and β-
lactam (including blaOXA, blaTEM, blaSHV and blaCTX-M) resistance gene
homologues. On the basis of homology, it would appear that these genes
originated from different bacterial taxa, with members of the
Enterobacteriaceae being a particularly rich source. The results
demonstrate that, even in the absence of recent antibiotic exposure, the
human gut microbiota is a considerable reservoir for antibiotic resistance
genes.
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This study has demonstrated that the gut can be a significant source of
aminoglycoside and β-lactam resistance genes, even in the absence of
recent antibiotic exposure. The results also demonstrate that PCR-based
approaches can be successfully applied to detect antibiotic resistance
genes in the human gut microbiota, without the need to isolate resistant
strains. This approach could also be used to rapidly screen other complex
environments for target genes.
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3.2 Introduction
Almost as soon as the widespread therapeutic use of antibiotics occurred,
bacteria displaying diverse and complex mechanisms of resistance
became problematic (Davies and Davies, 2010, Abraham and Chain,
1940). As the human gut is one of the most densely populated microbial
environments, it has been postulated that it can act as a considerable
reservoir for antibiotic resistance genes (Salyers et al., 2004). Thus, gut
microbes may disseminate antibiotic resistance genes to other
commensals or to bacteria transiently colonizing the gut (Broaders et al.,
2013). Given that antibiotics are known to exert significant and sustained
negative effects on the gut microbiota (Dethlefsen et al., 2008, Cotter et
al., 2012), possessing resistance genes can provide a significant
selective advantage to a subpopulation of microorganisms in individuals
undergoing antibiotic treatment (Sommer et al., 2009). The
aminoglycosides and β-lactams are two large families of antibiotics which
are frequently employed in clinical settings. The aminoglycosides, which
were first characterised in 1944, (Mingeot-Leclercq et al., 1999) function
by binding to the 30S subunit of the prokaryotic ribosome resulting in
disruption to protein synthesis. Resistance to aminoglycosides can be
through reduced aminoglycoside uptake or enzymatic modification of the
aminoglycoside through acetylation (AAC), adenylation (ANT) or
phosphorylation (APH). β-lactam antibiotics include the penicillins and
cephalosporins and inhibit bacteria through disruption of cell wall
biosynthesis (Page, 2012, Tipper and Strominger, 1965). Resistance to β-
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lactams can be due to alterations to penicillin binding proteins or to the
porins in the outer membrane (in Gram negative targets) or alternatively
through the production of β-lactamases, which hydrolyse the eponymous
β-lactam ring rendering the antibiotic inactive (Bush, 1989, Bush, 2010).
The question of the evolutionary origin of antibiotic resistance genes has
been the subject of much attention (Kotra and Mobashery, 1998, Page,
2012, Tipper, 1979). For quite some time it was thought that resistance
evolved following exposure of bacteria to new antibiotics (Hughes and
Datta, 1983). However, it is now apparent that repositories of antibiotic
resistance genes exist such that, following the development and
application of new antibiotics, bacteria possessing or acquiring such
genes will gain a selective advantage and thus resistance will increase
over time (Bhullar et al., 2012, D’costa et al., 2011). Previous studies
have employed PCR to detect resistance genes in specific pathogens
(Dallenne et al., 2010, Vannuffel et al., 1995), though studies employing
PCR to detect resistance genes in complex microbial environments have
been limited. In one instance, a PCR-based approach was used to
investigate the prevalence of gentamicin resistance genes in resistant
isolates from sewage, faeces (from cattle and chickens), municipal and
hospital sewage water and coastal water (Heuer et al., 2002). The
utilization of a PCR approach in that instance resulted in the identification
of diverse genes encoding gentamicin modifying enzymes from across a
broad host range, thus demonstrating the suitability of a PCR-based
approach to investigate resistance genes present in complex
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environments. However, the study did not investigate antibiotic resistance
genes in human gut microbiota and, to our knowledge, to date no such
PCR-based studies exist. Given these findings and other indications that
there exist large natural pools of antibiotic resistance genes within
complex microbial populations, it is likely that the human gut also
contains many such genes. However, until now, PCR-based strategies to
detect antibiotic resistance genes in the gut microbiota have involved an
initial culture-based screen for resistant isolates, followed by subsequent
PCR-based approaches to identify the associated resistance genes. This
does not take into consideration the fact that the vast majority of gut
microbes are not easily cultured (Eckburg et al., 2005), and thus antibiotic
resistance genes from such microorganisms would typically be
overlooked.
Here we utilize degenerate PCR primers to investigate the presence of β-
lactam resistance genes and each of the three categories of
aminoglycoside modifying enzymes within human metagenomic DNA and
in doing so demonstrate that the human gut microbiota is a reservoir for
antibiotic resistance genes. Additionally, we establish that a PCR-based
approach allows the rapid detection of such genes in the complex gut
microbiota environment, without the need for an initial isolation of strains.
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3.3 Materials and Methods
3.3.1 Recruitment of volunteers
Forty adults were recruited and each provided written, informed consent
for participation in this study. Approval for this trial was received from the
Clinical Research Ethics Committee of the Cork Teaching Hospitals,
Cork, Ireland. Volunteers were aged 28.8 ± 3.8 years, were free from
gastrointestinal disorders and had not been treated with antibiotics in the
6 months prior to sample collection. Fresh faecal samples were collected
and stored at -80°C until processed.
3.3.2 DNA Extraction
Stool samples were weighed, homogenised and due to the total volume
provided by each individual, samples had to be pooled to achieve the
required volume for our metagenomic DNA extraction protocol. To
facilitate this, an equal volume (250mg) from each individual was taken
and pooled to form one sample, from which metagenomic DNA was
extracted. The DNA extraction procedure used was optimised for total
bacterial genomic DNA extraction from stool samples. The stool sample
was homogenized in PBS and centrifuged at 1000g x 5 mins and the
supernatant was removed and retained. This was repeated 3 times. The
supernatant then underwent Nycodenz (Axis Shield, UK) density gradient
centrifugation separation, to separate out the bacterial cells from faecal
matter. Following enzymatic lysis of bacterial cells using lysozyme and
mutanolysin (Sigma Aldrich, Dublin, Ireland) protein precipitation using
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Proteinase K and ammonium acetate (Sigma Aldrich) was completed.
Bacterial DNA was then precipitated and washed using standard
chloroform and ethanol procedures. DNA was eluted in TE buffer.
3.3.3 PCR-based detection of β-lactam resistance gene homologues
PCR-based detection of β-lactam resistance genes was completed using
primers (MWG Eurofins, Germany) for the genes blaTEM (Bailey et al.,
2011, Tenover et al., 1994), blaSHV (Briñas et al., 2002) (both of which are
classified as Bush group 2b β-lactamases), blaCTX-M (Monstein et al.,
2009) (an extended spectrum β-lactamase (ESBL) which confers
resistance to cefotaxime), blaOXA (Briñas et al., 2002) (ESBL, Bush group
2d ESBL) and blaROB (Tenover et al., 1994) (confers high level ampicillin
resistance) (Table 1). PCRs were completed using bacterial
metagenomic DNA and all PCRs were performed in triplicate. PCRs were
completed on a G-storm PCR machine and for the primer sets blaTEM
primer set 1 (RH605/606), blaTEM primer set 2 and blaCTX-M, PCRs were
completed as previously outlined. For the primers blaOXA and blaROB the
PCR conditions were as follows: heated lid 110°C, 94°C x 5 mins
followed by 30 cycles of 94°C x 30s, 64°C x 30s (blaoxa) or 62°C (blaROB)
and 72°C x 30s followed by 72°C x 10 mins and held at 4°C. For blaSHV
PCRs were performed as follows: heated lid 110°C, 94°C x 5 mins
followed by 35 cycles of 94°C x 30s, 58°C x 30s and 72°C x 30s followed
by a final extension step of 72°C x 10 mins and held at 4°C. All PCRs
contained 25µl Biomix Red (Bioline, UK), 1 µl forward primer (10pmol
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concentration), 1 µl reverse primer (10pmol concentration), metagenomic
DNA (64ng) and PCR grade water (Bioline, UK), to a final volume of 50µl.
Negative controls were completed for all primer sets. Gel electrophoresis
was performed on all samples using 1.5% agarose gel in 1X TAE buffer.
3.3.4 PCR-based detection of aminoglycoside resistance gene
homologues
For the detection of aminoglycoside resistant genes, degenerate primer
sets were used which had previously been designed and shown to
amplify all known genes encoding gentamicin-modifying enzymes and
similar, but as yet undiscovered, sequences (Heuer et al., 2002). PCRs
were completed using primer sets (MWG Eurofins, Germany) for genes
belonging to each group of aminoglycoside modifying enzymes namely,
acetylation, adenylation and phosphorylation enzymes. DNA from positive
controls (kindly gifted to us from the Smalla laboratory, JKI,
Braunschweig) namely Escherichia coli S17-1 pAB2002 (aac(3)-Ia),
Pseudomonas aeruginosa 88.341F (aac(3)-Ib), Enterobacter aerogenes
17798 VDK (aac(3)-IIa), E. coli DH5α pSCH4203 (aac(3)-IIb), E. coli
DH5α pSCH4101 (aac(3)-VIa), P. aeruginosa PST-1 (aac(3)-IIIa),
Acinetobacter baumannii LBL.3 (aac(6’)-Ib), P. aeruginosa F-03 (aac(6’)-
IIa), E. coli DH5α pSCH5102 (aac(6’)-IIb), E. coli CV600 pIE723 (ant (2’’)-
I), E. coli DH5α pAM6306 (aph(2’’)-Ic) and E. coli NC95 (aph(2’’)-Id) were
used as positive controls for the PCR reactions. This ensured the
specificity of the respective primer pairs. PCRs for the detection of
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acetylation genes aac (3)-I, aac (3)-II, aac (3)-III, aac (3)-VI and aac (6),
adenylation genes ant (2”)-Ia and phosphorylation genes aph (2”)-Ic and
aph (2”)-Id were completed as previously outlined (Heuer et al., 2002)
(Table 1). Additionally, PCRs using primers for the bifunctional gene
aac(6’)-Ie-aph(2”) (De Fátima Silva Lopes et al., 2005, Schmitz et al.,
1999) (which encodes enzymes responsible for high level gentamicin
resistance, as well as concomitant resistance to tobramycin and
kanamycin) (Matsumura et al., 1984, Ubukata et al., 1984, Schmitz et al.,
1999, Hegstad et al., 2010, Ferretti et al., 1986) were completed as
follows: heated lid 110°C, 94°C x 5 mins followed by 30 cycles of 94°C x
30s, 47°C x 30s, 72°C x 30s, with a final extension step of 72°C x 10
mins and held at 4°C. All PCRs contained 25µl Biomix Red (Bioline, UK),
1 µl forward primer (10pmol concentration), 1 µl reverse primer (10pmol
concentration), metagenomic DNA (64ng) and PCR grade water (Bioline,
UK), to a final volume of 50µl. Negative controls were run for all primer
sets. All PCRs were performed in triplicate and analysed using gel
electrophoresis, as described above.
3.3.5 Cloning of PCR amplicons
Triplicate samples from successful PCR reactions were pooled and
cleaned using AMPure magnetic bead-based PCR clean up kit (Beckman
Coulter, UK). TOPO cloning reactions were performed on purified PCR
products using the TOPO TA cloning kit (Invitrogen, Dublin, Ireland) to
facilitate the sequencing of individual gene fragments. TOPO cloning
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reactions were then cloned into TOP10 E. coli (Invitrogen) as per the
manufacturer’s instructions and plated onto LB (Difco) containing the
appropriate antibiotic (either ampicillin 50µg/ml or kanamycin 50µg/ml;
Sigma Aldrich, Dublin, Ireland) to select for the presence of the cloning
vector. Transformants were selected from each TOPO cloning reaction
and grown overnight in LB broth containing the suitable selective
antibiotic (either ampicillin 50µg/ml or kanamycin 50µg/ml). Plasmids
were extracted from overnight samples using QIAprep Spin Mini Prep kit
(Qiagen, Sussex, UK) according to the manufacturer’s instructions and
sent for Sanger sequencing (Source BioSciences, Dublin, Ireland).
3.3.6 Bioinformatic analysis
Following Sanger sequencing, sequence reads were analysed using the
NCBI protein database (BlastX; (http://blast.ncbi.nlm.nih.gov/)). In the
event where multiple hits occurred, the BLAST hit which displayed
greatest homology is reported.
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3.4 Results and Discussion
3.4.1 A PCR-based approach highlights the presence of -lactamase
gene homologues in the gut microbiota
The results of the β-lactamase-specific PCRs demonstrated the presence
and diversity of class 2 β-lactamase genes in the gut microbiota of
healthy adults (Table 2 (Fouhy, 2013)). Of the β-lactam primers used, the
primers designed to amplify blaTEM genes yielded the greatest number of
unique sequence hits (42% of selected TOPO sub-clones gave a unique
hit). The majority of these genes exhibited a high percentage identity with
genes from various members of the Proteobacteria including E. coli,
Klebsiella, Salmonella, Serratia, Vibrio parahaemolyticus and Escherichia
vulneris. The resistance of strains of Salmonella and Serratia to β-
lactams via blaTEM genes has been noted (Morris et al., 2006, Perilli et al.,
1997, Zhao et al., 2007) and such strains have been associated with
nosocomial infections (Morosini et al., 1995). In contrast, there have been
relatively few studies of blaTEM genes in Vibrio parahaemolyticus and
Escherichia vulneris (Wong et al., 2012, Mokracka et al., 2012). The
identification of genes homologous to those from Enterobacteriaceae is
not surprising given the prevalence of resistance genes among members
of this family (Bush, 2010). It was notable that the blaTEM primers also
amplified genes that resembled blaTEM genes from some more unusual
sources, including two genes from uncultured bacteria and from a Sar 86
cluster (a divergent lineage of γ-Proteobacteria) bacteria. This approach
can thus provide an insight into possible novel/unusual sources of
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resistance genes, including those that culture-based approaches would
fail to detect. Such results also highlight that had initial screening for
resistant isolates been completed prior to PCR amplification of the
resistance genes, such unusual sources of resistance genes may have
been overlooked. Additionally, genes encoding ESBLs, including blaTEM-
116, blaTEM-195 and blaTEM-96 amongst others, were also identified, with their
closest homologues being members of the Proteobacteria (Table 2).
Using the blaSHV primers, multiple genes sharing homology with genes
from members of the Enterobacteriaceae, and Klebsiella and E. coli in
particular were detected. In addition, amplicons with low percentage
identity to genes from Alloprevotella rava and Parabacteroides johnsonii,
respectively, were also identified. This is again consistent with existing
research which states that Enterobacteriaceae are the primary source of
blaSHV genes (Coque et al., 2002, Paterson et al., 2003, Heritage et al.,
1999, Babini and Livermore, 2000, Pitout et al., 1997). Furthermore, the
amplicons sequenced resembled various different types of ESBL-
encoding SHV genes, including blaSHV-132, blaSHV-140 and blaSHV-48, thus
again highlighting the genuine degeneracy of the primers used.
Additional PCRs were completed to identify other ESBLs, specifically
CTX-M- and OXA-type β-lactamases (Table 2). A number of different
CTX-M β-lactamases were detected, including CTX-M-1, CTX-M-15 and
CTX-M-36. The fact that many of the β-lactamase genes detected using
our approach share homology with resistance genes found in members of
the phylum Proteobacteria is not surprising as, despite being typically
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less common than the Bacteroidetes or Firmicutes in the gut microbiota of
healthy adults (Eckburg et al., 2005), members of this genus have been
identified as sources of antibiotic resistance genes and have been
frequently associated with nosocomial infections and outbreaks (Coque et
al., 2002, Morosini et al., 1995, Bonnet, 2004, Pitout and Laupland,
2008). In the 1990s, TEM- and SHV-type ESBLs were the β-lactamases
most frequently observed among Enterobacteriaceae (Dallenne et al.,
2010). However, more recently, CTX-M-type ESBLs have spread rapidly
and are now the most prevalent ESBL in Enterobacteriaceae in several
parts of the world (Coque et al., 2008). In a recent report on antibiotic
resistance threats in the USA, the Centre for Disease Control stated that
ESBL-producing Enterobacteriaceae were a serious public health threat
(Cdc, 2013). The report estimates that 26,000 infections and 1,700
deaths that occur each year in the United States are attributable to
ESBLs and that upwards of 140,000 health-care related
Enterobacteriaceae infections occur annually. Therefore the detection of
homologues of ESBL-encoding genes in the gut microbiota of healthy
individuals is significant and provides evidence of the ubiquitous nature of
these resistance genes, even in the absence of recent antibiotic
exposure. With respect to the CTX-M-type ESBLs, it is particularly
notable that homologues of the blaCTX-M-15 gene were detected, as these
have received significant attention due to their recent rapid spread and
their association with multi-drug resistant E. coli responsible for outbreaks
of antibiotic resistant infections (Boyd et al., 2004, Lavollay et al., 2006).
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In such cases, these genes have been found on multi-drug resistance-
encoding regions of plasmids, thus facilitating the rapid transfer of these
genes. The presence of such genes within the gut microbiota raises
concerns that horizontal gene transfer may occur between commensals
or to bacteria passing through the gut. If the resistance genes detected in
our study are, or were to become, mobile, it would enable the gut to act
not only as a source of resistance genes, but also as a site of resistance
gene transfer. Although outside the scope of this study, studies
investigating whether these genes are located on or near mobile genetic
elements would be pertinent to ascertain the risk of the gut acting as a
site for horizontal gene transfer.
When the blaROB primer set was employed to detect the presence of
homologues of these ampicillin resistance-encoding genes, all amplicons
sequenced were identical and shared 44% identity to Staphylococcus
haemolyticus blaROB gene. Finally, this study did not detect blaOXA gene
homologues in our metagenomic sample. These findings are unexpected
and may have occurred as a result of the particular affinity of the primer
sets used.
3.4.2 A PCR-based approach highlights the presence of
aminoglycoside resistance encoding gene homologues in the gut
microbiota
Degenerate primers were selected that amplify genes encoding
aminoglycoside modifying enzymes from each of the enzyme modification
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groups, namely acetylation, adenylation and phosphorylation (Fouhy,
2013). When primers were applied to detect acetylation-associated
genes, it was established that the primers designed to target aac (3)-I,
aac (3)-II, and aac (3)-III homologues did not generate amplicons. In each
of these PCR reactions the positive controls successfully amplified, thus
we are satisfied that the lack of amplification products for our
metagenomic sample is a true result. However, a number of distinct aac
(6) and aac (3)-VI homologues were detected and were found to
resemble genes from a variety of genera, including Acinetobacter,
Pseudomonas and Enterobacter (Table 3). The presence of
aminoglycoside acetylation genes within these genera has been noted
previously (Cho et al., 2009, Lambert et al., 1994, Shaw et al., 1989, Park
et al., 2006). The detection of resistance genes resembling those seen in
A. baumannii is a concern, as many strains of this species have been
shown to exhibit multi-drug resistance (Dijkshoorn et al., 2007, Perez et
al., 2007). In addition, homologues of genes from Collinsella and
Salmonella were also detected. Primers designed to amplify bifunctional
aac(6’)-le-aph(2’’) genes were also employed. Our investigations
revealed the presence of homologues of such genes, resembling those
from S. aureus, E. faecium and S. epidermidis, all of which are known
sources of these genes (Vakulenko et al., 2003, Vanhoof et al., 1994,
Schmitz et al., 1999).
Homologues of aminoglycoside phosphorylation-encoding genes were
also detected using a PCR-based approach, with both aph (2”)-Ic and
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aph (2”)-Id like genes being detected. These genes shared homology with
genes from Enterococcus species, including E. faecium and E.
casseliflavus. Aminoglycoside resistant E. faecium have received
significant attention due to their role in nosocomial infections (Han et al.,
2011, Montecalvo et al., 1994). Notably, the role of mobile genetic
elements in the maintenance and dissemination of multi-drug resistance
in Enterococcus faecalis and E. faecium has previously been highlighted
(Hegstad et al., 2010, Leclercq, 1997, Mckay et al., 1994). While it is not
certain that the genes identified in this study are also associated with
mobile elements, the possibility that resistance genes could be
transferred to commensals is a concern. Homologues of aminoglycoside
adenylation genes, ant (2”)-Ia, were also successfully detected. These
resembled genes from Pasteurella, Acinetobacter and E. coli (Table 3),
and the findings are thus consistent with previous research showing that
these genes are most frequently detected in Gram negative bacteria
(Shaw et al., 1993). Overall, the results demonstrate that the gut
microbiota is a source of diverse aminoglycoside and β-lactam resistance
genes, despite having had no recent antibiotic exposure. If these genes
are expressed there is the potential that if antibiotic exposure occurred,
bacteria containing these resistance genes would become the dominant
component of the gut microbiota, as has been shown in previous studies
(Dethlefsen et al., 2008, Fouhy et al., 2012).
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3.5 Conclusions
This study has highlighted the merits of applying a PCR-based approach
to detect antibiotic resistance genes within the human gut microbiome.
The results clearly demonstrate that the human gut microbiota is a
considerable reservoir for resistance genes. Further studies are required
to determine the exact sources of these genes and to determine if they
have the potential to become mobile. Additionally, we have highlighted
the successful application of a PCR-based screen of a complex
environment without prior isolation of resistant isolates. The possibility
exists to couple this approach with lower throughput next-generation
sequencing strategies, such as that provided by the Ion PGM 314 chip, in
instances where great diversity is likely. Our approach could also be used
in conjunction with functional screening of metagenomic libraries to
enable the detection of genes present in a complex environment at a low
threshold and that may have avoided capture in the metagenomic library,
as shown in a recent study (De Vries et al., 2011). Such a PCR-based
approach is not being proposed as a substitute for ultra-deep high-
throughput shotgun sequencing of metagenomic DNA, rather it is a lower
cost, more targeted, alternative which facilitates the detection and in silico
analysis of specific gene sets of interest. Finally, while this study
demonstrates that the gut microbiota is a source of diverse resistance
genes, further studies are required to investigate the exact sources of
these genes, their expression and whether they have the potential to
become mobile. As the scientific community continues to gain knowledge
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with respect to the genetic mechanisms involved in providing resistance
to various antibiotics, the design of additional sets of degenerate primers
will be possible and will provide further opportunities for the use of PCR
to rapidly and efficiently detect antibiotic resistance genes in complex
microbial environments, including the human gut microbiota.
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Table 1 Primers used for the detection of β-lactamase and aminoglycoside resistant genes
Location Primer Sequence 5’-3’ Amplicon
Size (bp)
Tm
°C
Source
β-lactamase genes
BlaTEM
BlaROB
BlaSHV
BlaOXA
BlaCTX-M
AG resistant genes
aac (3)-I
aac (3)-II/VI
RH605
RH606
Bla_TEMF
Bla_TEMR
Bla_ROBF
Bla_ROBR
Bla_SHVF
Bla_SHVR
Bla_OXAF
Bla_OXAR
Bla_CTX-MF
Bla_CTX-MR
Faac3-1
Raac3-1
Faac3-2
Raac3-2
TTTCGTGTCGCCCTTATTCC
CCGGCTCCAGATTTATCAGC
TGGGTGCACGAGTGGGTTAC
TTATCCGCCTCCATCCAGTC
ATCAGCCACACAAGCCACCT
GTTTGCGATTTGGTATGCGA
CACTCAAGGATGTATTGTG
TTAGCGTTGCCAGTGCTCG
TTCAAGCCAAAGGCACGATAG
TCCGAGTTGACTGCCGGGTTG
CGTTGTAAAACGACGGCCAGTGAATGTG
CAGYACCAGTAARGTKATGGC
TGGGTRAARTARGTSACCAGAAYCAGCG
G
TTCATCGCGCTTGCTGCYTTYGA
GCCACTGCGGGATCGTCRCCRTA
GCGCACCCCGATGCMTCSATGG
GGCAACGGCCTCGGCGTARTGSA
692
526
692
885
702
600
239
189
60
57
62
58
64
55
58
58
Bailey et al.
(2011)
Tenover et al.
(1994)
Tenover et al.
(1994)
Briñas et al.
(2002)
Briñas et al.
(2002)
Monstein et al.
(2009)
Heuer et al.
(2002)
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AG: aminoglycoside
aac (6’)-II/Ib
ant (2”)-I
aph(2”)-I
aac(6’)-Ie-aph(2”)-Ia
Facc3-6
Raac3-6
Faac6
Raac6
Fant
Rant
Faphc
Faphd
Raph
aac-aphF
aac-aphR
aac6-aph2F
aac6-aph2R
GCCCATCCCGACGCATCSATGG
CGCCACCGCTTCGGCATARTGSA
CACAGTCGTACGTTGCKCTBGG
CCTGCCTTCTCGTAGCAKCGDAT
TGGGCGATCGATGCACGGCTRG
AAAGCGGCACGCAAGACCTCMAC
CCCAAGAGTCAACAAGGTGCAGA
GGCAATGACTGTATTGCATATGA
GAATCTCCAAAATCRATWATKCC
GAGCAATAAGGGCATACCAAAAATC
CCGTGCATTTGTCTTAAAAAACTGG
CCAAGAGCAATAAGGGCATACC
CACACTATCATAACCATCACCG
235
428
527
572
505
222
58
58
55
55
47
55
De Fatίma
Silva Lopes et
al. (2003)
Schmitz et al.
(1999)
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Table 2 Homologues of β-lactamase genes detected in the human gut
microbiota via PCR techniques
Accession # Gene description Closest homologue E
value
%
identity
BlaTEM
ADE18890.1
AAS46844.1
AEN02824.1
AEN02817.1
ACV88636.1
AEL87577.1
AEQ55231.1
ABQ14376.1
ADN79104.1
WP_010157942.1
ACI29961.1
AEQ39590.1
AAM22276.1
WP_019405145.1
AEW28787.1
ABY81267.1
AAF74292.1
AFU53026.1
ADE18896.1
AEN02826.1
BlaROB
YP_252228.1
BlaSHV
WP_009348253.1
WP_017896153.1
WP_008157744.1
β-lactamase TEM-1
β-lactamase TEM-1
β-lactamase TEM-1
β-lactamase TEM-1
β-lactamase TEM-1
ES β-lactamase TEM-116
β-lactamase TEM-1
β-lactamase
β-lactamase TEM
β-lactamase TEM
β-lactamase TEM-1
β-lactamase TEM-195
β-lactamase TEM-96
β-lactamase TEM
β-lactamase TEM-1
β-lactamase
ES β-lactamase
KPC-2 β lactamase
β-lactamase TEM-1
β-lactamase TEM-1
Hypothetical protein
SH0313
Hypothetical protein
HMPREF 9332
β-lactamase
Hypothetical protein
S. enterica subsp.
enterica
S. marcescens
K. pneumoniae
K. pneumoniae
E. coli
Vibrio
parahaemolyticus
E. coli
Uncultured soil
bacterium
Escherichia vulneris
Sar 86 cluster
bacterium
E. coli
E. coli
E. coli
K. pneumoniae
Uncultured bacterium
E. coli
E. coli
S. marcescens
Salmonella enterica
K. pneumoniae
S. haemolyticus
Alloprevotella rava
K. pneumoniae subsp.
pneumoniae
Parabacteroides
5e-154
2e-156
3e-111
1e-113
2e-151
5e-154
1e-35
6e-05
1e-15
9e-122
2e-153
5e-93
7e-139
4e-155
1e-133
4e-156
5e-155
2e-112
2e-113
4e-113
2e-33
3e-07
0.0
1.5
99
100
99
99
99
99
45
83
86
83
99
96
94
99
100
100
99
98
99
99
44
56
99
29
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ESBL: extended spectrum β-lactamase
CAJ47138.2
ADU15837.1
AEK80394.1
ABS72351.1
AAP03063.1
AEG79634.1
BlaCTX-M
ABG46354.1
AEZ49563.1
AEZ49551.1
ABG46356.1
ABW06480.1
AAB22638.1
BAD16611.1
YP_003717483.1
ABN09669.1
HMPREF 1077
β-lactamase
BlaSHV132
β-lactamase SHV140
β-lactamase SHV103
β-lactamase SHV48
ES β-lactamase SHV120
ES β-lactamase
β-lactamase CTX-M-1
β-lactamase CTX-M-1
ES β-lactamase
ES β lactamase CTX-M-15
β-lactamase penicillin
hydrolase
β-lactamase CTX-M-36
β-lactamase
β-lactamase CTX-M-61
johnsonii
K. pneumoniae
K. pneumoniae
K. pneumoniae
K. pneumoniae
K. pneumoniae
E. coli
E. coli
E. coli
K. pneumoniae
K. pneumoniae
K. pneumoniae
E. coli
E. coli
E. coli
S. enterica
0.0
0.0
0.0
0.0
0.0
0.0
3e-139
2e-138
1e-139
9e-139
6e-51
9e-140
8e-139
2e-139
2e-138
99
99
99
99
99
99
99
99
100
97
94
100
99
100
100
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Table 3 Homologues of aminoglycoside resistance genes detected in the
human gut microbiota via PCR techniques
Accession # Gene description Closest
homologue
E value % identity
aac (6)
AAA25680.1
WP_006234103.1
AAS45464.1
aac (6’)-Ie-aph (2”)
WP_002304968.1
WP_001028140.1
WP_001028143.1
WP_010729367.1
AAX82584.1
WP_002417297.1
AFR11868.1
AFM29914.1
aph (2”) Id
3SG8_A
3N4T_A
AAT77696.1
Aph (2”)-Ic
3TDVA
ant (2”) Ia
YP_005176240.1
WP_000314377.1
AG 6’-N-acetyltransferase
Hypothetical protein
Colaer00186
6’-N-acetyltransferase
Phosphotransferase
Acetyltransferase GNAT
Acetyltransferase GNAT
Bifunctional AAC/APH
partial sequence
Bifunctional AG modifying
enzyme
6’ AG acetyltransferase
Bifunctional AG 6’-N
acetytransferase/2’-AG
phosphotransferases
Gentamicin resistance
protein
Chain A crystal structure
AG 2’
phosphotransferases
Aph2’’ chain a
AG modifying enzyme
AG phosphotransferase
AG 2’-O-adenyltransferase
2’ AG
Pseudomonas
fluorescens
Collinsella
aerofaciens
A. baumannii
E. faecium
S. aureus
S. aureus
E. faecium
Enterococcus
faecalis
E. faecalis
S. epidermidis
Enterococcus
sp.
E.
casseliflavus
E.
casseliflavus
E. faecium
Enterococcus
gallinarum
Pasturella
mutocida
A. baumannii
4 e-48
0.0
3e-33
9e-108
1e-107
1e-107
5e-106
2e-112
3e-111
1e-43
7e-45
1e-110
2e-110
1e-68
2e-83
2e-97
3e-94
98
95
75
100
99
99
99
100
97
99
97
98
99
94
97
100
99
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AG: aminoglycoside
WP_000946493.1
ACJ47203.1
ACA48663.14
aac(3)-VI
AAA16194.1
WP_001642188.1
nucleotidlytransferase
2’ AG
AG adenyltransferase
AG adenyltransferase
aac 3-6
AG acetyltransferase
A. baumannii
E. coli
Morganella
morganii
Enterobacter
cloacae
S. enterica
subsp.
enterica
1e-94
6e-94
2e-96
2e-05
2e-20
99
99
99
77
98
Chapter 4
In silico assigned resistance genes confer
Bifidobacterium with partial resistance to
aminoglycosides but not to β-lactams
Published in PLoS ONE, Volume 8, Issue 12, doi:
10.1371/journal.pone.0082653, December, 2013
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4.1 Abstract
Bifidobacteria have received significant attention due to their contribution
to human gut health and the use of specific strains as probiotics. It is thus
not surprising that there has also been significant interest with respect to
their antibiotic resistance profile. Numerous culture-based studies have
demonstrated that bifidobacteria are resistant to the majority of
aminoglycosides, but are sensitive to β-lactams. However, limited
research exists with respect to the genetic basis for the resistance of
bifidobacteria to aminoglycosides. Here we performed an in-depth in
silico analysis of putative Bifidobacterium-encoded aminoglycoside
resistance proteins and β-lactamases and assess the contribution of
these proteins to antibiotic resistance.
The in silico-based screen detected putative aminoglycoside and β-
lactam resistance proteins across the Bifidobacterium genus. Laboratory-
based investigations of a number of representative bifidobacteria strains
confirmed that despite containing putative β-lactamases, these strains
were sensitive to β-lactams. In contrast, all strains were resistant to the
aminoglycosides tested. To assess the contribution of genes encoding
putative aminoglycoside resistance proteins in Bifidobacterium sp. two
genes, namely Bbr_0651 and Bbr_1586, were targeted for insertional
inactivation in B. breve UCC2003. As compared to the wild-type, the
UCC2003 insertion mutant strains exhibited decreased resistance to
gentamicin, kanamycin and streptomycin.
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This study highlights the associated risks of relying on the in silico
assignment of gene function. Although several putative β-lactam
resistance proteins are located in bifidobacteria, their presence does not
coincide with resistance to these antibiotics. In contrast however, this
approach has resulted in the identification of two loci that contribute to the
aminoglycoside resistance of B. breve UCC2003 and, potentially, many
other bifidobacteria.
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4.2 Introduction
Following the discovery of penicillin by Alexander Fleming (Fleming,
1979), exponential antibiotic discovery and development occurred which
revolutionized medicine. However, during this same period, target
bacteria developed sophisticated mechanisms of resistance against many
of the most commonly prescribed antibiotics (Davies and Davies, 2010). It
is thus not surprising that considerable efforts have been and are still
being made to investigate the genetic mechanisms involved in the
transfer, acquisition and expression of antibiotic resistance genes, in
order to curtail or prevent the further development of resistance (Bush,
2012, Walsh, 2000).
The mechanisms underlying resistance to aminoglycosides and to -
lactams are among those that have been the focus of particular attention.
Briefly, aminoglycosides are a family of broad spectrum antibiotics that
were first reported in 1944 (Mingeot-Leclercq et al., 1999), whose
bactericidal activity results from their binding to the 30S subunit of the
prokaryotic ribosome and the subsequent impairment of protein synthesis
(Jacoby and Gorini, 1967, Mingeot-Leclercq et al., 1999). Aminoglycoside
resistance can be mediated through reduced aminoglycoside uptake
(Davies and Wright, 1997), or through enzymatic modification of the
aminoglycoside through the activity of the N-acetyltransferases (AAC), O-
nucleotidyltransferases (ANT) or O-phosphotransferases (APH).
Aminoglycoside resistance genes have been classified based on the
enzymatic modification mechanism used by the resultant protein and the
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chemical position at which the aminoglycoside is modified (Shaw et al.,
1993).
β-lactam antibiotics are a class of broad spectrum antibiotics which
include the penicillins and cephalosporins (Kotra and Mobashery, 1998).
β-lactams inhibit bacteria by their interference with normal cell wall
synthesis, via disruption of the final cross-linking stage of cell wall
peptidoglycan formation, resulting in a significantly weakened cell wall
polymer, ultimately leading to bacterial cell death (Page, 2012, Tipper,
1979, Tipper and Strominger, 1965). β-lactam resistance can arise
through mutation of target penicillin binding proteins (PBPs;
(Georgopapadakou, 1993, Pitout et al., 1997)), as well as through the
production of β-lactamases (Abraham and Chain, 1940), which catalyze
the hydrolysis of the eponymous β-lactam rings present in β-lactam
antibiotics, rendering the antibiotic inactive. β-lactamase classification has
undergone significant rounds of change from the initial Ambler
classification proposed in 1973 (Richmond and Sykes, 1973) and the
classification schemes of Bush and colleagues (Ambler, 1980, Bush,
1989, Bush and Jacoby, 2010, Bush et al., 1995).
The antibiotic resistance genes of pathogenic bacteria have been the
focus of greatest attention. Similarly, antibiotic sensitivity is regarded as a
desirable trait among candidate probiotic strains for the feed
(Commission, 2008) and human (Huys et al., 2013, Vankerckhoven et al.,
2008) markets. Such a phenotype ensures that their consumption does
not further increase the risk of antibiotic resistance gene dissemination,
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especially in situations where such genes are located on mobile genetic
elements. Gut-associated bifidobacteria are generally viewed as
beneficial microbes and many strains have been attributed with health-
promoting characteristics (Chouraqui et al., 2004, He et al., 2007, Wang
et al., 2004, Xiao et al., 2003). Thus, it is not surprising that many
bifidobacteria are used, or have been studied with a view to their potential
use, as probiotics in functional foods (Kailasapathy and Chin, 2000). As a
consequence, there has been considerable interest in determining if
certain bifidobacteria possess antibiotic resistance genes (Kheadr et al.,
2004, Mayrhofer et al., 2011, Xiao et al., 2010, Sato and Iino, 2010).
These studies established that the tested bifidobacteria strains are
generally resistant to aminoglycoside antibiotics (Yazid et al., 2001), but
are sensitive to β-lactams (D'aimmo et al., 2007, Kheadr et al., 2004,
Vlková et al., 2006, Xiao et al., 2010). In a previous study, we found that
combined ampicillin and gentamicin treatment in infants, caused a
significant decrease in the proportion of bifidobacteria present 4 weeks
after antibiotic administration ceased, while also significantly altering the
bifidobacteria species present (Fouhy et al., 2012). We were therefore
interested in investigating differences in the distribution of genes
encoding β-lactam or aminoglycoside resistance proteins among
members of the Bifidobacterium genus.
To date little is known about the genetic mechanisms that underlie
aminoglycoside resistance in bifidobacteria. Despite the existence of
some specific studies (Kiwaki and Sato, 2009, Sato and Iino, 2010,
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Masco et al., 2006), the presence of antibiotic resistance genes has been
more frequently inferred through the annotation of DNA sequences and
the identification of genes bearing some homology to genes previously
assigned as being potential resistance determinants. Given the risks
associated with relying exclusively on rapid in silico assignments, here we
present an in-depth bioinformatic analysis of putative β-lactam and
aminoglycoside resistance proteins that are Bifidobacterium-encoded. We
have investigated if a correlation exists between these proteins and
antibiotic resistance and, in the case of aminoglycoside resistance, have
demonstrated the contribution of the assigned resistance genes to this
phenotype.
- 167 -
4.3 Materials and Methods
4.3.1 NCBI database search for Bifidobacterium-associated β-lactam
and aminoglycoside resistance proteins
Using the NCBI protein database, a search for putative β-lactamases and
aminoglycoside resistance proteins associated with bifidobacteria was
completed using the terms ‘beta-lactamase’ and ‘Bifidobacterium’
(searched on 28/8/12) and ‘aminoglycoside’ and ‘Bifidobacterium’ (search
completed on 29/8/12). This approach was taken so that all such
proteins, regardless of the basis upon which they were assigned, would
be revealed. Following the removal of duplicates and sequences that did
not originate from Bifidobacterium, all remaining sequences were used as
drivers for subsequent rounds of BLAST investigations. All subsequent
distinct sequences detected were employed for additional BLAST-based
investigations until a finalized list was achieved. Additionally, further
BLAST-based investigations using known -lactamase and
aminoglycoside resistance proteins as drivers were completed to ensure
no additional sequences were overlooked.
4.3.2 Classification of β-lactamases and aminoglycoside resistance
protein sequences from bifidobacteria
Putative Bifidobacterium-associated β-lactamase and aminoglycoside
resistance proteins were subjected to in silico analysis with a view to
classifying them using the Ambler method for β-lactamases (Ambler,
1980), or assigning them into one of the 3 main enzyme modification
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groups associated with aminoglycoside resistance (Shaw et al., 1993). To
this end, the putative Bifidobacterium-associated resistance determinants
were aligned (MegAlign Clustal W, LaserGene) against representative
sequences from each class (A-D for the β-lactamases) and from each of
the 3 enzyme groups (AAC, APH and ANT for the aminoglycosides)
(Bush and Jacoby, 2010, Bush et al., 1995) (Table 1).
4.3.3 Laboratory based assessments of antibiotic resistance
The antibiotic susceptibility of bifidobacteria strains was investigated in a
number of different ways. Disc diffusion assays were carried out
according to the British Society for Antimicrobial Chemotherapy (BSAC)
guidelines (Andrews, 2009, Andrews, 2001c, Andrews, 2001a). Briefly the
bifidobacteria strains were cultured overnight anaerobically and delivered
onto Iso-Sensitest agar plates (Oxoid, Fisher Scientific, Dublin, Ireland)
using a swab in three directions. Antimicrobial discs containing ampicillin
(25 µg), penicillin (10 µg) (VWR International, Dublin, Ireland), neomycin
(30 µg), gentamicin (200 µg), kanamycin (30 µg) and streptomycin (25
µg) (Fisher Scientific, Dublin, Ireland) were dispensed manually onto the
agar plates. Following anaerobic incubation at 37°C for 48 hours, the
diameters of the zones of inhibition (mm) were measured. All tests were
carried out in triplicate.
Minimum inhibitory concentration tests (MICs) using 4 aminoglycosides
i.e. neomycin, gentamicin, streptomycin and kanamycin (Sigma Aldrich,
Dublin, Ireland) were performed as per the micro-dilution method, as
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described in detail by others (Andrews, 2001b). Briefly, bifidobacteria
were grown overnight anaerobically at 37°C in MRS broth supplemented
with 0.05% cysteine (Sigma Aldrich, Wexford, Ireland). Cultures were
adjusted to an OD600 of 0.1 (≈ 1 x 105 cfu/ml) in fresh MRS broth (media
pH 6.8). Stock solutions of each of the aminoglycoside antibiotics were
prepared in sterile distilled water and a 2-fold dilution series was
performed. An inoculum of 100 µl of culture was added to each well of the
96 well plate (resulting in a final concentration of ≈ 5 x 104 cfu/ml)
(Sarstedt, Wexford, Ireland). Additionally, each 96 well plate contained
positive (MRS + culture) and negative controls (MRS only), and tests
were carried out in triplicate. Plates were incubated anaerobically (using
anaerobic gas jars and Anaerocult P anaerobic gas pack inserts (Merck
Millipore Ltd, Cork, Ireland)) at 37°C for 24 hours and the MIC was
determined as the lowest concentration of antimicrobial agent at which no
visible growth was recorded. MICs were also carried out on E. coli XL1-
blue which had been transformed with plasmid-encoded copies of the
putative aminoglycoside resistance genes Bbr_0651, Bbr_1586 and
Bbr_0651+0650. Protocols were as described above except that LB broth
(pH 7.1) (Difco, Fisher Scientific, Ireland) was used for culturing and
growth conditions were 24 hours aerobically at 37°C.
To test for β-lactamase activity, nitrocefin tests were performed as
previously described (Moubareck et al., 2005, Lee and Rosenblatt, 1983),
i.e. β-lactamase nitrocefin sticks (Fisher Scientific, Ireland), were dipped
into a single colony for each species being tested and assessed for 1-2
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minutes and again after 15 minutes for the appearance of a pink colour,
indicative of β-lactamase activity. Staphylococcus aureus DPC 5286 was
used as the positive control.
4.3.4 Disruption of the Bbr_0651 and Bbr_1586 genes from B. breve
UCC2003
Site specific homologous recombination was used to disrupt 2 genes
present in B. breve UCC2003, namely Bbr_0651 and Bbr_1586, using
protocols similar to those previously described (O' Connell Motherway et
al., 2009, Mazé et al., 2007). Briefly, internal fragments of Bbr_0651 and
Bbr_1586, were amplified by PCR using specifically designed primers
(MWG Eurofins, Germany) (Table S1), resulting in 500bp and 400bp
products respectively. These fragments were cloned into the pORI19
vector and a tetracycline resistance marker (tetW gene) from the pAM5
vector (Álvarez-Martín et al., 2007) was subcloned to generate the
plasmids pORI19-tet-0651 and pORI19-tet-1586 (Table 2). The correct
sequence of each cloned insert was verified by sequencing (Source
BioScience, Dublin, Ireland).
Being derivatives of pORI19 these plasmids cannot replicate in B. breve
UCC2003, due to a lack of a functional replication protein (Law et al.,
1995), and instead are utilized with a view to integrating into and
disrupting target genes. To facilitate methylation, the pORI19 plasmids
were introduced via electroporation into EC101 E. coli cells containing
pNZ-M.BbrII-M.BbrIII. The resulting methylated pORI19-tet-0651 and
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pORI19-tet-1586 constructs were electroporated into B. breve UCC2003.
Transformants were selected based on presence of tetracycline
resistance. Transformants were expected to carry Bbr_0651 or Bbr_1586
gene disruptions, respectively. To verify the suspected chromosomal
integration of these pORI19 constructs, colony PCRs were performed on
a selection of tetracycline resistant transformants, using a forward primer
upstream of the integration region and a reverse primer based on pORI19
(Table S1).
4.3.5 Complementation studies
DNA fragments containing the gene Bbr_1586 and its native promoter
region were generated by PCR amplification from B. breve UCC2003
chromosomal DNA, using Pfu Ultra II Hotstart Mastermix (Agilent
Technologies, Cork, Ireland) and sequence specific primers (Table S1).
The amplicons and the pBC1.2 plasmid were digested with HindIII and
XbaI (Roche Diagnostics, Sussex, UK) and subsequently ligated using T4
DNA ligase (Roche Diagnostics, Sussex, UK). This resulted in the
complementation plasmid pBC1.2-Bbr_1586 (Table 2). The dialysed
ligations were electroporated into E. coli XL1-blue and the resulting
plasmids verified by PCR and restriction digest analysis. Finally, the
plasmid pBC1.2-Bbr_1586 was electroporated into competent B. breve
UCC2003-1586-tet cells. Transformants from the complemented strain
were selected and the presence of the construct confirmed.
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4.3.6 Studies of wild-type B. breve UCC2003 with additional copies
of aminoglycoside resistance genes
Studies were also completed to investigate if the addition of extra
plasmid-encoded copies of the putative aminoglycoside resistance genes
Bbr_0651, Bbr_0651+0650 or Bbr_1586 would result in enhanced
resistance of the wild-type B. breve UCC2003. Competent B. breve
UCC2003 cells were prepared and transformed with the constructs
pBC1.2-0651, pBC1.2-0651+0650 or pBC1.2-1586. Transformants were
selected and the presence of the plasmid inserts was confirmed.
4.3.7 Heterologous expression of putative aminoglycoside
resistance genes in E. coli
Plasmid-encoded copies of the entire putative aminoglycoside resistance
genes Bbr_0651, Bbr_0651+0650 and Bbr_1586, along with their native
promoters were transformed via electroporation into competent E. coli
XL1-blue. Following confirmation of the presence of the correct plasmid
insert in the transformants, MIC assays were completed, using the
protocol outlined above.
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4.4 Results
4.4.1 Putative -lactamases associated with Bifidobacterium species
In order to identify Bifidobacterium-associated proteins which have been
annotated, or possibly mis-annotated, as β-lactamases, the NCBI protein
database was screened for Bifidobacterium-associated proteins which
had been annotated as -lactamases or which had been noted to contain
-lactamase associated motifs (searched on 28/8/12). The proteins
identified were in turn employed as drivers for BLAST analysis (of non-
redundant proteins), to identify and assess the distribution of related
Bifidobacterium-associated proteins. Subsequent rounds of BLAST
analysis, employing the related, yet distinct, protein sequences as drivers,
ultimately resulted in saturation. To ensure that other potential -
lactamases were not overlooked, further BLAST-based investigations,
using known -lactamase proteins as drivers, were also carried out to
screen all publically available Bifidobacterium genomes.
The resultant proteins fell into a number of different categories (Table 3).
The most common protein was that annotated variably as a metallo-beta-
lactamase family protein, a metal-dependent hydrolase or ribonuclease J
such as HMPREF0168_0178 from B. dentium ATCC 27679. This protein
is conserved, at high (>90%) percentage identity, across almost all
publically available Bifidobacterium genomes and is a member of the
protein family 07521 (Pfam07521; RNA-metabolising metallo-beta-
lactamases). A considerable number of other proteins are linked by virtue
of containing domains typical of Pfam13354 (a β-lactamase enzyme
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family of proteins). These proteins are not highly conserved, with distinct
subgroups such as those represented by HMPREF0168_1872 from B.
dentium ATCC 27679, BBB_1387 from B. bifidum BGN4, BBB_1559 from
B. bifidum BGN4 and Bbr_0236 from B. breve UCC2003, respectively,
being apparent. Other unique members of Pfam13354 are BIFADO_
0224 (B. adolescentis L2-32), BLJ0695 (B. longum subsp. longum JDM
301) and BAD_1308 (B. adolescentis ATCC 15703). B. dentium genomes
also share a conserved protein, representative of Pfam00144 (a β-
lactamase family), such as HMPREF0168_1378 from B. dentium ATCC
27679. B. catenulatum DSM 16992 (BIFCAT_01331) and B.
pseudocatenulatum DSM 20438 (BIFPSEUDO_02501) also contained
proteins from this family (PF00144) which were highly conserved (>90%
identity). However, these were distinct from other PF00144 family
proteins associated with B. dentium ATCC 27679. The remaining protein
of potential relevance is Blon_2358 from B. longum subsp. infantis ATCC
15697. This protein has been assigned as a -lactamase but, unlike the
other proteins referred to above, its closest homologues are not other
Bifidobacterium-associated proteins but, rather, are proteins that have
been found in the genomes of various clostridia, enterococci and
lactobacilli. In addition to containing domains corresponding to
Pfam07251, this protein is also representative of Pfam12706, i.e. the
lactamase_B_2 family of proteins.
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4.4.2 Putative aminoglycoside resistance proteins associated with
Bifidobacterium species
An identical approach to that taken for the β-lactamases, was taken to
identify Bifidobacterium-associated proteins which had been annotated,
or potentially mis-annotated, as aminoglycoside resistance proteins. A
search of the NCBI protein database using the terms ‘aminoglycoside’
and ‘Bifidobacterium’ was completed (search completed on 29/8/12). The
analysis revealed that putative aminoglycoside resistance proteins are
widely distributed across the Bifidobacterium genus, and are particularly
common among strains of B. longum (Table 4). Furthermore, it appears
that all putative Bifidobacterium-associated aminoglycoside resistance
proteins can be broadly classified into 3 groups i.e. those containing
proteins of the family Pfam01636 (phosphotransferase enzyme family),
proteins containing a protein kinase family domain, c109925, or those
which appear to contain both. While some of these proteins appeared to
be highly conserved within or across bifidobacteria strains and species,
some proteins appear to be much more distantly related. The results
indicated that only one putative protein was solely associated with the
protein family Pfam01636, namely BBMN_137 from B. longum BBMN68.
In a number of other instances proteins which were members of
Pfam01636 and which also contained the c109925 domain, were noted.
In some cases these proteins were annotated as aminoglycoside
phosphotransferases, e.g. BIF_01665 (B. animalis subsp. lactis Bb12),
while in other cases they were annotated as desulfatases, e.g. BL_1642
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(B. longum NCC 2705), or homoserine kinases, e.g. BBMN_1674 (B.
longum BBMN8). In addition, B. bifidum BGN4 BBB_0978 and B. bifidum
S17 BBIF_0997 also exhibit characteristics of Pfam01636 and possess a
protein kinase domain, but have been annotated as an N-acetyl
hexosamine kinase and a mucin desulfatase, respectively. In this
instance, laboratory-based investigations have previously established that
this gene does indeed encode N-acetyl hexosamine kinase (Nishimoto
and Kitaoka, 2007). Some sequences which were annotated as being
from Pfam01636 and also contained a protein kinase family domain were
highly conserved (with >90% percentage identity) e.g. BLD_1766 (B.
longum DJ010A) and BLIG_01601 from B. longum subsp. infantis CCUG
52486). However, in other instances, these proteins were more distantly
related e.g. BBIF_0997 (B. bifidum S17) and Bbr_1586 (B. breve
UCC2003).
Proteins containing a protein kinase family domain, c109925, only and
also annotated as aminoglycoside phosphotransferase or hypothetical
proteins are also widely distributed across Bifidobacterium species. Some
of these, such as BLD_0109 (B. longum DJ010A), Blon_0773 (B. longum
subsp. infantis ATCC 15697) and BLJ_1379 (B. longum subsp. longum
JDM301), are highly conserved while others, such as BLJ_1379 (B.
longum subsp. longum JDM301) and BIFANG_02451 (B. angulatum
DSM 20098), are more distantly related. Finally, 4 proteins (Bbr_0651,
BIFBRE_03589, CECT7263_10981 and HMPREF9228_1217) were
annotated as containing both a protein kinase family domain from
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c109925, while also containing a protein from the Pfam07462 (merozoite
surface proteins). These 4 proteins were very highly conserved within the
B. breve species sharing >99% percentage identity, while being more
distantly related to proteins from other Bifidobacterium species, e.g.
BIFANG_02451 from B. angulatum DSM 20098, which did not contain
any protein of the Pfam07462.
We also investigated if the β-lactamases and aminoglycoside resistant
protein sequences detected in bifidobacteria, could be classified
according to the Ambler classes A-D for β-lactamases and acetylation,
adenylation and phosphorylation enzymes for aminoglycosides. However,
due to insufficient similarity with the sequences of known β-lactamases
and aminoglycoside resistance proteins from other genera, such
classifications were not possible.
4.4.3 Laboratory-based assessment of the antibiotic resistance of
representative bifidobacterial strains
Laboratory tests were conducted with a number of representative
Bifidobacterium species to determine if the presence of putative antibiotic
resistance proteins corresponded to antibiotic resistance. The specific
strains used had been determined, on the basis of the in silico screen, to
contain putative β-lactam and/or aminoglycoside resistance genes. The
use of different species and strains enabled us to determine if the results
were genus, species or strain specific. The strains tested were B. breve
UCC2003, B. breve DSM 20213, B. gallicum DSM 20093, B. animalis
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subsp. lactis Bb12, B. angulatum DSM 20098 and B. pseudocatenulatum
DSM 20438 (Table 2). Disc diffusion assays were performed using both
aminoglycoside [kanamycin (30µg), gentamicin (200 µg), streptomycin
(25 µg) and neomycin (30 µg)] and β-lactam antibiotic discs [ampicillin
(25 µg) and penicillin (10 µg)]. Following anaerobic incubation at 37°C for
48 hours, zones of inhibition were measured (Table 5). All tests were
performed in triplicate. The results indicated that all strains tested were
highly sensitive to the -lactam antibiotics tested (all zones ≥ 52mm in
diameter), thus establishing that the annotated β-lactamase genes did not
confer resistance to the β-lactam antibiotics in the strains tested.
Additionally, the β-lactamase nitrocefin tests also demonstrated a lack of
β-lactamase activity among the bifidobacteria strains tested. In contrast,
when these strains were tested using aminoglycoside antibiotic discs,
each of the strains were shown to be highly resistant to each of the
antibiotics, i.e. zone of inhibition was small or absent (Table 5).
4.4.4 Disruption of the Bbr_0651 and Bbr_1586 genes of B. breve
UCC2003
An insertional inactivation approach was implemented to determine to
what extent putative aminoglycoside resistance genes contribute to the
observed aminoglycoside resistance in bifidobacteria. B. breve UCC2003
was selected as a target, due to the success with which gene disruptions
have been previously created in this strain (O' Connell Motherway et al.,
2011, O' Connell Motherway et al., 2013). The genes Bbr_0651 and
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Bbr_1586 were targeted for disruption. The gene Bbr_0651 encodes a
putative conserved hypothetical secreted protein which shares 99%
identity with other putative phosphotransferase enzymes (e.g.
BIFBRE_03589 from B. breve DSM 20213) and also shares 71% identity
with an aminoglycoside phosphotransferase from B. longum subsp.
longum ATCC 55813 (HMPREF0175_1250). The gene Bbr_1586
encodes a putative phosphotranferase family enzyme, which also shares
91% identity with a putative aminoglycoside phosphotransferase from B.
longum subsp. longum ATCC 55813 (HMPREF0175_1250).
To determine if disruptions to the genes Bbr_0651 and Bbr_1586 which
encode putative aminoglycoside resistance proteins impact on the
aminoglycoside resistant phenotype of B. breve UCC2003, disc diffusion
assays were carried out. Zones of inhibition were measured and
compared to the wild-type, B. breve UCC2003. Differences in the
inhibition zones were noted between the mutants and the wild-type,
suggesting reduced aminoglycoside resistance in the mutants as
compared to the wild-type B. breve UCC2003 (Table 5). Additionally,
MICs were performed to compare aminoglycoside resistance of the wild-
type to that of the two insertion mutants. As shown in Table 6, after 24
hours incubation, the insertion mutants were more sensitive to
gentamicin, streptomycin and kanamycin, but not neomycin, as compared
to the wild-type strain. These results thereby demonstrate that both
Bbr_0651 and Bbr_1586 contribute to aminoglycoside resistance and can
be assigned as aminoglycoside resistance determinants. To verify that
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the observed changes to phenotype were as a direct result of disruption
to the genes Bbr_0651 and Bbr_1586, rather than as an indirect
consequence of the mutagenesis strategy, MICs were conducted on
another insertion mutant created in B. breve UCC2003, namely B. breve
UCC2003-gosG (O' Connell Motherway et al., 2013). This mutant was
created previously using the same protocol that was used to create the
mutants Bbr_0651 and Bbr_1586, but in this instance the Bbr_0529
(gosG) gene is disrupted. The antibiotic resistance phenotype of this
mutant was similar to that of the wild-type B. breve UCC2003 (Table 6).
To further confirm that the observed reduction in aminoglycoside
resistance of the insertion mutant was as a direct result of disruption to
the putative AG resistance proteins, complementation studies were
performed with one of the mutants. The MIC results demonstrate that
following complementation, the resistance of the insertion mutant
Bbr_1586 was restored to levels almost identical to those of the wild-type
(Table 6). Additionally, MICs were determined upon addition of extra
plasmid-encoded copies of the putative aminoglycoside resistance genes
Bbr_0651, Bbr_0651+0650 or Bbr_1586 into wild-type B. breve UCC2003
to determine if enhanced resistance to aminoglycosides would occur
(Table 6). The results established that the addition of the construct
pBC1.2-Bbr_1586 resulted in a 2-fold increased resistance to both
streptomycin and kanamycin, relative to that of the parental strain. No
increase in resistance to either gentamicin or neomycin was observed.
Furthermore, the addition of either pBC1.2-Bbr_0651+0650 or pBC1.2-
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Bbr_0651 did not increase the resistance of UCC2003 to any of the
tested aminoglycosides. Finally, the introduction of Bbr_0651 or
Bbr_0651+0650 into E. coli XL1-blue resulted in a 2-fold increased
resistance to gentamicin and neomycin, while the introduction of
Bbr_1586 also increased resistance to neomycin by 2-fold, relative to the
control E. coli XL1-blue-pBC1.2 strain (Table 6).
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4.5 Discussion
The human microbiota contributes to numerous vital gut functions
including nutrient metabolism, vitamin biosynthesis and immune system
development (O' Hara and Shanahan, 2006). However, it has more
recently been postulated that this complex microbial population is also a
sizeable reservoir for antibiotic resistance genes (Salyers et al., 2004,
Sommer et al., 2009), and that microbes containing such genes can
become dominant in the human gastrointestinal tract following antibiotic
exposure (Fallani et al., 2010, Murphy et al., 2010, Fouhy et al., 2012).
There is also a risk that such genes could be transferred to other
microbes, including those passing through the gastrointestinal tract, and
thus could contribute to the dissemination of antibiotic resistance genes
(Salyers et al., 2004). Commensal bifidobacteria have received significant
attention as a consequence of frequent reports of the beneficial impact of
particular species or strains on health (Cani et al., 2007, He et al., 2007,
Mitsuoka, 1990), with only one species, B. dentium, being a known
human (cariogenic) pathogen (Ventura et al., 2009). Furthermore, given
the frequent use of Bifidobacterium strains as probiotics, any association
between these microbes and potentially transferrable antibiotic resistance
would be a cause for concern.
Several studies have utilized culture-based approaches to determine the
resistance or sensitivity of bifidobacteria to various families of antibiotics,
though the genetics underlying this resistance has not been examined
extensively (Kheadr et al., 2004, Moubareck et al., 2005, Vlková et al.,
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2006, Xiao et al., 2010). The exceptional studies that exist have focused
on mutations to genes encoding specific targets and the resulting
increased antibiotic resistance. In one instance the genetic basis for the
enhanced resistance of mutants of B. bifidum Yakult strain YIT4007 was
investigated (Sato and Iino, 2010). Briefly, YIT 4007 was isolated from the
progenitor strain YIT 4001 by screening mutants of YIT 4001 for
enhanced resistance to neomycin, erythromycin and streptomycin. To
investigate the potential transfer of resistance, genetic tests on the
mutants were also performed. The study identified several chromosomal
mutations, namely mutations on 3 copies of the 23S ribosomal RNA
genes, an 8bp deletion of the rluD gene and a mutation on the rspL gene,
which they considered to be responsible for the observed increased
resistance to aminoglycoside antibiotics, at levels at which the progenitor
strain was sensitive. As these mutations were not located on mobile
genetic elements, it was concluded that this strain posed no risk of
antibiotic resistance transfer. Another study investigated antibiotic
resistance levels in 26 B. breve strains and found that a Yakult probiotic
strain demonstrated atypically high resistance to streptomycin (Kiwaki
and Sato, 2009). Genetic analysis determined that a mutation to the rpsL
gene, which encodes the ribosomal protein S12, was responsible. In light
of the general rarity of studies investigating the genetic basis for innate
aminoglycoside resistance in bifidobacteria, this study examined the
contribution of in silico assigned aminoglycoside resistance proteins to
the resistance phenotype of bifidobacteria. Indeed, to our knowledge,
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ours is the first study that utilizes a targeted in silico based approach to
assess the existence and prevalence of putative β-lactamase and
aminoglycoside resistance proteins in the Bifidobacterium genus and to
subsequently investigate if representative genes confer a resistant
phenotype.
With respect to the putative β-lactamases, it was noted that several
proteins of potential relevance have been assigned across the
Bifidobacterium genus. However, none of these were clear
representatives of any of the Ambler classes of β-lactamases. When all of
the sequences were considered it appeared they could be grouped
broadly into one of three groups, i.e. those which were members of Pfam
00144, those of Pfam 07521 or Pfam 12706. Most frequently these
sequences were annotated as hypothetical proteins, while others were
annotated as β-lactamases. To detect such a high prevalence of putative
β-lactamases amongst bifidobacteria was surprising given that previous
laboratory based investigations have shown bifidobacteria to be sensitive
to commonly prescribed β-lactams (Kheadr et al., 2004, Vlková et al.,
2006, Xiao et al., 2010, Moubareck et al., 2005, Lim et al., 1993). Indeed,
for example, in 2010 Xiao et al. demonstrated that 23 investigated
bifidobacterial strains were sensitive to all β-lactams tested (Xiao et al.,
2010). In order to examine whether these annotated β-lactamase
sequences resulted in a resistance phenotype, we selected a
representative number of bifidobacteria strains, which had been identified
in the in silico screen as containing putative β-lactamases, and studied
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these further. Using a culture-based approach, the results indicated that
none of the representative bifidobacterial strains which were tested were
resistant to the β-lactam antibiotics. These results draw into question the
significance of the high frequency of putative β-lactamases or
hypothetical proteins closely related to β-lactamases in bifidobacteria
genomes. The fact that the tested bifidobacteria were sensitive to β-
lactam antibiotics and showed no β-lactamase activity (as assessed using
the nitrocefin test), despite the presence of annotated β-lactams in their
genome, as well as the lack of sequence homology when compared to
known β-lactamase sequences, led us to conclude that this is most likely
due to significant mis-annotation of protein sequences across publically
available Bifidobacterium genomes. Alternatively, it could be proposed
that these β-lactamase genes are repressed in bifidobacteria. While this
possibility could be assessed by expression-based studies, which may be
investigated in future studies, we think it more likely that the mis-
annotation of these putative resistance genes is the basis for the absence
of resistance. Indeed, there are previous examples of the mis-assignment
of genes as penicillin resistance genes, such as the mis-annotation of the
bile salt hydrolase genes as penicillin acylases (Jones et al., 2008,
Lambert et al., 2008). With the development of high-throughput genome
sequencing methods, automated approaches to annotation became
increasingly popular (Schnoes et al., 2009). However, this study provides
an example of how mis-annotation of the first bifidobacteria genomes has
led to further mis-annotation of subsequent genome sequences. Notably,
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several studies have investigated the extent of mis-annotation of
genomes and noted the frequency of this issue (Andorf et al., 2007,
Brenner, 1999, Devos and Valencia, 2001, Jones et al., 2007), with one
study finding an 8% error rate across just 340 genes (Brenner, 1999).
Such an approach, which is likely to continue as sequencing becomes
even more efficient and cost effective, and is coupled to automated
annotation, could cause undue concern about the safety of a species, for
example, in the case where antibiotic resistance protein sequences are
detected in a potential probiotic bacterium. Thus, our results highlight the
necessity for laboratory-based investigations into the function of
annotated proteins.
Various culture-based studies have demonstrated that bifidobacteria are
resistant to the aminoglycoside family of antibiotics (Kheadr et al., 2004,
Vlková et al., 2006, Xiao et al., 2010). This phenomenon was also
apparent in the representative strains employed for this study. This
resistance has been suggested to be due to the absence of appropriate
cytochrome-mediated transport systems in bifidobacteria for
aminoglycoside uptake (Bryan et al., 1979). This theory was first
proposed in 1979, when it was demonstrated that Bacteroides fragilis and
Clostridium perfringens were resistant to aminoglycoside antibiotics due
to an inability to synthesize cytochrome structures and thus cannot utilize
electron transport mediated transfer that is proposed to facilitate the entry
of aminoglycosides into the cells (Bryan et al., 1979). It has since been
accepted that bifidobacteria are intrinsically resistant to aminoglycoside
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antibiotics by the same mechanism (Talwalkar and Kailasapathy, 2004).
However, we hypothesized that the resistance proteins detected in our in
silico screen could be providing additional resistance beyond this intrinsic
resistance and thus could contribute to the survival of bifidobacteria at
higher concentrations of aminoglycosides.
The in silico screen highlighted the prevalence of putative aminoglycoside
resistance proteins across members of the Bifidobacterium genus.
Though a high frequency of aminoglycoside resistance proteins and
related hypothetical proteins were detected, the sequences could be
broadly categorised as those which were members of the Pfam 01636,
those containing a protein kinase family domain c109925 and those
which belonged to the Pfam 01636 and contained the domain c109925.
To investigate the hypothesis that these putative resistance proteins
contribute to aminoglycoside resistance in bifidobacteria, putative
aminoglycoside resistance genes from one strain were mutated. More
specifically, using B. breve UCC2003 as a representative strain, we
disrupted the 2 genes present in this strain, which were detected in the in
silico screen as being the genes potentially encoding aminoglycoside
resistance proteins. Following confirmation that successful homologous
recombination had occurred (at the targeted gene specific sites) within B.
breve UCC2003, aminoglycoside resistance of the respective mutants
was tested. These experiments demonstrated that disruption of either of
these 2 aminoglycoside resistance genes impacted on the resistance
phenotype of B. breve UCC2003 (Table 5). Thus, we propose that while
- 188 -
the lack of cytochrome-mediated transport of the aminoglycosides into
the cells may be an important contributor to the observed resistance
phenotype among bifidobacteria and alone are sufficient to result in the
strains being considered to be clinically resistant, these annotated
aminoglycoside resistance proteins are true aminoglycoside resistance
proteins, which further enhance this intrinsic resistance. To investigate
this hypothesis further, MICs were conducted to compare the resistance
of the mutants compared to the wild-type at higher levels of
aminoglycoside antibiotics. The results established that the mutants
exhibited greater sensitivities to gentamicin, streptomycin and kanamycin
compared to the wild-type strain (Table 6). Unfortunately, the strategy
employed precluded the creation of a double mutant that lacks both
Bbr_1586 and Bbr_0651. Should methods be developed to create
deletion mutants in Bifidobacterium in the future, such a mutant can be
created in order to determine if the inactivation of both aminoglycoside
resistance genes results in a more pronounced aminoglycoside sensitive
phenotype. Through complementation studies, it was demonstrated that
reintroduction of the Bbr_1586 gene restored resistance to gentamicin
and kanamycin to levels which were essentially identical to those of the
wild-type (Table 6). Additionally, when an extra, plasmid-borne copy of
the gene Bbr_1586 was added to wild-type B. breve UCC2003, a 2-fold
increased resistance was seen for streptomycin and kanamycin.
However, additional copies of Bbr_1586 did not enhance resistance of
the wild-type B. breve UCC2003 to neomycin and gentamicin. This may
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be due to the fact that the resistance of the wild-type to these antibiotics
was already high (Table 6), and thus the aminoglycoside resistance
proteins may have been saturated or unable to provide additional
resistance to such high levels of antibiotics. Moreover, when an additional
copy of either Bbr_0651+0650 or Bbr_0651 was added to the wild-type B.
breve UCC2003, no additional enhanced resistance occurred for any of
the aminoglycosides tested. This suggests that the genome-encoded
copy of this gene is already performing its function optimally. The results
in relation to Bbr_1586 and streptomycin resistance are puzzling in that,
while disruption to the putative aminoglycoside resistance genes resulted
in a reduction in streptomycin resistance and additional plasmid-encoded
copies of these genes increased the resistance to streptomycin compared
to wild-type levels, complementation failed to restore streptomycin levels
to those seen in the wild-type. One possible explanation is that there are
additional genes downstream of Bbr_1586, which contribute to
streptomycin resistance and are impacted upon in a polar manner
following mutagenesis by plasmid insertion. The role of Bbr_0651 and
Bbr_1586 as aminoglycoside resistance determinants was further
confirmed through the provision of enhanced protection against at least
one aminoglycoside upon their expression in E. coli XL1-blue.
Ultimately, it is evident that both Bbr_0651 and Bbr_1586 contribute to
aminoglycoside resistance in B. breve UCC2003. Importantly however,
given that these resistance genes are not located on or near mobile
genetic elements, they are unlikely to pose a risk of transferring antibiotic
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resistance to other bacteria populations. In fact it may be beneficial for
species of Bifidobacterium to possess such non-transferable
aminoglycoside resistance genes. Such species would survive higher
levels of aminoglycosides than species without this additional genetic
resistance, and so they may be more suitable as potential probiotics for
use during aminoglycoside therapy. The results of this study re-
emphasise the fact that annotation of genomes is a predictive process
and that the results generated must be interpreted cautiously.
Nonetheless, this approach did accurately predict the presence of
aminoglycoside resistance proteins in bifidobacterial genomes. Crucially,
laboratory based experiments were carried out to validate these
annotations and similar such laboratory experiments are required to
assess other putative antibiotic resistance genes in bifidobacteria and
other genera.
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Table 1 Representative sequences used as drivers for Blast based
investigations into Bifidobacterium-associated aminoglycoside resistant
proteins and β-lactamases
Aminoglycoside
resistance gene
classification
groups
Representative
sequences
β-
lactamase
gene
classes
Representative
gene name
Representative
gene accession
number
APH M20305 Class A TEM1 YP_209323.1
V00618 TEM1 AFN82055.1
M29953 SHV-2 YP_001966240.1
X07753 PSE YP_005086938.1
APH (6’) X05648 CepA YP_210868.1
X01702 Sme_1 CAA82281.1
AAC 3 X01385 Bla KPC YP_003754012.1
M55426 Class B IMP-1 YP_005980003.1
M22999 VIM-1 YP_003813035.1
AAC-Ia & Ib L06157 CcrA YP_004735262.1
AAC 6’ Ic M94066 L1 YP_006185056.1
ANT X02340 CphA YP_004391384.1
X04555 Sph1 YP_005188946.1
Class C AMP C AAG59351.1
Class D OXA-1 AFB82783.1
OXA-10 YP_001715358.1
OXA-23 YP_002317955.1
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Table 2 Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristics Ref or Source
E.coli strains
EC101 Cloning host, repA+ , kanr Law et al. (1995)
XL1-blue Tetr Stratagene
XL1-blue-pBC1.2-Bbr_0651 Heterologous expression of
Bbr_0651
This study
XL1-blue-pBC1.2-
Bbr_0651+0650
Heterologous expression of
Bbr_0651+0650
This study
XL1-blue-pBC1.2-Bbr_1586 Heterologous expression of
Bbr_1586
This study
B. breve strains
UCC2003 Isolated from nursing stool Mazé et al. (2007)
UCC2003-0651-tet pORI19-0651-tet insertion
mutant of B. breve
UCC2003
This study
UCC2003-1586-tet pORI19-1586-tet insertion
mutant of B. breve
UCC2003
This study
B. breve UCC2003-gosG pORI19-tet-Bbr_0529
insertion mutant of
UCC2003
O’ Connell Motherway et
al. (2013)
UCC2003-1586-tet-pBC1.2-
Bbr_1586
pORI19-1586-tet insertion
mutant complemented strain
of B. breve UCC2003
This study
UCC2003-pBC1.2-
Bbr_0651
pBC1.2-Bbr_0651 construct
in B. breve UCC2003
This study
UCC2003-pBC1.2-
Bbr_0651+0650
pBC1.2-Bbr_0651+0650
construct in B. breve
UCC2003
This study
UCC2003-pBC1.2-
Bbr_1586
pBC1.2-Bbr_1586 construct
in B. breve UCC2003
This study
UCC2003-pBC1.2 B. breve UCC2003
harbouring pBC1.2
This study
Bifidobacteria strains
B. gallicum DSM 20093 Contains putative β-
lactamase protein
Teagasc Culture
Collection
B. animalis subsp. lactis Contains putative β- Teagasc Culture
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Bb12 lactamase and AG
resistance proteins
Collection
B. angulatum DSM 20098 Contains putative β-
lactamase and AG
resistance proteins
Teagasc Culture
Collection
B. pseudocatenulatum DSM
20438
Contains putative β-
lactamase and AG
resistance proteins
Teagasc Culture
Collection
B. breve DSM 20213 Contains putative β-
lactamase and AG
resistance proteins
Teagasc Culture
Collection
B. breve UCC2003 Contains putative β-
lactamase and AG
resistance proteins
Teagasc Culture
Collection
Plasmids
pAM5 pBC1-puC19-Tcr Alvarez-Martín et al.
(2007)
pORI19 Emr, repA-, ori+, cloning
vector
Law et al. (1995)
pORI19-tet-0651 Internal 500bp fragments of
Bbr_0651 and tetW cloned
in pORI19
This study
pORI19-tet-1586 Internal 400bp fragments of
Bbr_1586 and tetW cloned
in pORI19
This study
pBC1.2 pBC1-pSC101-Cmr Alvarez-Martín et al.
(2007)
pBC1.2-0651 Bbr_0651 cloned in pBC1.2 This study
pBC1.2-0651+0650 Bbr_0651+Bbr_0650 cloned
in pBC1.2
This study
pBC1.2-1586 Bbr_1586 cloned in pBC1.2 This study
AG: aminoglycoside
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Table 3 Bifidobacterium derived β-lactamase protein sequences
Bifidobacterium
strain
Accession
number*
Gene name Assigned as Pfam
B. dentium ATCC
27679
ZP_07457312.1a HMPREF0168_1
872
Conserved
hypothetical
protein
PF13354
ZP_07456818.1b HMPREF0168_1
378
β-lactamase PF00144
ZP_07455619.1d HMPREF0168_0
178
Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. dentium Bd1 YP_003359579.1
a
BDP_0063 Hypothetical
protein
PF13354
YP_003360049.1
b
BDP_0556 Hypothetical
protein
PF00144
YP_003361167.1
d
BDP_1754 Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. dentium ATCC
27678
ZP_02917480.1a BIFDEN_00760 Hypothetical
protein
PF11354
ZP_02916953.1b BIFDEN_00213 Hypothetical
protein
PF00144
ZP_02918099.1d BIFDEN_01398 Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. gallicum DSM
20093
ZP_05965566.1d BIFGAL_03078 Metallo-beta-
lactamase
family protein
Metal
dependent
hydrolase
with
PF07521
B. adolescentis L2-
32
ZP_02027818.1 BIFADO_0224 Hypothetical
protein
PF13354
ZP_02029327.1d BIFADO_01784 Hypothetical
protein
PF07521
B. animalis subsp.
lactis Bb12
YP_005575727.1
d
BIF_01983 Hydrolase Metal
dependent
hydrolase
with
PF07521
B. animalis subsp.
animalis ATCC
25527
YP_006280466.1
d
BANAN_06475 Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
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B. animalis subsp.
lactis AD011
YP_002469408.1
d
BLA_0533 β-lactamase-
like protein
Metal
dependent
hydrolase
with
PF07521
B. bifidum BGN4 YP_006394858.1f BBB_1387 Penicillin
binding
protein
PF13354
YP_006395029.1
g
BBB_1559 β-lactamase PF13354
YP_006393888.1
d
BBB_0414 Ribo-
nuclease J
Metal
dependent
hydrolase
with
PF07521
B. bifidum NCIMB
41171
ZP_07803038.1g BBNG_01520 Conserved
hypothetical
protein
PF13354
ZP_07803204.1f BBNG_01686 β-lactamase PF13354
ZP_07801866.1d BBNG_00347 Conserved
hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. bifidum PRL
2010
YP_003971645.1
g
BBPR_1582 β-lactamase PF13354
YP_003971485.1f BBPR_1404 β-lactamase PF13354
YP_003970583.1
d
BBPR_0437 Metal-
dependent
hydrolase
Metal
dependent
hydrolase
with
PF07521
B. longum subsp.
longum JDM 301
YP_003660997.1 BLJ_0695 β-lactamase PF13354
B. adolescentis
ATCC 15703
YP_910171.1 BAD_1308 β-lactamase PF13354
YP_910159.1d BAD_1296 Hypothetical
protein
PF07521
B. breve UCC2003 ABE94945.1e Bbr_0236 Conserved
hypothetical
protein with
β-lactamase
motif
PF13354
ABE95207.1d Bbr_0510 Metal-
dependent
hydrolase
Metal
dependent
hydrolase
with
PF07521
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B. breve ACS 071
VSch8b
YP_005582166.1
e
HMPREF9228_0
250
Hypothetical
protein
PF13354
YP_005583195.1
d
HMPREF9228_1
387
Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. breve DSM
20213
ZP_06595304.1e BIFBRE_03112 Putative β-
lactamase
PF13354
ZP_06595596.1d BIFBRE_03411 Metallo-beta-
lactamase
family protein
Metal
dependent
hydrolase
with
PF07521
B. breve CECT
7263
EHS86772.1e CECT7263_1096
8
Putative β-
lactamase
PF13354
EHS85412.1d CECT7263_1198
1
Metallo-beta-
lactamase
family protein
Metal
dependent
hydrolase
with
PF07521
B. catenulatum
DSM 16992
ZP_03324536.1c BIFCAT_01331 Hypothetical
protein
PF00144
ZP_03324350.1d BIFCAT_01138 Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. bifidum S17 YP_003939138.1f BBIF_1359 β-lactamase PF13354
YP_003938240.1
d
BBIF_0461 Metallo-beta-
lactamase
domain-
containing
protein
Metal
dependent
hydrolase
with
PF07521
YP_003939303.1
g
BBFI_1524 β-lactamase PF13354
B.
pseudocatenulatum
DSM 20438
ZP_03741949.1c BIFPSEUDO_02
501
Hypothetical
protein
PF00144
ZP_03742801.1d BIFPSEUDO_03
375
Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. longum
NCC2705
NP696361.1d BL_1192 Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. longum subsp.
infantis ATCC
55813
ZP_03976420.1d HMPREF0175_0
795
Metal
dependent
hydrolase
Metal
dependent
hydrolase
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with
PF07521
B. longum BBMN68 YP_004000557.1
d
BBMN68_955 Hydrolase Metal
dependent
hydrolase
with
PF07521
B. longum DJ010A YP_001954894.1
d
BLD_0950 Metallo-beta-
lactamase
superfamily
Metal
dependent
hydrolase
with
PF07521
hydrolase
B. longum subsp.
longum JCM 1217
YP_004220181.1
d
BLLJ_0420 Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. longum subsp.
longum JDM301
YP_00366798.1d BLJ_0491 β-lactamase
domain-
containing
protein
Metal
dependent
hydrolase
with
PF07521
B. longum subsp.
infantis ATCC
15697
YP_005585858.1
d
BLIJ_2111 Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
YP_002323794.1 BLon_2358 β-lactamase PF12706
and 07521
B. animalis subsp.
lactis HN019
ZP_02963481.1d BIFLAC_07662 Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
B. gallicum DSM
20093
ZP_05965566.1d BIFGAL_03078 Metallo-beta-
lactamase
family protein
Metal
dependent
hydrolase
with
PF07521
B. angulatum DSM
20098
ZP_04447555.1d BIFANG_02533 Hypothetical
protein
Metal
dependent
hydrolase
with
PF07521
* Same superscript indicates proteins share >90% sequence percentage identity
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Table 4 Bifidobacterium derived aminoglycoside resistance proteins
Bifidobacterium
strain
Accession
number*
Gene name Assigned as Pfam
B. longum DJ010A YP_00195405.
3a
BLD_0109 AG phospho-
transferase
Proteins containing a
protein kinase family
domain, c109925
ZP_00121257.
2a
Blon_0300115
4
Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
ZP_00121797.
2b
BLD_1766 Hypothetical
protein
Phosphotransferase
family with PF 01636
and proteins
containing a protein
kinase family
domain, c109925
B. longum BBMN68 YP_00399975
1.1a
BBMN68_137 AG phospho-
transferases
Phosphotransferase
family with PF 01636
YP_00400127
2.1b
BBMN_1674 Homoserine
kinase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. longum subsp.
infantis CCUG
52486
ZP_04663835.
1a
BLIG_01916 Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
ZP_04664566.
1b
BLIG_01601 Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. longum NCC
2705
NP695320.1a BL_0091 Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
NP696793.1b BL_1642 Desulfatase Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. longum KACC
91563
YP_00558689
3.1a
BLNIAS_
00852
Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
B. adolescentis L2-
32
ZP_02029839.
1i
BIFADO_0230
0
Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
B. longum subsp.
infantis ATCC
55813
ZP_03976875.
1a
HMPREF0175
_1250
AG phospho-
transferase
Proteins containing a
protein kinase family
domain, c109925
B. longum subsp.
infantis ATCC
15697
YP_00232225
4.1a
Blon_0773 AG phospho-
transferase
Proteins containing a
protein kinase family
domain, c109925
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YP_00232361
2.1a
Blon_2173 AG phospho-
transferase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. longum subsp.
longum JDM301
YP_00366165
4.1a
BLJ_1379 AG phospho-
transferases
Proteins containing a
protein kinase family
domain, c109925
B. breve UCC2003 ABE95342.1 c Bbr_0651 Conserved
Hypothetical
secreted
protein
Merozoite surface
protein 1 (MSP1) C-
terminus of the PF
07462 and proteins
containing a protein
kinase family
domain, c109925
ABE96255.1 d Bbr_1586 AG phospho-
transferases
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. breve DSM
20213
ZP_06595772.
1c
BIFBRE_0358
9
Conserved
hypothetical
protein
Merozoite surface
protein 1 (MSP1) C-
terminus of the PF
07462 and proteins
containing a protein
kinase family
domain, c109925
ZP_06596651.
1d
BIFBRE_0449
8
Mucin
desulfating
sulfatase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. breve CECT
7263
EHS85254.1d CECT7263_14
691
Mucin
desulfating
sulfatase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
EHS85519.1c CECT7263_10
981
Hypothetical
protein
Merozoite surface
protein 1 (MSP1) C-
terminus of the PF
07462 and proteins
containing a protein
kinase family
domain, c109925
B. breve ACS 071
VSch 8b
YP_00558303
9.1c
HMPREF9228
_1217
Phospho-
transferase
enzyme
domain protein
Merozoite surface
protein 1 (MSP1) C-
terminus of the PF
07462 and proteins
containing a protein
kinase family
domain, c109925
YP_00558341
8.1d
HMPREF9228
_1637
Putative
mucin-
Proteins containing a
protein kinase family
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desulfating
sulfatase
domain, c109925
and
phosphotransferase
family with PF 01636
B. animalis subsp.
lactis Bb12
YP_00557565
3.1e
BIF_00526 Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
YP_00557607
1.1f
BIF_01665 AG 3'
phosphor-
transferase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. dentium ATCC
27678
ZP_02918244.
1g
BIFDEN_0154
8
Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. dentium Bd1 YP_00336104
1.1g
BDP_1625 AG phosphor-
transferase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. dentium ATCC
27679
ZP_07455726.
1g
HMPREF0168
_0285
Conserved
hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
enzyme family of the
PF 01636
B. dentium JCVHM
P022
ZP_07696282.
1g
HMPREF9003
_0562
Conserved
hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
enzyme family of the
PF 01636
B. catenulatum
DSM 16992
ZP_03323625.
1h
BIFCAT_0039
4
Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B.
pseudocatenulatum
DSM 20435
ZP_03742521.
1h
BIFPSEUDO_
03094
Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
- 209 -
B. adolescentis
ATCC 15703
YP_910027.1i BAD_1164 Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. bifidum S17 YP_00393827
4.1j
BBIF_0495 Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
YP_00393877
6.1k
BBIF_0997 Mucin de-
sulfatase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
YP_00393952
6.1l
BBIF_1747 AG
transferase
Phosphotransferase
enzyme family of the
PF 01636 and AG
phosphotransferases
of the aph family cd
05150
B. bifidum PRL
2010
YP_00397061
4.1j
BBPR_0470 AG phospho-
transferase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. bifidum BGN4 YP_00639392
1.1j
BBB_0447 AG phospho-
transferase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
YP_00639444
9.1k
BBB_0978 N-acetyl
hexosamine
kinase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. bifidum NCIMB
41171
ZP_07801902.
1j
BBNG_00382 Conserved
hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. angulatum DSM
20098
ZP_04447474.
1m
BIFANG_0245
1
Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
B. animalis subsp.
lactis HN019
YP_00246970
3.1e
BLA_0835 AG phospho-
transferase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
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family with PF 01636
ZP_02963731.
1e
BIFLAC_0495
0
Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. animalis subsp.
animalis ATCC
25527
YP_00628040
2.1e
BANAN_0615
5
AG phospho-
transferase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
YP_00627924
4.1n
BANAN_0027
0
AG phospho-
transferase
Phosphotransferase
family with PF 01636
and aminoglycoside
phosphotransferases
of the aph family cd
05150
B. longum subsp.
longum JCM1217
YP_00422138
1.1b
BLLJ_1622 AG phospho-
transferase
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
Bifidobacterium sp.
12_1_47BFAA
ZP_07941182.
1b
HMPREF0177
_00575
Phospho-
transferase
enzyme family
protein
Proteins containing a
protein kinase family
domain, c109925
and
phosphotransferase
family with PF 01636
B. longum subsp.
infantis 157F
YP_00420931
7.1a
BLIF_1400 Hypothetical
protein
Proteins containing a
protein kinase family
domain, c109925
* Same superscript indicates proteins share >90% sequence percentage identity
AG: aminoglycoside
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Table 5 Antibiotic resistance of bifidobacteria strains as assessed through antibiotic
disc assays
Antibiotic (microgram/per disc)
β-lactams Aminoglycosides
Bifidobacteria species AMP
25
PEN
10 IU
KAN
30
GEN
200
STR
25
NEO
30
B. breve DSM 20213 71mm 65mm No zone 22mm 16mm 14mm
B. animalis subsp. lactis Bb12 65mm 55mm No zone 28mm 21mm 20mm
B. pseudocatenulatum DSM
20438
61mm 56mm 8mm 10mm 13mm 20mm
B. gallicum DSM 20093 60mm 59mm No zone 24mm 30mm 10mm
B. angulatum DSM 20098 64mm 65mm 4mm 23mm 16mm 10mm
B. breve UCC2003 67mm 56mm No zone 26mm 21mm 10mm
B. breve UCC2003-0651-tet 52mm 57mm 10mm 40mm 33mm 14mm
B. breve UCC2003-1586-tet 62mm 57mm 9mm 41mm 31mm 15mm
B. breve UCC2003-1586-tet-
pBC1.2-Bbr_1586
62mm 59mm No zone 30mm 33mm 13mm
AMP, ampicillin; PEN, penicillin; KAN, kanamycin; GEN, gentamicin; STR, streptomycin;
NEO, neomycin
Values are average of triplicate plate results (SD±1mm for all samples, on all antibiotics)
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Table 6 MIC values (mg/L) of wild-type B. breve UCC2003 compared to mutants
as determined by broth micro-dilution assay (MRS+cysteine for Bifidobacterium
and LB broth for E. coli cultures)
Antibiotic (mg/L)
GEN NEO STR KAN
Sample 1-1024 1-1024 2-4096 2-4096
B. breve UCC2003 wild-type >1024 >1024 1024 >4096
B. breve UCC2003-0651-tet 256 >1024 256 1024
B. breve UCC2003-1586-tet 256 >1024 256 1024
B. breve UCC2003-gosG >1024 >1024 2048 >4096
B. breve UCC2003-1586-tet-pBC1.2-
Bbr_1586
>1024 1024 256 4096
B. breve UCC2003 wild-type* 4096 4096 1024 4096
B. breve UCC2003-pBC1.2_Bbr_1586* 4096 4096 2048 8192
B. breve UCC2003-pBC1.2_Bbr_0651* 4096 4096 1024 4096
B. breve UCC2003-
pBC1.2_Bbr_0651+0650*
4096 4096 1024 4096
E. coli XL1-blue-pBC1.2 <1 4 <2 <2
E. coli XL1-blue-pBC1.2_Bbr_0651+0650 2 8 <2 <2
E. coli XL1-blue-pBC1.2_Bbr_0651 2 8 <2 <2
E. coli XL1-blue-pBC1.2_Bbr_1586 <1 8 <2 <2
GEN, gentamicin; NEO, neomycin; STR, streptomycin; KAN, kanamycin
Values based on triplicate readings, which were identical in all cases
* Higher ranges of antibiotics used to test effect of additional gene copies on MICs compared to wild-
type (High range used: 256-16384mg/L for Gent/Neo; 1024-65536mg/L for Strep/Kan)
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Table S1 Primers used in this study
Primer name
Primers for insertions mutants
Bbr_0651f (500bp insert product)
Bbr_0651r
Bbr_1586f (400bp insert product)
Bbr_1586r
Pori19f
Pori19r
Primers for complementation
study and additional plasmid-
encoded gene tests
Bbr_0651fhind3
Primer sequence
TGCGGAAAGCTTCGGTTCATCGCGAGGGACAG
CTATGCTCTAGACTCCATCTGCAACCATAG
TGCGGAAAGCTTGTATACAAATTCATCGAGCAC
CTATGCTCTAGAGCATGATGGTGTCGAGGTCG
ATTGTGAGCGGATAACAATTTCAC
GATTAAGTTGGGTAACGCCAG
TCGCTTAAGCTTGCTGCGCTTGTTCCATGACC
Source
This study
This study
This study
This study
This study
Law et al.
(1995)
This study
Bbr_0651rxbaI
Bbr_0651+ 0650r2xbaI
Bbr_1586fhind3
Bbr_1586xbaI(1586 complement
strain)
GAACTGTCTAGACTCGTTGGTGCCCGTCGCCG
CTGCCATCTAGAGACCGATGAGGCCACCGTG
TCGCTTAAGCTTGAGACCTTCGACCTTCAGCCCAG
GAACTGTCTAGAGCGCCGCCCGTAACCAGAACAGT
This study
This study
This study
This study
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Gut microbial diversity is reduced and is
associated with colonic inflammation in a piglet
model of Short Bowel Syndrome
Published in Gut Microbes, Volume 4, Issue 3, May-June 2013,
Pages 212-221
- 255 -
6.1 Abstract
Following small bowel resection (SBR) the luminal environment is altered,
which contributes to clinical manifestations of short bowel syndrome
(SBS) including malabsorption, mucosal inflammation and bacterial
overgrowth. However, the impact of SBR on the colon has not been well-
defined. The aims of this study were to characterise the colonic
microbiota following SBR and to assess the impact of SBR on mucosal
inflammation in the colon.
Female (4-week old) piglets (5-6/group) received a 75% SBR, a
transection (sham) or no surgery. Compositional analysis of the colonic
microbiota was performed by high-throughput sequencing, two- and six-
weeks post-surgery. The gene expression of the pro-inflammatory
cytokines interleukin (IL)-1β, IL-6, IL-8, IL-18 and tumour necrosis factor
(TNF)-α in the colonic mucosa was assessed by qRT-PCR and the
number of macrophages and percentage inducible nitric oxide synthase
(iNOS) staining in the colonic epithelium were quantified by
immunohistochemistry.
Analysis of the colonic microbiota demonstrated that there was a
significant level of dysbiosis both two- and six-weeks post-SBR,
particularly in the phylum Firmicutes, coupled with a decrease in overall
bacterial diversity in the colon. This decrease in diversity was associated
with an increase in colonic inflammation six weeks post-surgery.
SBR significantly decreased the diversity of the colonic microbiota and
this was associated with an increase in colonic mucosal inflammation.
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This study supports the hypothesis that SBR has a significant impact on
the colon and that this may play an important role in defining clinical
outcome.
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6.2 Introduction
Short bowel syndrome (SBS) is the clinical state of malabsorption and
malnutrition that occurs following small bowel resection (SBR) (Sukhotnik
et al., 2002). Surgical resection of the small bowel may be required for
the treatment of a range of conditions including congenital bowel
abnormalities and necrotising enterocolitis in children, and Crohn’s
disease, trauma and malignancy in adults (Quirós-Tejeira et al., 2004).
Although the underlying reason for SBR between adults and children may
differ, the clinical manifestations and consequences of SBS are similar.
The symptoms of SBS reflect the loss of absorptive surface area and
functional disturbance of the remaining intestine and include diarrhoea,
vomiting, malabsorption, dehydration and electrolyte imbalance,
malnutrition and bacterial overgrowth.
Most cases of SBS occur in the neonatal age group and the mortality
associated with the condition ranges from 15-25% (Höllwarth, 1999,
Schalamon et al., 2003). The gut microbiota is known to be a major factor
in determining the clinical outcome in children (Goulet and Joly, 2010).
The effects of an alteration in the microbiota on the small intestine are
well studied in this cohort and include increased risk of bacterial
overgrowth, bacteraemia, villous atrophy and small intestinal mucosal
inflammation, which can result in a loss of intestinal epithelial barrier
function and can lead to sepsis (Cole et al., 2008, Cole et al., 2010,
Kaufman et al., 1997). In both adult patients with SBS and a piglet SBS
- 258 -
model, the colon is known to play a critical role in determining clinical
outcome, and significant morphological adaptation of the colonic mucosa
has been observed following resection (Goulet et al., 2009, Joly et al.,
2009, Healey et al., 2010). However, the actual impact of changes in the
microbiota on the colon itself is poorly understood. Anecdotal evidence
suggests that changes in the composition of the colonic microbiota
contribute to the generation of symptoms including malnutrition due to
decreased bile acid deconjugation, insufficient breakdown of nutrients,
and diarrhoea and play a key role in development of serious
complications such as septicemia. However, very little is known about
specific changes to the colonic microbiota following SBR or the impact
these changes may have on colonic mucosal inflammation, the adaptive
response and severity of symptoms in SBS.
Despite an obvious clinical need, there are a number of barriers to the
study of gut function and immune regulation in SBS. Patients with SBS
are a complex, heterogeneous group and access to tissue is limited.
Thus, many studies are based on animal models. Rodent SBS models,
although useful for molecular and cellular analysis, may not accurately
reflect the physiology and pathophysiology of the human intestine. The
pig is accepted as the best model for the study of human intestinal
biology and diet (Kararli, 1995, Miller and Ullrey, 1987, Moughan et al.,
1992) and, with a similar intestinal microbiota to that of humans
(Buzoianu et al., 2012, Eckburg et al., 2005, Flint et al., 2007) it is an
ideal model for the study of complex gastrointestinal diseases.
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The aims of this study were (1) to utilize high-throughput sequencing to
characterise changes in the colonic diversity and microbial composition
following SBR, (2) to examine the influence of surgical resection on
colonic mucosal inflammation and (3) to examine whether there is a
correlation between microbial differences and inflammation in a pre-
clinical piglet model of SBS in children.
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6.3 Materials and Methods
6.3.1 Animals
This study was approved by the Animal Ethics Committee of the Murdoch
Childrens Research Institute. Weaned female 3-week-old piglets
(Landrace/Large White cross; Aussie Pride Pork) were transported to the
University of Melbourne Centre for Animal Biotechnology and
acclimatised prior to surgery. Piglets were fed a polymeric infant formula
diet (Karicare De-Lact, Nutricia) supplemented to meet the daily
requirements for piglets as described previously (Pereira-Fantini et al.,
2011, Healey et al., 2010, Stephens et al., 2009). Water was given twice
daily. Piglets were housed separately throughout the study to allow
accurate daily monitoring of food and water intake and stool output.
6.3.2 Clinical Assessment and Growth
Piglet weight was measured weekly before feeding. Faecal samples were
collected weekly and stool consistency was scored by the Royal
Children's Hospital Laboratory Services, Melbourne, Australia using the
following scale: 0=formed, 1=semi-formed, 2=unformed, and 3=fluid.
6.3.3 Experimental Design
At 4 weeks of age, piglets underwent either a 75% proximal small bowel
resection (SBR, n=12) or a transection and re-anastomosis (sham, n=10)
operation. One group of piglets did not receive any surgery (non-
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operation control; NOC, n=12). The 75% SBR included the removal of the
small bowel from 90 cm distal to the ligament of Treitz to 225 cm proximal
to the ileocaecal valve. During the sham procedure the intestine was
transected and re-anastomosed at a site 225 cm proximal to the
ileocaecal valve. Piglets received intramuscular amoxicillin (70 mg/kg;
CSL Limited) 24 hours pre-surgery. On the day of surgery, piglets were
anaesthetised and given amoxicillin. Piglets received amoxicillin and oral
rehydration salts (Sanofi-Aventis Australia) for three days post-surgery in
line with current clinical practice. Water and the polymeric infant formula
diet were re-introduced from the third day post-operation. All piglets in the
NOC group followed the same antibiotic and feeding regime.
6.3.4 Sample collection
Animals in the SBR and sham groups were sacrificed either two- or six-
weeks post-surgery and at age-matched times in the NOC group. Colonic
tissue was collected 3 cm and 10 cm distal to the caecum in the two-
week and six-week groups, respectively, at locations optimised for age,
as based on a previous study (Pereira-Fantini et al., 2011). A 3 cm
section from each site was divided in half longitudinally and fixed in 10%
neutral buffered formalin (Australian Biostain Pty Ltd) or snap frozen in
liquid nitrogen. Colonic content was collected from the excised colonic
tissue sample.
6.3.5 DNA extraction and amplicon sequencing
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DNA was extracted from colonic content using the standard QIAamp DNA
Stool Mini Kit protocol (Qiagen, 51504), with the addition of an initial bead
beating step. The 16S rRNA amplicons were generated using a
previously outlined approach (Murphy et al., 2010a). Amplicons were
generated using one forward primer and a combination of four reverse
primers as described previously (Murphy et al., 2010b). Each primer
contained a distinct multiple identifier (MID) allowing pooling of the
amplicons and subsequent separation of the results for analysis.
Duplicate PCR products were pooled and cleaned using Agencourt
AMPure kit (Beckman Coulter, A63880). Quantification was completed
using Quant-iT Picogreen quantification kit (Invitrogen, P7589) and the
Nanodrop 3300 (Thermo Scientific). The V4 region of the 16S rRNA was
sequenced at the Teagasc 454-Sequencing facility on a Genome
Sequencer FLX platform (Roche Diagnostics Ltd.).
6.3.6 Bioinformatic analysis
Raw sequencing reads were quality trimmed using the RDP
Pyrosequencing Pipeline applying the following criteria (i) exact matches
to primer sequences and barcode tags (ii) no ambiguous bases (Ns), and
(iii) read-lengths no shorter than 150 base pairs. Trimmed FASTA
sequences were then BLASTED (Altschul et al., 1997) against the SILVA
(v100) database for 16S reads (Pruesse et al., 2007). Phylum, family and
genus counts were extracted from MEGAN (Huson et al., 2007) using a
bit score cut-off of 86 (Pruesse et al., 2007). Clustering into operational
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taxonomical units (OTUs), alignments, chimera-checking and alpha
diversities were implemented using the Qiime suite of tools (Caporaso et
al., 2010). A phylogenetic tree was generated using the FastTree
package (Price et al., 2010) and principal coordinate analysis (PCoA),
measuring dissimilarities at phylogenetic distances based on unweighted
Unifrac analysis, was performed with Qiime suite of tools (Caporaso et
al., 2010). PCoA plots were visualised with KiNG software package
(http://kinemage.biochem.duke.edu/software/king.php).
6.3.7 Quantitative PCR
Absolute quantification was completed using the Roche LightCycler 480
platform (Roche Diagnostics). Samples consisted of 2 µl PCR grade
water, 1 µl forward primer F1 (5’ AYTGGGYDTAAAGNG; 0.15 µM), 1 µl
reverse primer R1 (5’TACCRGGGTHTCTAATCC; 0.15 µM), 1 µl template
DNA and 5 µl SYBR green (Roche Diagnostics, 04887352001). Bacteria
were quantified using 16S rRNA counts based on a standard curve, using
a previously outlined calculation (Zhang et al., 2009). All reactions were
run in triplicate.
6.3.8 Real-time reverse transcription PCR (qRT-PCR)
The muscle layer was stripped from 100 mg of colonic tissue leaving the
colonic mucosa, which comprised the epithelium and the lamina propria.
Total RNA was extracted from the mucosa using TRIzol (Invitrogen,
15596-026). Complementary DNA (cDNA) was synthesised with the
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Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science,
04897030001). PCR primers were designed against pig gene sequences
using Roche Universal ProbeLibrary Assay Design Centre (Roche
Applied Science, 04683633001). Primer sequences and probe
combinations are listed in Table S1. PCR reactions were performed in
triplicate on the LightCycler 480. The 2-ΔΔCt method (Livak and
Schmittgen, 2001) was used to calculate relative changes in gene
expression using RPL32 as a housekeeping gene and relative to a pre-
operation group (n=6).
6.3.9 Microscopic assessment of inflammation
Immunohistochemistry was performed on formalin-fixed, paraffin-
embedded colon tissues sectioned at 5 µm. To identify macrophages,
antigen retrieval was performed with proteinase K followed by addition of
primary antibody (MAC387; 1:1000; Abcam, ab22506) for two hours at
room temperature. Staining of inducible nitric oxide synthase (iNOS) was
carried out by performing antigen retrieval in citrate buffer (pH 6.0) and
adding primary antibody (iNOS; 1:100; Abcam, ab15323) overnight at
4°C. Secondary staining and 3,3-Diaminobenzidine (DAB) detection was
performed using Histostain-Plus 3rd Gen IHC Detection Kit (Invitrogen,
85-9073). Negative controls were included in which the primary antibody
was substituted with antibody diluent. Slides were viewed under an
apochromat 10x objective lens using a Nikon Eclipse 80i microscope
(Nikon Instruments Inc), equipped with a DS-Ri1 CCD camera (Nikon)
- 265 -
and controlled by NIS-Elements acquisition software version 4.00 (Nikon).
For each set of analyses, ten fields of view of the epithelium were
collected. Macrophages were quantified by counting the number of
positively-stained cells in the colonic epithelium using ImageJ (Rasband,
1997-2012). The amount of iNOS epithelial cytoplasmic staining was
quantified by colour deconvolution using ImageJ (Ruifrok and Johnston,
2001).
6.3.10 Statistical analysis
Data are presented as mean values with their standard error (SEM).
Statistical analysis was performed using one-way ANOVA at each time-
point, followed by Tukey’s post-hoc test (GraphPad Prism Software 5.0).
Sequencing analysis was completed using Minitab Release 15.1.1.0
(Minitab Inc 2007). To identify if significant differences occurred at
phylum, family and genus levels between the three groups, non-
parametric Kruskal-Wallis or Mann-Whitney tests were performed
followed by Tukey’s post-hoc test. This test was also used for comparing
the changes in total bacterial counts in the three groups. The non-
parametric Spearman rank correlation was used to determine
relationships between diversity and inflammation. Statistical significance
was accepted at p < 0.05.
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6.4 Results
6.4.1 Piglets that received a small bowel resection had a poorer
clinical outcome
Food intake was monitored throughout the study and all diets were
isocaloric and isonitrogenous. However, piglets that received a small
bowel resection (SBR) had suboptimal weight gain compared to the non-
operation control (NOC) and sham-operated piglets (Figure 1A). This was
significant from the 2-week time-point (p = 0.004), up until and including
the 6-week time-point (p < 0.0001). The sham group also had a
significantly lower mean weight than the NOC group at the 5-week and 6-
week time-points (p = 0.041 and p < 0.0001). Piglets in the SBR group
failed to resolve diarrhoea at either the 2-week (p = 0.002 and p = 0.005)
or 6-week (p < 0.0001) time-points (Figure 1B).
6.4.2 Total colonic bacterial number is unaltered following small
bowel resection
Absolute quantification, using qPCR, was used to determine the impact of
surgery on total numbers of bacteria. The results indicate that there were
no significant differences in the total 16S rRNA gene copies
(representative of total bacteria numbers) between any of the groups at
either week two (p = 0.7845) or week six (p = 0.8784; data not shown).
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6.4.3 Surgical resection of the small intestine decreases bacterial
diversity in the colon
The colonic content from NOC, sham and SBR piglets was sequenced
two- and six-weeks post-surgery. A total of 318,784 V4 16S sequence
reads were generated, averaging at 9,376 per sample. Species richness,
coverage and diversity estimations were calculated for each data set
(Table 1). Rarefaction curves for each sample were parallel or
approaching parallel, with the x axis indicating total bacteria diversity was
well represented (Figure S1A). There was a trend towards a decrease in
the level of diversity in the SBR group compared to the NOC and sham
groups at the two-week time-point as assessed by the Chao 1 calculation
(Figure 2A and B and Table 1), and the Simpson and Shannon indices
(Table 1). By six weeks, however, there was a significant decrease in
diversity in the SBR group compared to the NOC and sham groups as
demonstrated by the Chao 1 calculation (p = 0.004; Figure 2A and B), the
Simpson index (p = 0.008) and the Shannon index (p = 0.003; Table 1).
Principle component analysis revealed that the SBR groups at week two
and week six clustered together, and were distinct from the NOC and
sham groups, which clustered together at both times (Figure S1B).
6.4.4 The composition of the pig microbiota is altered two weeks
after small bowel resection
Two weeks post-SBR, the majority of changes were detected at the
family and genus levels. There were significant differences at the family
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level between the SBR group and the NOC and sham groups (Figure 2C;
Table 2). These included a significant increase in Veillonellaceae (p =
0.0018 and p = 0.0115) and a significant decrease in Ruminococcaceae
(p = 0.0012 and p = 0.0244) in the SBR group compared to the NOC and
sham groups (Figure 2C; Table 2). Peptostreptococcaceae was
undetectable in any of the piglets in the SBR group at week two (Table 2).
At the genus level, there was a significant increase in Acidaminococcus in
the SBR group compared to the NOC and sham groups (p = 0.0015 and
p = 0.0033; Table 2).
6.4.5 Small bowel resection leads to dysbiosis of the gut microbiota
six weeks post-surgery
Six weeks post-surgery, there were significant decreases in the
proportions of Bacteroidetes (p = 0.0018 and p = 0.0013) and significantly
increased proportions of Fusobacteria (p = 0.0072 and p = 0.0032) in the
SBR group compared to the NOC and sham groups at this time-point
(Figure 2C; Table 2). The majority of differences were observed at the
level of the family, particularly in members of the Firmicutes phylum
(Figure 2C; Table 2). At six weeks, there was a significant decrease in
members of the Peptostreptococcaceae (p = 0.0477 and p = 0.0154) and
Ruminococcaceae (p = 0.00001 and p = 0.0002) families in the six-week
SBR group compared to the six-week NOC and sham groups.
Peptococcaceae were undetectable in the majority of SBR piglets at
week six. Conversely, there was a significant increase in the proportions
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of Veillonellaceae (p = 0.00001 and p = 0.0007) and Fusobacteriaceae (p
= 0.0072 and p = 0.0032) in the SBR group compared to the NOC and
sham groups at the six-week time-point. Increases at the family level
were reflected at the genus level, with increases in the proportion of
Megasphaera (p = 0.0156) in the SBR group compared to the NOC
group, and Acidaminococcus (p = 0.0006 and p = 0.0063), and
Fusobacterium (p = 0.0073 and p = 0.0032) compared to both the NOC
and sham groups. Clostridium proportions were significantly decreased in
the SBR group compared to the sham group (p = 0.0433).
6.4.6 There is an increase in colonic inflammation following small
bowel resection, which is associated with decreased diversity
The gene expression of a panel of pro-inflammatory cytokines was
assessed in the colon. Two weeks after surgery, there was no difference
in inflammatory gene expression amongst groups (Figure 3A-D). There
was, however, a significant increase in the expression of IL-1β (p =
0.045), IL-18 (p = 0.006) and TNF-α (p = 0.036) in the SBR group
compared to the sham group six-weeks post-surgery (Figures 3A, C, D),
and IL-8 was significantly increased in the SBR group compared to both
the NOC and sham groups (p=0.025 and p=0.034; Figure 3B).
In the case of IL-1β and IL-8, the increase in these pro-inflammatory
cytokines correlated with the observed decrease in colonic bacterial
diversity (r = -0.829 and r = -0.771, respectively; Table 3). The increase in
colonic pro-inflammatory cytokines was also associated with a
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concomitant increase in the total number of macrophages present in the
colonic epithelium of the SBR group compared to the NOC and sham
groups at six weeks (Figure 4A). At this time-point, there was also a
significant increase in the amount of the inflammatory marker iNOS in the
colonic epithelium of the SBR group compared to both the NOC and the
sham (p = 0.03; Figure 4B).
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6.5 Discussion
This study provides the first comprehensive description of the changes in
the colonic microbiota following small bowel resection. Not only does this
study take advantage of high-throughput sequencing to identify and
characterise the dysbiosis that occurs following SBR using an established
preclinical piglet model of SBS in children, it also links these changes with
local mucosal inflammatory responses.
Following SBR, the luminal environment becomes altered due to rapid
shunting of luminal content from the upper intestine into the lower
intestine, due to shortened bowel length and increased intestinal transit
(Compher et al., 2007). This exposes the colon and its resident bacteria
to both digesta and intestinal and pancreatico-biliary secretions that
would normally be broken down or absorbed in the upper intestinal tract,
which could potentially impact on the composition of bacteria in the lumen
(Begley et al., 2005). Evidence on the impact of SBR on bacterial
composition is largely anecdotal; however any changes in bacterial
composition are likely to have important implications for patients with
SBS, in terms of management of their condition.
This study has established that there is a significant decrease in overall
bacterial diversity in the colon in a piglet model of SBS that is particularly
evident six weeks post-resection. This is consistent with other
inflammatory conditions including Crohn’s disease (Ott et al., 2004)
ulcerative colitis, (Mclaughlin et al., 2010) and antibiotic-associated
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diarrhoea (Chang et al., 2008) and has previously been described in adult
patients with SBS (Joly et al., 2010). A decrease in microbial diversity
also corresponds to decreased metabolic diversity, which has potential
implications for SBS patients including insufficient breakdown of dietary
components such as complex polysaccharides leading to malabsorption,
reduced energy availability and decreased production of short-chain fatty
acids (Gerritsen et al., 2011).
This decrease in diversity is due to certain species becoming dominant in
the colon, to the detriment of others. At two weeks post-surgery,
members of the Firmicutes phylum underwent the most significant
alterations, with an increase in the proportion of Veillonellaceae family
and a decrease in the proportion of Ruminococcaceae family in the SBR
group relative to the NOC and sham group. Major differences in bacterial
composition were observed six weeks post-surgery. The phylum
Fusobacteria was significantly increased in the SBR group relative to the
NOC and sham groups. Gram negative bacteria in this phylum express
pro-inflammatory molecules such as lipopolysaccharide, which is known
to trigger inflammation in the gut (Heimesaat et al., 2006, Ma et al., 2012,
Lapthorne et al., 2012). At the family level, the majority of changes were
again within the Firmicutes phylum, with a decrease in the proportion of
Clostridiaceae, Peptostreptococcaceae and Peptococcaceae in the SBR
group compared to the sham group at six weeks. These Gram positive
anaerobic bacteria may provide CpG DNA with immunomodulatory
activities and their decrease or absence is postulated to disrupt the
- 273 -
crosstalk between the host mucosal immune system and the microbiota
(Manichanh et al., 2006). The increase in the Veillonellaceae family and
the decrease in Ruminococcaceae family observed in the SBR group at
two weeks was sustained at the six week time-point. Several studies
have linked alterations in each of these families with systemic and local
inflammation (Chen et al., 2011, Sokol et al., 2008). As the delicate
balance between host epithelial cells and resident bacteria is already
disturbed in patients with SBS, due to the unfavourably altered luminal
environment, these specific changes in key bacterial families may further
exacerbate the clinical manifestations of SBS.
Interestingly, there were also alterations in some bacterial families in the
sham surgery group. The proportion of Enterobacteriaceae was
significantly decreased and the proportion of Prevotellaceae was
significantly increased in the sham group compared to the NOC group at
the two week time-point. This increase in Prevotellaceae was sustained
at the six week time-point and there was also a decrease in the
proportion of Lactobacillaceae at this time. It is known that surgical
trauma often results postoperative ileus and in the activation of resident
macrophages and the upregulation of functional activity of pro-
inflammatory cytokines (Kalff et al., 2003). Thus, the sham surgery,
although relatively minor compared to the massive small bowel resection
surgery, would also have an effect on the gut microbiota.
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A limited number of studies have examined the bacterial community in
SBS patients using culture- and microscopy-based techniques. These
studies suggest that there is a shift in the microbiota, and that the
microbiota of SBS patients is composed primarily of Gram positive
organisms such as lactobacilli (Bongaerts et al., 2000). More recent
studies that used quantitative PCR to identify changes in the microbiota in
adult patients with SBS, confirmed that there is enrichment in lactobacilli
in these patients (Joly et al., 2010, Mayeur et al., 2013). Using high-
throughput DNA sequencing, we observed no significant difference in the
proportion of Lactobacillus spp. at either time-point. Given that a
purported 70-80% of gut bacteria are unculturable, our results may reflect
the more comprehensive identification of previously unidentified bacterial
content (Wilson et al., 1990) and may also indicate that there are
important differences between adult and paediatric SBS patients in terms
of their microbiota.
Despite significant differences in pro-inflammatory bacteria in the SBR
group two weeks post-surgery, there was no increase in pro-inflammatory
colonic cytokine expression at this time-point. However, six weeks post-
SBR, there were significant increases in the pro-inflammatory cytokines
IL-1β, IL-8, IL-18 and TNF-α in the SBR group. This was coupled with an
increase in the number of macrophages in the colon, as well as an
increase in colonic iNOS in the SBR group. This increase in mucosal
inflammation coincided with a marked decrease in diversity and dysbiosis
at the later time-point. Consistent with this observation, there was a
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correlation between a decrease in bacterial diversity and an increase in
colonic IL-8 and IL-1β. Several studies have shown a link between
diversity and inflammation, although there is debate as to which is the
causative agent (Craven et al., 2012, Ott et al., 2004, Manichanh et al.,
2006). In our study, the decrease in diversity was evident two weeks
post-surgery, but significant markers of inflammation did not occur until
six weeks post-SBR. Thus, it is our hypothesis that the colonic microbiota
is negatively impacted by the altered luminal environment following the
surgical resection, resulting in a decrease in diversity, which initiates a
pro-inflammatory response in the colon.
This study has identified and characterised dysbiosis in the colon that
occurs following SBR and challenges current accepted theories regarding
specific alterations in the microbiota of patients with SBS. We have
shown a reduction in diversity following SBR due to certain bacterial
species establishing dominance and described inflammation in the colon
that persists for six weeks after SBR. We suggest that this inflammation is
a consequence, rather than a trigger of the dysbiosis and that the overall
composition of the microbiota may be more relevant than the presence or
absence of a single species. This study has highlighted that the colon is
significantly impacted by proximal SBR and the role that the colon may
play in determining the clinical outcome following a resection has been
underappreciated.
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Table 1 Surgical resection decreases the diversity of colonic bacteria
Data set NOC
Week 2
Sham
Week 2
SBR
Week 2
NOC
Week 6
Sham
Week 6
SBR
Week 6
Chao 1 richness
estimation
Shannon’s index
for diversity
Number of
observed species
Simpson’s diversity
index
905±41
6.9±0.2
552±16
0.96±0.01
892±123
6.5±0.6
571±80
0.95±0.02
718±59
5.7±0.3
475±44
0.93±0.01
1224±82
7.1±0.1
726±46
0.98±0.01
1276±97
7.4±0.2
777±63
0.98±0.00
716±34
5.5±0.2
428±15
0.93±0.01
Estimation of diversity within the non-operation control (NOC), sham and
small bowel resection (SBR) groups at two- and six- weeks post surgery
as assessed by Chao 1 richness estimation, Shannon’s index for
diversity, number of observed species and Simpson’s diversity index.
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Table 2 Small bowel resection alters the composition of the colonic
microbiota over time
Weeks post-surgery Week 2 Week 6
Group NOC Sham SBR NOC Sham SBR
Phylum:
Firmicutes 52.6±5.0 52.1±10.6 68.5±6.1 61.7±6.5 67.7±3.6 68.2±4.2
Proteobacteria 27.8±5.1 23.1±14.6 11.9±4.6 10.6±3.3 6.0±0.6 6.2±1.8
Bacteroidetes 17.9±2.5 19.1±5.8 10.1±1.7 22.3±2.6 23.2±1.9 10.0±1.6**††
Fusobacteria 0.9±0.4 3.8±3.1 8.5±2.7 4.7±2.3 2.8±1.4 15.4±2.4**††
Actinobacteria 0.7±0.2 2.0±1.5 1.0±0.4 0.7±0.2 0.3±0.1 0.3±0.1
Family:
Enterobacteriaceae 31.8±6.9 5.8±2.5** 1.0±0.5*** 6.7±2.7 1.9±0.7 4.0±2.1
Ruminococcaceae 28.1±3.1 27.0±4.2 5.2±2.5**† 41.5±5.2 36.1±4.1 3.9±1.6***†††
Veillonellaceae 19.5±4.9 36.7±8.4 70.5±7.1**† 9.9±2.9 28.0±6.5 64.2±6.6
***†
††
Peptostreptococcaceae 4.6±1.5 2.1±1.5 0 2.8±0.6 3.7±1.4 0*†
Prevotellaceae 3.9±0.6 14.4±2.8* 7.1±0.5 2.0±0.9 9.7±1.8** 5.8±0.7**
Bacteroidaceae 3.5±0.8 1.1±0.6 2.4±1.1 9.0±2.1 6.0±0.9 2.9±1.2
Erysipelotrichaceae 2.5±0.9 1.4±0.7 0.4±0.2 10.0±6.0 3.8±1.3 0
Clostridiaceae 2.1±0.5 1.0±0.5 0 0.7±0.1 2.7±1.3 0.1±0.0
Lactobacillaceae 1.5±0.6 2.1±1.1 1.2±0.3 2.9±0.8 0.2±0.1* 0.8±0.4
Fusobacteriaceae 1.4±0.6 7.5±3.9 11.9±4.1 8.3±4.3 4.8±2.5 18.2±3.0**††
Peptococcaceae 1.1±0.5 0.9±0.3 0.4±0.4 6.3±1.9 3.2±0.7 0**
Genus:
Enterobacteriaceae
family members 48.8±8.7 9.4±3.7*** 1.4±0.7*** 11.6±2.8 3.6±1.1 5.7±2.9
Bacteroides 5.8±1.3 2.1±1.1 3.5±1.5 21.2±3.2 11.5±1.6 4.3±1.7
Parabacteroides 5.1±1.2 10.9±3.3 1.6±1.1 19.2±4.5 10.9±3.4 0.6±0.2*
Prevotella 6.7±1.6 23.2±4.5* 10.4±1.2 3.1±1.5 18.9±3.4*
*
9.6±0.9*
Clostridium 3.4±0.7 1.8±0.9 0 1.8±0.6 5.1±2.6 0.1±0.1†
Fusobacterium 2.7±1.4 12.4±6.6 17.7±6.2 11.9±5.1 9.0±4.8 29.9±4.3**††
Megasphaera 17.1±6.0 27.3±4.4 31.4±6.1 6.2±2.5 23.5±7.7 18.3±3.0*
Acidaminococcus 4.5±1.2 8.0±2.8 31.7±6.7**†
†
3.6±2.3 11.1±6.5 30.2±5.1***†
†
Peptococcus 1.9±0.9 1.5±0.6 0.7±0.6 14.9±5.7 6.1±1.7 0.1±0.1
Lactobacillus 4.0±1.8 3.4±1.8 1.7±0.4 6.4±1.9 0.4±0.2* 1.3±0.6
The composition of the colonic microbiota is altered two and six weeks post-
surgery in the small bowel resection (SBR) group. Values are relative
proportions of operational taxonomic units (OTUs) ± SEM, n=5-6/group/time-
point. Statistical significance was determined using a general linear model
ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001 compared to non-operation control
(NOC) group; †p < 0.05, ††p < 0.01, †††p < 0.001 compared to sham group
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Table 3 A decrease in colonic bacterial diversity is associated with an increase
in inflammatory cytokines
The expression of colonic IL-1β and IL-8 negatively correlate with colonic
bacterial diversity as assessed by Spearman’s rank correlation
coefficient.
Bacterial alpha diversity IL-1β IL-8 IL18 TNF-α
Spearman r
p value
-0.8286
0.0583
-0.7714
0.1028
-0.2571
0.6583
-0.4857
0.3556
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Figure 1 Clinical effects of small bowel resection. (A) The weight of
piglets that received a small bowel resection (SBR) was significantly
lower two weeks post-surgery than those that received a sham surgery
(Sham) or no surgery (NOC; **p < 0.01). This suboptimal weight gain was
sustained for the duration of the experiment (***p < 0.001 at week 3, P <
.0001 at weeks 4, 5 and 6). The sham piglets also had a significantly
lower weight gain at weeks 5 (#p < 0.05) and 6 (###p < 0.0001)
compared to the NOC group. Values are expressed as mean ± SEM;
n=12 NOC, n=10 sham, n=12 SBR at pre-op, week 1 and week 2; n=6
NOC, n=5 sham, n=6 SBR at weeks 3, 4, 5 and 6. (B) Piglets in the SBR
group had a significantly higher stool consistency score than the sham
and NOC groups two weeks (**p < 0.01) and six weeks (***p < 0.001)
post-surgery. Values are expressed as mean ± SEM; n=5-6/group/time-
point
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Figure 2 Surgical resection of the small intestine decreases the diversity
of colonic bacteria and alters the relative proportion of families in the
Firmicutes phylum. (A) There is a decrease in the number of distinct
operational taxonomic units (OTUs) representing bacterial genera two
and six weeks post-surgery in the small bowel resection (SBR) group
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compared to the non-operation control (NOC) and sham group. This is
translated into a decrease in overall bacterial diversity as calculated by
the Chao 1 richness estimation (B). (C) Pie charts representing the major
bacterial phyla and the relative proportion of families in the Firmicutes
family at the two- and six-week time-point in the NOC, sham and SBR
groups
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Figure 3 Surgical resection alters the expression of pro-inflammatory
cytokines in the colon. In the colon, the gene expression of IL-1β (A), IL-
18 (C) and TNF-α (D) was significantly higher in the SBR group
compared to the sham group at six weeks (*p<0.05, **p<0.01). IL8 (B)
was significantly higher in the colon in the small bowel resection (SBR)
group compared to the non-operation control (NOC) and sham group at
six weeks (*p<0.05). Values are expressed as mean ± SEM; n=5-
6/group/time-point
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Figure 4 There is an increase in inflammatory cells and mediators in the
colonic epithelium following small bowel resection. There was an increase
in the number of macrophages (A) and the percentage of cytoplasmic
inducible nitric oxide synthase (iNOS) staining (B) in the colonic
epithelium six weeks post-surgery. Immunohistochemistry images
illustrate representative staining six weeks post-surgery. Scale bar
represents 100 µm. Values are expressed as mean ± SEM; n=5-6/group
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Supplementary information
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Table S1 List of primer sequences and Universal ProbeLibrary probe
combinations used in this study
Primer Sequence 5’ to 3’ UPL
Probe
RPL32 Forward aactggccatcagggtcac #64
RPL32 Reverse cacaactggaactcctgtctattc
IL1B Forward ccaattcagggaccctacc #19
IL1B Reverse catggctgcttcagaaacct
IL8 Forward ttcttctttatccccaaactgg #41
IL8 Reverse ccacatgtcctcaaggtagga
IL18 Forward actttactttgtagctgaaaacgatg #85
IL18 Reverse tttaggttcaagcttgccaaa
TNF Forward ttgtcgctacatcgctgaac #32
TNF Reverse ccagtagggcggttacagac
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Figure S1 Rarefaction curve and principle coordinate analysis of samples
sequenced by high-throughput DNA sequencing. (A) Rarefaction curves
for each group at 97% similarity indicated that the total bacterial diversity
present was well represented. Number of operational taxonomic units
(OTUs) identified as a function of the number of sequence tags sampled.
(B) Principle component analysis revealed that the small bowel resection
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(SBR) groups at week 2 and week 6 clustered together, and were distinct
from the non-operation control (NOC) and sham groups
Chapter 7
The microbial composition of the human appendix
from patients following appendectomy
Published in mBio, Volume 4, Issue 1, January 2013, e00366-
12
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7.1 Abstract
The human appendix is historically considered a vestige of evolutionary
development with an unknown function. While limited data are available
on the microbial composition of the appendix, it has been postulated that
this organ could serve as a microbial reservoir for repopulating the
gastrointestinal tract in times of necessity. We aimed to explore the
microbial composition of the human appendix, using high-throughput
sequencing of the 16S rRNA gene V4 region. Seven patients aged 5y-
25y presenting with symptoms of acute appendicitis were included in this
study. Results showed considerable diversity and inter-individual
variability among the microbial composition of the appendix samples. In
general however, Firmicutes were the dominant phylum with the majority
of additional sequences being assigned at varying levels to
Proteobacteria, Bacteroidetes, Actinobacteria and Fusobacteria. Despite
the large diversity of microbiota found within the appendix, however, a
few major families and genera were found to comprise the majority of the
sequences present. Interestingly also, certain taxa not generally
associated with the human intestine including the oral-associated
pathogens Gemella, Parvimonas, and Fusobacterium were identified
among the appendix samples. The prevalence of genera such as
Fusobacterium could also be linked to the severity of inflammation of the
organ. We conclude that the human appendix contains a wealth of
microbiota distinct from other niches within the human microbiome. The
microbial composition of the human appendix is subject to extreme
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variability and holds a diversity of biota that may play an important, as-
yet-unknown role in human health.
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7.2 Introduction
It has recently been hypothesised that the human appendix functions as a
reservoir of beneficial microbes for recovery, following events of pathogen
colonization, diarrhoeal disease or antibiotic treatment (Laurin et al.,
2011, Smith et al., 2009). Parker and co-workers theorize that the
vermiform appendix serves as microbial reservoir or ‘safe-house’ for
beneficial bacteria capable of repopulating the gut. The associated
lymphoid tissue of the appendix has been recognised to provide an ideal
environment for bacterial growth in biofilms acting as an enteric reservoir
(Bollinger et al., 2003, Bollinger et al., 2007). Furthermore, the presence
of the appendix may reduce the risk of Clostridium difficile recurrence (Im
et al., 2011), the protective effect being attributed to the presence of
beneficial microbial biofilms and/or due to an immune defence (Na and
Kelly, 2011). Conversely, however, another recent study suggested that
the appendix may actually promote C. difficile acquisition, carriage and
disease (Merchant et al., 2011).
Acute appendicitis is one of the most common causes of abdominal pain
with surgical appendectomy being the standard choice of treatment and
still considered a clinical emergency. It is now indicated that obstructions
in the organ are unlikely to be the primary cause of appendicitis (Carr,
2000) and the role of bacterial infection is believed central to appendix
inflammation (Swidsinski et al., 2011). Despite this however, there are
limited data on the causal agents of acute appendicitis and of the
microbial composition of the human appendix. Culturing-dependent
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studies have documented the dominance of Bacteroides species in both
healthy and inflamed appendices (Elhag et al., 1986, Roberts, 1988), in
addition to Escherichia coli and Streptococcus sp. being recovered from
the tissue (Roberts, 1988). Recent studies using fluorescence in situ
hybridisation (FISH) reported that local invasion with species of
Fusobacterium is the cause in the majority of cases of suppurative
appendicitis (Swidsinski et al., 2011, Swidsinski et al.). The presence of
Fusobacterium sp. in the mucosal lesions correlated positively with the
severity of acute appendicitis and other faecal-associated organisms
including members of Bacteroides, Eubacterium rectale,
Faecalibacterium prausnitzii and Akkermansia muciniphila inversely
correlated with inflammation associated with the organ (Swidsinski et al.,
2011).
In this study, we determined the microbial composition of the human
appendix, using next-generation sequencing technologies. The data
presented provides, to our knowledge, the first account of the entire
microbiota of this organ and provides insight into the diversity of its
associated taxa. Important information regarding the bacterial diversity of
inflamed appendices is presented and although full conclusions cannot
yet be made, it is a first step towards assigning a role for the microbiota of
the appendix in human health.
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7.3 Materials and Methods
7.3.1 Participants
Approval for the study protocol was obtained from the Clinical Research
Ethics Committee of the Cork Teaching Hospitals, Cork, Ireland. Informed
consent was obtained from all subjects or from parents of children, in
accordance with the local Clinical Research Ethics Committee guidelines.
The subject details, pre-operative antibiotics administered and the macro-
and micro-scopic details of the appendices are outlined in Table 1.
Material from 7 appendices removed during laparoscopic emergent
appendectomy was used in this study. One stool sample (patient B) was
also taken for comparative analysis. All patients were fasting >15 hr prior
to surgery. Samples were transported under anaerobic conditions and
kept at 4°C until processing.
7.3.2 Generation of 16S rRNA amplicons for 454 sequencing
Total bacterial metagenomic DNA was extracted from appendix and stool
samples (triplicate samples for each subject) using the QIAamp DNA
Stool Mini Kit (Qiagen) (Hussey et al., 2011). 16S rRNA bacterial gene
amplicons (V4) were generated with a view sequencing using the Roche
Genome Sequencer FLX platform. Amplicons of 239 bp were generated
using a combination of one forward, i.e. F1 (5’ AYTGGGYDTAAAGNG),
and a combination of 4 reverse, R1 (5’ TACCRGGGTHTCTAATCC), R2
(5’ TACCAGAGTATCTAATTC), R3 (5’ CTACDSRGGTMTCTAATC) and
R4 (5’ TACNVGGGTATCTAATC), primers. These primers also contained
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an A (F primer) or B (R primers) adapter and different versions of the F
primer, each containing a distinct multiple identifier (MID), were employed
for each sample. PCRs were performed using Biomix Red (MyBio) and
conditions were as follows: 94°C for 2 min followed by 35 cycles of 94°C
for 1 min, 52°C for 1 min and 72°C for 1 min followed by a temperature
step of 72°C for 2 min. All samples were completed in duplicate. PCR
products were cleaned using Agentcourt AMPure kit (Beckman Coulter
Genomics) as per manufacturer’s instructions. Samples were quantified
using Quant-iT Picogreen quantification kit (Biosciences, Ireland) and the
Nanodrop 3300 (Thermo Scientific). Equimolar solutions of samples
were pooled for sequencing, cleaned and re-quantified (as above).
Emulsion based clonal amplification was completed as part of the 454-
pyrosequencing process. Sequencing was performed at the Teagasc 454
Sequencing facility on a Genome Sequencer FLX platform (Roche
Diagnostics Ltd) according to the manufacturer’s protocols.
7.3.3 Bioinformatic analysis
16S rRNA sequencing reads were quality trimmed using a locally
installed version of the Ribosomal Database Project (RDP)
Pyrosequencing Pipeline applying the criteria as previously described
(O'sullivan et al., 2011). Trimmed FASTA sequences were BLASTed
(Altschul et al., 1990) against a locally installed version of SILVA 16S
rRNA database (Pruesse et al., 2007). The resulting BLAST output was
parsed using MEGAN (version 4.6) (Huson et al., 2007) using modified
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accession look-up tables for mapping the SILVA assignments to NCBI
taxonomy. MEGAN assigns reads to NCBI taxonomies by employing the
Lowest Common Ancestor algorithm. Bit scores (bit-score of 86) as
previously described for 16S rRNA data (Urich et al., 2008) were used
from within MEGAN to filter the results prior to tree construction and
summarization of taxa. Phylum, family and genera counts for each
subject were extracted from MEGAN. Clustering and diversity analysis of
the sequence data was performed using the MOTHUR software package
(Schloss and Handelsman, 2008, Schloss et al., 2009).
7.3.4 qPCR-based analysis
Absolute quantification of total bacterial numbers was performed by
qPCR using the Roche 480 Lightcycler platform. To quantify total 16S
rRNA bacterial counts, a standard curve was established using copy
numbers of 16S rRNA/µl from 109-102 copies 16S rRNA/µl. Values were
then converted to copies 16S rRNA/g appendix or wet stool using the
previous calculation (Zhang et al., 2009). Samples were made up of 2 µl
of PCR grade water, 1 µl of forward primer F1 (5’
AYTGGGYDTAAAGNG) (0.15 µM), 1 µl of the reverse primer R1 (5’
TACCRGGGTHTCTAATCC) (0.15 µM), 1 µl DNA and 5 µl of SYBR
green (Roche Diagnostics Ltd), giving a final reaction volume of 10 µl. All
samples, negative controls (where template DNA was replaced with PCR
grade water) and standards were run in triplicate.
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7.3.5 Statistical Analysis
Minitab Release 15.1.1.0 (Minitab Inc. 2007) was used to run non-
parametric statistics (Kruskal-Wallis tests) to determine differences
between the microbial numbers from the appendices as determined by
PCR. Statistical significance was accepted at p<0.05.
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7.4 Results
The 7 patients from whom appendices were surgically removed had been
fasting prior to surgery and received pre-operative antibiotics (Table 1).
Both the macroscopic appearance of the appendices and the microscopic
histopathology was used to determine the severity of the disease of the
organ. Samples A, B and D were deemed macroscopically to be the
most inflamed with the pathohistology indicating a diagnosis of acute
appendicitis whereas samples C, E, F and G appeared not as red or
inflamed and therefore are considered as healthier samples.
7.4.1 QPCR analysis of appendix samples
Shifts in phyla may be due to a depletion or increase of bacteria which
may alter the final bacterial numbers. QPCR, therefore, was performed to
determine total bacterial numbers of the 7 appendices. Absolute
quantification revealed that all appendix samples harboured between 104-
106 copies of 16S rRNA/g appendix (Figure 1). Statistical analysis, using
the Kruskal-Wallis test revealed that there was a significant difference in
total 16S rRNA gene copies across the 7 appendix samples (p<0.01) with
sample D having the highest total numbers (Figure 1). The microbial load
of the appendices was compared to the faecal sample from patient B.
The stool sample from patient B had 107 copies of 16S rRNA/g wet stool
whereas the comparative appendix sample just harboured 104 copies.
This value for the stool sample is comparable to results obtained by
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similar methods for faecal samples (Fouhy et al., 2012 ), despite the use
of antibiotics in the current study.
7.4.2 Compositional high-throughput sequencing
The microbial content of the appendices and stool sample was
investigated by high-throughput sequencing (Roche-454 GS-FLX
Titanium) of 16S rRNA (V4) amplicons generated from extracted DNA.
The sequence reads averaged at 9,934 reads per appendix sample and
11,010 reads represented the stool sample. Diversity, richness and
coverage estimations were calculated for each data set at 97% similarity
levels (Table 2). The Chao1 estimator of species richness indicated a
sufficient level of overall phylotype diversity (Table 2). The Shannon index
is reflective of both species numbers and evenness of their abundance
and therefore the index is increased by having additional unique species
or having greater species evenness. The Shannon indices indicated a
high level of overall diversity within samples with all values exceeding 4.2.
The Good’s coverage, a measure of sampling completeness, ranged from
85.7-93.8% for all samples, indicating sufficient overall sampling.
7.4.3 Individual variation of the microbiota of the human appendix
The overall phyla distribution of the appendix samples are shown in
Figure 2 and indicate that the individual composition data sets show
much variation with respect to each other. Across the 7 appendix
samples, there was considerable diversity observed with 15 phyla in total
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represented. In general, however, the appendices were dominated by 5
major phyla; Firmicutes, Proteobacteria, Bacteroidetes, Fusobacteria and
Actinobacteria with others detected at low levels (<1-2%) in certain
samples including Deferribacteres, Verrucomicrobia, Deinococcus-
thermus, Chloroflexi, Lentisphaerae, Viridiplantae, Spirochaetes,
Candidate division TM7, OP10 and OP11.
Firmicutes were generally the dominant phylum comprising 30%-75% of
the total assignable sequences among the 7 appendix samples.
Proteobacteria, were also well represented, however, and in sample C
(37%) and E (46%) were the predominant phylum. Although the average
Actinobacteria represented was just 3%, sample E harboured relatively
high levels (11%) of this phylum. Bacteroidetes varied between samples
(4%-12%) but generally were not largely represented (Figure 2). The
levels of the phylum Fusobacteria varied considerably between samples,
with levels ranging from <1%-29% of assignable reads. Fusobacteria was
most represented in the inflamed sample D.
7.4.4 Sub-populations of the microbiota of the appendix
At the family level, it appeared that the sub-populations of the assigned
phyla also differed somewhat between samples (Figure 3). In general,
Lachnospiraceae were the dominant sub-group of Firmicutes and
corresponded to 46% of total assignable sequences in sample A,
however, >12 sub-populations of Firmicutes were identified within the 7
appendices with the remaining majority of reads being assigned to the
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families Ruminococcaceae, Lactobacillaceae and Streptococcaceae
(Figure 3). Of the sub-populations of Proteobacteria identified, there was
a considerable large proportionate amount of reads assigned in each
sample to the family Enterobacteriaceae. The families Bacteroidaceae,
Fusobacteriaceae and Bifidobacteriaceae comprised the dominant or only
family of the phyla Bacteroidetes, Fusobacteria and Actinobacteria
respectively in all samples (Figure 3).
At genus level, despite the large diversity of bacteria represented, a low
number of taxa comprised the majority of the bacteria found within the
samples (Table 3). Although a large number of phyla (>15), families (>40)
and their subpopulations are represented within the 7 samples tested
indicating a high level of microbial diversity, it is evident that in certain
samples a few major families and genera comprise the majority of the
sequences (Table 3). It should be noted, however, that percentages are
based on the sequences that can be assigned at this level and
assignments to genus level are difficult owing to limited taxonomic
assignments within certain families and phyla. Members of the families
Enterobacteriaceae, Lachnospiraceae and the genera Fusobacterium,
Lactobacillus, Bacteroides and Bifidobacterium are represented in the
majority of samples at varying levels (Table 3). Fusobacterium sp., in
particular Fusobacterium nucleatum, are generally regarded as oral
pathogens but are also commonly found in the lining of the gut, have
been identified in the stomach (Bik et al., 2006) and most notably as the
likely etiological agents of acute appendicitis (Swidsinski et al., 2011). In
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addition, the genus Gemella usually associated with mucous membranes
of oral cavities (Diaz et al., 2012) is represented in samples A and B.
Parvimonas was identified in high numbers in samples D and G (Figure
4) which is also generally considered with the oral microbiome and as a
peridontal pathogen (Ota-Tsuzuki and Alves Mayer, 2009). Parvimonas
micros, however, has been previously identified from appendix tissue of
patients with acute appendicitis (Rautio et al., 2000).
7.4.5 Comparative analysis of the microbial composition of the
appendix with the microbiota of the gut
The microbiota of the healthy adult gut is generally regarded to be
dominated by a small number of phyla with considerable inter-individual
variation (Eckburg et al., 2005, Tap et al., 2009, Claesson et al., 2011,
Claesson et al., 2012). Studies on young adults have indicated the
majority of bacteria belong to the phylum Firmicutes or Bacteroidetes
followed by Proteobacteria and Actinobacteria (Eckburg et al., 2005, Tap
et al., 2009). The results from the appendix samples in this study indicate
in addition to the above phyla, the substantial presence of Fusobacteria
at phylum level and a more diverse biota at family and genus levels when
compared to data previously presented (Claesson et al., 2011) (Figures
2-4).
For further comparison, we used one faecal sample (patient B) and the
microbial composition was compared to its corresponding appendix
sample at phyla (Figure 2), family (Figure 3) and genus levels (Figure 4).
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At phylum level, the stool sample harboured Firmicutes, Bacteroidetes,
Proteobacteria and Actinobacteria (Figure 2). The appendix sample from
the same patient however had, in addition to the above 4 phyla, a
significant proportion of sequences designated to the phylum
Fusobacteria (7%) and 2% of reads were also assigned to the other phyla
Deferribacteres, Verrucomicrobia, Viridiplantae and Candidate division
OP11. Examining the subpopulations (Figure 3, Table 3), it is also clear
that there is more diversity within the appendix sample than the faecal
sample. Of the subpopulations of the phylum Firmicutes, just
Lachnospiraceae, Ruminococcaceae and Streptococcaceae were
represented in the stool whereas the subpopulation of Firmicutes in the
appendix sample comprised of 11 families with the most reads being
assigned to Lachnospiraceae (Figure 3). Taken together, these data
suggest that there is a more diverse microbial composition in the human
appendix than in the human intestine. It is also evident however that
despite some apparent differences, the microbiota represented in both
samples share some of the dominant biota represented at phylum, family
and genus levels (Figures 2, 3 and Table 3).
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7.5 Discussion
This study represents a ‘first look’ at the bacterial composition of the
human appendix by next-generation sequencing technologies. Overall,
this work reveals that the appendix harbours a wealth of microbiota
distinct from other niches within the human microbiome and shows
considerable inter-individual variation. However, comparison of the
differences between samples may be limited, given that the patients in
this study varied in age, gender and clinical presentation (Table 1). Also,
antibiotic use has been widely documented to disturb the gut microbiota
(for review see (Cotter et al.)) and due to the nature of the clinical
admittance of the patients participating in this study, it was unavoidable
that antibiotics were taken prior to surgery. However, it should be
emphasized that the appendix may “protect” the microbiota from full
antibiotic exposure given that it is outside of the main flow of intestinal
contents. It cannot be ruled out that the composition of the stool sample
used in this study was not affected by antibiotic use however the
microbiota of the stool sample in this study is not dramatically different to
those presented in previous studies (Eckburg et al., 2005, Claesson et
al., 2011, Tap et al., 2009).
qPCR analysis of the total bacterial numbers suggests that the appendix
contains fewer bacteria within the tissue than found in the comparative
faecal sample (Figure 1). Culturing techniques also indicated a lower
overall bacterial count within the appendix than found with the
comparative stool sample (data not shown). This is expected as the
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bacterial density increases from the upper (ileum, jejunum) to lower
(cecum) colonic sites (Marteau et al., 2001, Simon, 1995). Compositional
sequencing revealed a diverse microbiota with at least 15 phyla identified
within the human appendix. In addition to the 4 major phyla associated
with the gut, Fusobacteria were largely represented among samples
(Figure 2). The presence of this phylum and the proportionate reads
assigned to the genus Fusobacterium is interesting as species of
Fusobacterium have been suggested to be a causative agent of acute
appendicitis (Swidsinski et al., 2011, Swidsinski et al.). Appendicitis is a
clinical diagnosis and therefore its uniformity cannot be assumed. The
severity of the disease of the appendix samples in this study was based
on a macroscopic and pathohistological analysis (Table 1). The levels of
Firmicutes, Proteobacteria and Bacteroidetes varied among samples,
regardless of disease state (Figure 2), whereas the levels of
Actinobacteria were most represented in the non-perforated sample E
(11%). The phylum Fusobacteria, and at genus level Fusobacterium sp.,
were most represented in sample D (Table 3). Appendix sample D
presented as a red and inflamed appendix and a clinical diagnosis of
acute appendicitis was given. Fusobacterium sp. were also found at
varying levels among other appendix samples except in samples E and F,
which were deemed to be healthier samples in this study (Tables 1 and
3).
Is there a role for the microbiota of the human appendix in gut health?
The function of the appendix as a microbial reservoir for the gut has been
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proposed and has recently received much attention (Laurin et al., 2011,
Smith et al., 2009). Based on this study, the appendix appears to harbour
a large diversity of gut microbes including significant amounts of
‘beneficial bacteria’ or indicators of gut health including the genera
Bacteroides, Lactobacillus and Bifidobacterium (Figure 4). It is plausible
that these bacteria present in biofilms on the epithelial layer of the
appendix may serve as a reservoir when eradicated from the gut. The
genus Clostridium was not largely represented in any appendix sample
(Figure 4) and therefore these results would not indicate that the
appendix serves as an organ to carry this organism as previously
suggested (Merchant et al., 2011).
The composition of the appendix differed somewhat from the stool
sample in this study (Figures 2-4). This is not surprising, however, based
on their differing ecological conditions. The appendix is an extension of
the cecum which has a lower pH and higher fatty acid content and in
consequence has been found to harbour varying bacteria from those
found in the faecal samples (Marteau et al., 2001). However, despite
some variation, the profiles were not radically different and the appendix
does contain a high proportion of intestinal-associated microbes. In
addition to these however, there were also a number of phyla found that
are not generally regarded as gut microbes including Deinococcus-
thermus, Spirochaetes and Chloroflexi. Deinococcus-related organisms
are largely associated with extreme environments, however have recently
been identified in the human stomach (Bik et al., 2006) and in endodontic
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infections (Li et al.). The presence of these phyla indicates
environmentally resistant organisms reside within the appendix. At genus
level, Parvimonas and Gemella were represented which are generally
considered pathogenic organisms of the oral cavity (Diaz et al., 2012,
Ota-Tsuzuki and Alves Mayer, 2009). The high incidence of oral
pathogens in the appendix samples is interesting as microbial community
analysis has previously implied that the oral cavity and GI tract share few
bacterial species (He et al.).
This study presents a first comprehensive view of the microbiota of the
human appendix. It would appear that this organ harbours a diverse
microbiota and, although it shares a substantial amount of microbes with
the intestinal tract, it has its own defined microbiome. The study
presented here provides some insights into the composition of the human
appendix and information on pathogens present that may possibly
contribute to appendicitis. The microbial diversity may be shaped through
the co-evolution of the microbial communities and specific ecological
factors of the appendix tissue. It may also be the case that the microbial
dynamics of surrounding intestinal niches influence the microbiota of this
organ. Further studies of this diverse biota may be fruitful in ultimately
assigning it a role in gut health.
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Table 1 Description of patients and appendix samples
Sample Gender Age
(y)
Macroscopic
Appearance
†Microscopic
Analysis
Type of Antibiotics
A M 14 congested appendix acute appendicitis Amoxicillin/clavulanate
B* M 17 mucosal
haemorrhagic, red
inflamed
appearance
acute suppurative
appendicitis
Amoxicillin/clavulanate
+ Gentamicin
C F 20 no perforation no evidence of
active
inflammation
Amoxicillin/clavulanate
D M 13 congested appendix,
red appearance
acute appendicitis Amoxicillin/clavulanate
+ Gentamicin +
Metronidazole
E M 25 no perforation,
congested surface
serositis Amoxicillin/clavulanate
F M 5 no perforation no evidence of
inflammation
Amoxicillin/clavulanate
G F 14 no perforation no pathological
changes
Amoxicillin/clavulanate
* Stool sample received for patient
† Result of the pathohistological analysis of the appendices
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Table 2 Estimation of diversity at 97% similarity level within each data set
*Appendix samples A-G and comparative Stool sample B
Sample* A B C D E F G Stool
Chao1
Richness
790 697 466 705 358 834 727 694
Shannon
Index
5.5 5.3 4.7 4.8 4.2 5.3 5.3 5
Good’s
Coverage
86.8 86.7 90.8 93.8 85.7 92.4 89.4 93.9
- 321 -
Table 3 Comparison of the dominant subpopulations of the appendix
samples A-G and the stool sample (S)
Genus A B C D E F G S
Enterobacteriaceae members 9% 25% 36% 9% 49% 27% 25% 11%
Lachnospiracheae incertae sedis * 10% 6% * 11% * * 16%
Ruminococcaceae incertae sedis 8% 4% 3% * * 7% 4% 6%
Fusobacterium 3% 8% 9% 41% * * 7% *
Lactobacillus 16% 4% * * 4% 23% 7% *
Bacteroides 7% 9% 7% 7% 4% 4% 5% 18%
Bifidobacterium 4% 3% 3% * 12% * * 15%
Eubacterium * * * 10% * * * *
Streptococcus * * * * 10% * * 5%
Parvimonas * * * 21% * * 18% *
Parabacteroides * * * * * * * 8%
Oscillibacter * * * * * 3% * *
Gemella 5% 3% * * * * * *
Faecalibacterium * * * 3% * 4% * *
Alistipes * * * * * * 5% *
Mucspirillium 5% * * * * 5% * *
Allobaculum 9% * * * * * * *
Blautia * * * * * * * 7%
Other genera 23% 34% 28% 9% 10% 27% 29% 14%
Not assigned 11% * 8% * * * * *
*Only genera representing >3% of assignable sequences. Percentages
are representative of the relative abundances of total sequences
assignable at genus level. All genera present in <3% are grouped
together as “Other genera”
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Figure 1 The numbers of bacteria quantified by real-time QPCR. Error
bars represent the standard error of the mean (n=3). Red bars represent
appendix samples A-G, Blue bar represents the stool sample
- 323 -
Figure 2 Phyla distribution among appendix samples (A-G) and the stool sample.
Firmicutes ; Proteobacteria ; Bacteroidetes ; Actinobacteria ; Fusobacteria ;
Other phyla ; Not assigned
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Figure 3 Family-level comparison of appendix samples A-G and the stool sample.
Similar bar colours correspond to samples within a particular phylum. Families of
lower abundance are grouped together. Lachnospiraceae ; Ruminococcaceae ;
Lactobacillaceae ; Erysipelotrichaceae ; Peptostreptococcaceae ;
Streptococcaceae ; Clostridiales family XI incertae sedis ; Veillonellaceae ;
Staphylococcaceae ; Clostridiaceae ; Eubacteriaceae ; Enterobacteriaceae ;
Desulfovibrionaceae ; Succinivibrionaceae ; Alcaligenaceae ; Bacteroidaceae ;
Rikenellaceae ; Porphyromonadaceae ; Bifidobacteriaceae ; Fusobacteriaceae Other families ; Not assigned
Appendix
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Abstract
We previously demonstrated that microbial metabolism in the gut
influenced the composition of bioactive fatty acids in host adipose tissue.
This study compared the impact of dietary supplementation for 8 weeks
with human-derived Bifidobacterium breve strains on fat distribution and
composition and the composition of the gut microbiota in mice.
C57BL/6 mice (n=8/group) received either B. breve DPC 6330 or B. breve
NCIMB 702258 (109 microorganisms) daily for 8 weeks compared with
unsupplemented controls. Tissue fatty acid composition was assessed by
gas-liquid chromatography and 16S rRNA pyrosequencing was employed
to investigate microbiota composition.
Visceral fat mass, and brain stearic-, arachidonic- and docosahexaenoic
acids were higher in B. breve NCIMB 702258 supplemented mice
compared with the other two groups (p<0.05). In addition, both B. breve
DPC 6330 and B. breve NCIMB 702258 supplementation resulted in
higher propionate in caecum, compared with unsupplemented controls
(p<0.05). Compositional sequencing of the gut microbiota revealed a
tendency for greater proportions of Clostridiaceae (25% vs. 12% vs. 18%;
p=0.08) and lesser proportions of Eubacteriaceae (3% vs. 12% vs. 13%;
p=0.06) in B. breve DPC 6330 supplemented mice compared with B.
breve NCIMB 702258 supplemented mice and unsupplemented controls.
The response of fatty acid metabolism to administration of bifidobacteria
is strain-dependent, and strain-strain differences are important factors
with respect to modulation of the gut microbial community by ingested
microorganisms.
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Introduction
The human gut microbiota comprises trillions of microorganisms,
reaching cell numbers that outnumber that of host cells, and contains at
least 100-fold more genes than the human genome (Qin et al., 2010).
The collective genome of these microorganims (the microbiome)
contributes to a broad range of metabolic and biochemical functions that
the host could not otherwise perform (Ley et al., 2006). Recent research
has revealed an interaction between the gut microbiota and host
metabolism, energy utilization and fat storage, suggesting that intestinal
microbes play a direct role in the development of obesity (Bäckhed et al.,
2004, Ley et al., 2005, Ley et al., 2006, Turnbaugh et al., 2006).
Metagenomic analyses have also revealed that the caecal microbiota of
ob/ob mice and obese individuals are more efficient at energy extraction
from the diet and at producing short chain fatty acids (SCFAs) than those
of normal phenotype (Schwiertz et al., 2010, Turnbaugh et al., 2006).
These SCFAs can then be utilized for de novo synthesis of lipids and
glucose (Wolever et al., 1989), thus providing an additional source of
energy for the host. While some studies of bacterial communities in the
gut microbiota in both mouse models and in humans, using compositional
sequencing, have revealed an increase in the ratio of Firmicutes to
Bacteroidetes in obese subjects (Ley et al., 2006, Turnbaugh et al.,
2008), the identity of the microbial populations that are associated with
obesity continues to be the subject of much debate, with others reporting
a decreased Firmicutes to Bacteroidetes ratio in overweight and obese
individuals (Murphy et al., 2010, Schwiertz et al., 2010). Another study
reported no link between the proportion of Firmicutes and Bacteroidetes
and human obesity (Duncan et al., 2008). Whether alterations in the
microbiota are a cause, or consequence of obesity, is controversial, with
the role of the gut microbiota in fat metabolism and obesity being more
complex than first considered (Duncan et al., 2008, Hildebrandt et al.,
2009, Murphy et al., 2010). Thus, the interrelation between the gut
microbial composition, diet, and host adiposity has to be further
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investigated. Knowledge of the interactions between energy intake and
specific microbial populations, and their influence on body weight is
limited to small-scale clinical trials (Ley et al., 2006). Among the
gastrointestinal bacteria, Bifidobacterium is an important commensal
group, accounting for an estimated 3% of the intestinal microbiota from
an average adult (Turroni et al., 2009a, Turroni et al., 2009b). Due to their
well-documented beneficial health effects (Leahy et al., 2005),
bifidobacteria have attracted significant interest for probiotic applications
in pharmaceutical and dairy products. In relation to host energy
metabolism, higher numbers of bifidobacteria have been documented in
normal-weight adults and adolescents than in their overweight
counterparts (Collado et al., 2008, Kalliomäki et al., 2008). However,
some recent studies suggest that the role of bifidobacteria in weight
management may be species specific. Thus, Santacruz et al. reported
that weight loss was associated with a reduction in the numbers of
Bifidobacterium breve and Bifidobacterium bifidum and an increase in the
numbers of Bifidobacterium catenulatum (Santacruz et al., 2009).
A promising mechanism by which the manipulation of the gut microbiota
can affect host metabolism and fat storage is the modulation of fatty acid
composition of host cellular membranes. We have previously shown that
dietary supplementation with a conjugated linoleic acid (CLA)-producing
Bifidobacterium strain of human origin (B. breve NCIMB 702258)
influenced the composition of bioactive fatty acids in host liver and
adipose tissue, in different animal species (Wall et al., 2010, Wall et al.,
2009). Thus, in this study, we compared the impact of administering two
different CLA-producing strains of the same species, i.e. B. breve DPC
6330 and B. breve NCIMB 702258, on host fat distribution and
composition. Furthermore, we performed a high-throughput
pyrosequence-based assessment of the impact of oral administration of
these B. breve strains on the diversity of the resident gut microbiota.
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Materials and Methods
Animals and treatment
Wild-type C57BL/6 male mice, aged 7-8 weeks, were obtained from
Charles River (L’arbresle, France) and housed under barrier-maintained
conditions within the Biological Services Unit, University College Cork
(UCC). All animal experiments were approved by the UCC Animal Ethics
Committee and experimental procedures were conducted under the
appropriate license from the Irish Government. Mice were allowed to
acclimatise for 1 week before the start of the study and were fed ad
libitum with Teklad Global rodent standard diet (Harlan Laboratories,
Madison, WI, USA, #2018S) with free access to water at all times. Mice
were housed in groups of four per cage and kept in a controlled
environment at 25C under a 12-hr-light/12-hr-dark cycle. After 1 week of
acclimatisation, the mice were divided into three groups (n=8/group): a
control group fed with standard diet and placebo freeze-dried powder
(15% w/v trehalose in dH2O), a group fed with standard diet and B. breve
DPC 6330 (approximate daily dose of 109 microorganisms) and a group
fed standard diet and B. breve NCIMB 702258 (approximate daily dose of
109 microorganisms). The diet contained the following nutrient
composition: crude protein (18.6%), carbohydrate (44.2%), fat (6.2%),
crude fibre (3.5%), neutral detergent fibre (14.7%), and ash (5.3%). The
fatty acids present in the diet included palmitic acid (C16:0, 0.7%), stearic
acid (C18:0, 0.2%), oleic acid (C18:1n-9, 1.2%), linoleic acid (C18:2n-6,
3.1%), and linolenic acid (C18:3n-3, 0.3%). Body weight and food intake
was assessed weekly. Following 8 weeks on experimental diets, the
animals were sacrificed by decapitation. Liver, brain, fat pads
(epididymal, perirenal and mesenteric), gastrointestinal tract (GIT) from
stomach to anus, and caecal contents were removed, blotted dry on filter
paper, weighed and flash-frozen immediately in liquid nitrogen. All
samples were stored at -80C until processed. Blood samples were
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collected from fasted animals, and allowed to clot for 2 hours at 4C
before centrifuging for 20 min at 2000 x g.
Preparation and administration of B. breve NCIMB 702258 and B.
breve DPC 6330
We have previously shown that B. breve NCIMB 702258 and B. breve
DPC 6330 are efficient CLA producers, converting up to 65% and 76%,
respectively, of linoleic acid to c9, t11 CLA when grown in 0.5 mg/ml
linoleic acid in vitro (Barrett et al., 2007, Coakley et al., 2003). Rifampicin
resistant variants of B. breve NCIMB 702258 and B. breve DPC 6330
were isolated by spread-plating ~109 colony forming units (CFU) from an
overnight culture onto MRS agar (de Man, Rogosa & Sharpe; Difco
Laboratories, Detroit, MI, USA) supplemented with 0.05% (w/v) L-
cysteine hydrochloride (98% pure; Sigma Chemical Co., Poole, Dorset,
UK) (mMRS) containing 500 g/ml rifampicin (Sigma). Following
anaerobic incubation (anaerobic jars with Anaerocult A gas packs; Merck,
Darmstadt, Germany) at 37°C for 3 days, colonies were stocked in
mMRS broth containing 40% (v/v) glycerol and stored at -80C. To
confirm that the rifampicin resistant variant was identical to the parent
strain, molecular fingerprinting using pulse-field gel electrophoresis was
employed.
Prior to freeze drying, B. breve NCIMB 702258 and B. breve DPC 6330
were grown in mMRS by incubating overnight at 37C under anaerobic
conditions. The culture was washed twice in phosphate buffered saline
(PBS) and resuspended at a concentration of ~21010 cells/ml in 15%
(w/v) trehalose (Sigma) in dH2O. One millilitre aliquots were freeze-dried
using a 24 hr programme (freeze temp. -40C, condenser set point -60,
vacuum set point 600 m Torr). Each mouse that received the bacterial
strains consumed approximately 1109 live microorganisms per day. This
was achieved by resuspending appropriate quantities of freeze-dried
powder in water which mice consumed ad libitum. Mice that did not
- 332 -
receive the bacterial strains received placebo freeze-dried powder (15%
(w/v) trehalose in dH2O). Water containing either the bacterial strains or
placebo freeze-dried powder was the only water supply provided to the
animals throughout the trial. Freeze dried powders with the bacterial
strains were undergoing continuous quality control of cell counts for the
duration of the trial by plating serial dilutions on mMRS agar
supplemented with 100 µg of mupirocin (Oxoid)/ml and 100 µg rifampicin
(Sigma)/ml and incubating plates anaerobically for 72 hr at 37C.
Culture-dependent microbial analysis
Fresh faecal samples were taken from C57BL/6 mice every week for
microbial analysis. Microbial analysis of the faecal samples involved
enumeration of the B. breve strains by plating serial dilutions on mMRS
agar supplemented with 100 µg of mupirocin (Oxoid)/ml, 100 µg
rifampicin (Sigma)/ml and 50 U/ml nystatin (Sigma). Agar plates were
incubated anaerobically for 72 hr at 37C. In addition, proximal colonic
contents were sampled at sacrifice for enumeration of the administered B.
breve strains.
Lipid extraction and fatty acid analysis
Lipids were extracted with chloroform:methanol (2:1 v/v; Fisher Scientific,
Dublin, Ireland) according to the method by Folch et al. (Folch et al.,
1957). Fatty acid methyl esters (FAME) were prepared using first 10 ml
0.5N NaOH (Sigma) in methanol for 10 min at 90oC followed by 10 ml
14% BF3 in methanol (Sigma) for 10 min at 90oC (Park and Goins,
1994)(23). FAME were recovered with hexane (Fisher Scientific). Prior to
gas-liquid chromatography (GLC) analysis, samples were dried over 0.5 g
of anhydrous sodium sulphate (Sigma) for 1 hr and stored at -20oC.
FAME were separated by GLC (Varian 3800, Varian, Walnut Creek, CA,
USA) fitted with a flame ionization detector, using a Chrompack CP Sil 88
column (Chrompack, Middleton, The Netherlands, 100 m  0.25 mm i.d.,
0.20 μm film thickness) and Helium as carrier gas. The column oven was
- 333 -
programmed to be held initially at 80oC for 8 min then increased
8.5oC/min to a final column temperature of 200oC. The injection volume
used was 0.6 μl, with automatic sample injection on a SPI 1093 splitless
on-column temperature programmable injector. Peaks were integrated
using the Varian Star Chromatography Workstation version 6.0 software
and peaks were identified by comparison of retention times with pure
FAME standards (Nu-Chek Prep, Elysian, MN, USA). The percentage of
individual fatty acids was calculated according to the peak areas relative
to the total area (total fatty acids were set at 100%). All fatty acid results
are shown as mean  standard error of the mean (SEM) g/100 g FAME.
SCFA analysis
Approximately 100 mg caecal content was vortex mixed with 1.0 mL Milli-
Q water and, after standing for 10 min at room temperature, centrifuged
at 10 000g for 5 min to pellet bacteria and other solids. The supernatant
was collected, 3.0 mM 2-ethylbutyric acid (Sigma) added as internal
standard, and samples filtered before being transferred to clean vials.
Calibration was done using standard solutions containing 10.0 mM, 8.0
mM, 6.0 mM, 4.0 mM, 2.0 mM, 1.0 mM and 0.5 mM of acetic acid,
propionic acid, iso-butyric acid and butyric acid (Sigma). The
concentration of SCFA was determined using a Varian 3500 GC flame
ionization system, fitted with a Nukol-FFAP column (30 m x 0.32 mm x
0.25 µm; Sigma). Helium was used as the carrier gas at a flow rate of 1.3
mL/min. The initial oven temperature was 100C for 0.5 min, raised to
180C at 8C/min and held for 1 min, then increased to 200C at
20C/min, and finally held at 200C for 5 min. The temperature of the
detector and the injector were set at 250C and 240C, respectively.
Peaks were integrated using the Varian Star Chromatography
Workstation version 6.0 software. Standards were included in each run to
maintain the calibration.
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Measurement of triglycerides in liver
Liver lipids were extracted and purified according to the method of Folch
et al. (Folch et al., 1957). After mixing thoroughly, the samples were dried
under nitrogen and resolubilised in 5% (v/v) Triton X-100 in dH2O. The
concentration of triglycerides was determined using a commercial kit
(EnzyChrom Triglyceride Assay kit, BioAssay Systems, CA, USA).
Results were normalised to the weight of the samples.
Measurements of serum parameters
Serum variables were determined with commercial kits. Glucose in serum
was determined using QuantiChrom glucose assay kit (BioAssay
Systems), serum insulin concentration was measured using Ultra
Sensitive Mouse ELISA kit (Crystal Chem Inc., IL, USA), leptin in serum
was measured using Mouse Leptin ELISA kit (Crystal Chem Inc.), and
serum triglyceride concentrations using EnzyChrom Triglyceride Assay kit
(BioAssay Systems).
Culture-independent microbial analysis
For analysis of the microbial community composition of caecal contents,
total DNA was extracted from the caecal contents of all mice using the
QIAamp DNA stool mini kit according to the manufacturer’s instructions
(Qiagen, West Sussex, UK) coupled with an initial bead-beating step.
Universal 16s rRNA primers, designed to amplify from highly conserved
regions corresponding to those flanking the V4 region, i.e. the forward
primer F1 (5’-AYTGGGYDTAAAGNG) and a combination of four reverse
primers R1 (5’-TACCRGGGTHTCTAATCC), R2 (5’-
TACCAGAGTATCTAATTC), R3 (5’-CTACDSRGGTMTCTAATC) and R4
(5’-TACNVGGGTATCTAATC) (RDP's Pyrosequencing Pipeline:
http://pyro.cme.msu.edu/pyro/help.jsp) were used for Taq-based PCR
amplification. Sequencing was performed on a Roche 454 GS-FLX using
Titanium chemistry by the Teagasc 454 Sequencing Platform. Resulting
raw sequences reads were quality trimmed as previously described
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(Claesson et al., 2009). Trimmed FASTA sequences were then BLASTed
(Altschul et al., 1997) against a previously published 16S-specific
database (Urich et al., 2008) using default parameters. The resulting
BLAST output was parsed using MEGAN (Huson et al., 2007). MEGAN
assigns reads to NCBI taxonomies by employing the Lowest Common
Ancestor algorithm. Bit scores were used from within MEGAN for filtering
the results prior to tree construction and summarization. A bit-score of 86
was selected as previously used for 16S ribosomal sequence data (Urich
et al., 2008). Phylum and family counts for each subject were extracted
from MEGAN. Clustering and alpha diversities were generated with the
MOTHUR software package (Schloss and Handelsman, 2008). Beta
diversities and principle coordinate analysis (PCoA) of sequence reads
were calculated using the Qiime suite of tools (Caporaso et al., 2010).
Statistical analysis
Results in the text, tables and figures are presented as Mean per group 
SEM. To assess if differences between treatment groups were significant,
data were analysed using one-way analysis of variance (ANOVA)
followed by post hoc Tukey’s multiple comparison tests using GraphPad
Prism version 4.0 for Windows (GraphPad Software, San Diego, CA,
USA). Statistical analyses of compositional data were performed using
Minitab release 15.1.1.0 (www.minitab.com). The non-parametric
Kruskal-Wallis test was used to estimate the relationships between
different groups. Statistical significances were accepted at p<0.05, and
trends for statistically significant differences were recognized at p<0.10.
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Results
Survival and transit of B. breve DPC 6330 and B. breve NCIMB
702258 in C57BL/6 mice
Quantification of the numbers of the administered B. breve strains in the
faeces of mice confirmed their gastrointestinal transit and survival. Stool
recovery of B. breve DPC 6330 and B. breve NCIMB 702258 were
approximately 1.1  106 CFU/g faeces and 8.2  106 CFU/g faeces after
two weeks of feeding the respective strain and remained at similar
numbers for week four and six. At week eight, there was a decline in the
numbers of excreted B. breve strains, with stool recovery of B. breve
DPC 6330 and B. breve NCIMB 702258 being 1.2  105 CFU/g faeces
and 3.4  105 CFU/g faeces, in their respective groups.
At sacrifice, B. breve DPC 6330 and B. breve NCIMB 702258 were
detected in the large intestine at 7  105 CFU /g content and 1  106 CFU
/g content, respectively, in the mice administered the strains.
Dietary supplementation with B. breve NCIMB 702258, but not B.
breve DPC 6330, increases visceral host fat storage
The weight of visceral body fat; the sum of epididymal, mesenteric and
perirenal fat pads, was significantly higher in mice that were fed B. breve
NCIMB 702258 compared to unsupplemented mice (1.71 ± 0.13 g vs.
1.20 ± 0.10 g; p<0.05, Table 1). This increase in visceral fat mass
correlated with a tendency for greater circulating leptin for B. breve
NCIMB 702258 supplemented mice compared with unsupplemented
controls (5.2 ± 0.9 ng/mL vs. 2.4 ± 0.7 ng/mL; p=0.06, Table 2). There
was no significant difference in body mass between the groups over the
8-week feeding period (Table 1). No effect on liver mass or liver
triglycerides was observed following administration of B. breve NCIMB
702258. In contrast, administration of B. breve DPC 6330 was associated
with a higher concentration of liver triglycerides compared to
unsupplemented mice (p<0.05; Table 1). Neither of the administered B.
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breve strains affected the levels of circulating insulin, glucose or
triglycerides, compared with unsupplemented mice (Table 2). In addition,
no difference in feed intake was observed between the groups (data not
shown).
Higher gut levels of SCFAs following administration of B. breve DPC
6330 and B. breve NCIMB 702258
Analysis of caecal SCFAs, the major fermentation end-products and
source of energy for the host, showed that propionate was significantly
higher in mice that received B. breve DPC 6330 and B. breve NCIMB
702258 compared with unsupplemented mice (p<0.05; Table 3). Higher
concentrations of iso-butyrate were also observed in mice supplemented
with B. breve NCIMB 702258 compared with unsupplemented controls
(p<0.05; Table 3). In addition, the mean total SCFA concentration
(acetate, propionate, butyrate, iso-butyrate) detected in the caecal
contents was 24% higher in mice fed B. breve DPC 6330 compared with
unsupplemented controls (p=0.07; Table 3).
Contrasting effects on host tissue fatty acid composition of dietary
supplementation with B. breve DPC 6330 and B. breve NCIMB
702258
To investigate the effects of dietary supplementation with B. breve DPC
6330 and B. breve NCIMB 702258 on fatty acid composition of host
tissues, fatty acid profiling was performed on brain, epididymal adipose
tissue and liver. Significant differences in tissue fatty acid composition
were observed following supplementation with the B. breve strains (Table
4, Table 5 and Table 6). Mice that were administered B. breve NCIMB
702258 had significantly higher stearic acid (C18:0), arachidonic acid
(ARA, C20:4n-6) and docosahexaenoic acid (DHA, C22:6n-3) in brain
compared with both unsupplemented mice (p<0.05) and mice
supplemented with B. breve DPC 6330 (p<0.05; Table 4), whereas
dietary supplementation with B. breve DPC 6330 resulted in higher
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myristic acid (C14:0) in brain compared with both unsupplemented mice
and mice supplemented with B. breve NCIMB 702258 (p<0.05; Table 4).
However, both groups of B. breve supplemented mice exhibited
significantly lower palmitic acid (C16:0), palmitoleic acid (C16:1c9) and
dihomo--linolenic acid (C20:3n-6) in brain compared with
unsupplemented controls (p<0.05; Table 4).
Mice that received B. breve DPC 6330 exhibited significantly higher
myristic acid, palmitic acid, palmitoleic acid and DHA in epididymal
adipose tissue compared to unsupplemented mice (p<0.05; Table 5). In
contrast, these fatty acids were not higher in epididymal adipose tissue of
the mice supplemented with B. breve NCIMB 702258. Mice that received
B. breve DPC 6330 also had significantly lower oleic acid (C18:1c9) in
epididymal adipose tissue compared with both unsupplemented mice and
mice supplemented with B. breve NCIMB 702258 (p<0.05; Table 5). In
contrast to a higher concentration of DHA in epididymal adipose tissue of
mice fed B. breve DPC 6330, these mice had a lower concentration of
DHA in liver compared with unsupplemented mice (p<0.05; Table 6).
There was a tendency for higher concentrations of c9, t11 CLA in the
livers of mice receiving B. breve NCIMB 702258 compared to mice
supplemented with B. breve DPC 6330 and unsupplemented controls
(0.031 ± 0.006 g/100g FAME vs. 0.015 ± 0.007 g/100g FAME, and 0.013
± 0.006 g/100g FAME, respectively; p=0.06).
Contrasting effects on gut microbiota composition of dietary
supplementation with B. breve NCIMB 702258 and B. breve DPC
6330
At the end of the 8 week study, the microbial composition of the gut
microbiota of individual mice was elucidated through high-throughput
pyrosequencing (Roche-454 Titanium) of 16S rRNA (V4) amplicons
generated from DNA extracted from the caecal content. A total of 103,711
reads were sequenced, averaging at 4509 reads per animal. Species-
richness, coverage, and diversity estimations were calculated for each
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data set (Table S1). At the 97% similarity level, the Shannon index, a
metric for community diversity, revealed a high level of overall biodiversity
within all samples with values exceeding 5.1. The Good’s coverage at the
97% similarity level ranged between 88-95% for all the datasets. The
Chao1 richness also indicated a sufficient level of overall diversity (Table
S1). Rarefaction curves for each dataset were parallel or approaching
parallel with the x axis, indicating that the total bacterial diversity present
within these is well represented and that additional sampling would yield
a limited increase in species richness (Figure S1).
In agreement with previous work (Ley et al., 2005, Ley et al., 2006,
Turnbaugh et al., 2006), taxonomy-based analysis showed that at the
phylum level, the mouse gut microbiota was dominated by Firmicutes and
Bacteroidetes (together harbouring on average 94% of sequences; Figure
1). At the family level, the most dominant groups were Bacteroidaceae,
Clostridiaceae, Eubacteriaceae and Lactobacillaceae (Figure 2).
A comparison of the composition of the microbiota of B. breve NCIMB
702258 supplemented mice, B. breve DPC 6330 supplemented mice and
unsupplemented mice showed that administration of these strains altered
the composition of the gut microbiota differently at both phylum, family
and genus levels. There was a tendency for a reduction in the Firmicutes
population from 74% in the unsupplemented mice to 68% in B. breve
NCIMB 702258 supplemented mice and 67% in B. breve DPC 6330 fed
mice (p=0.08, Figure 1). All other phyla remained at relatively similar
proportions across the groups. At the family level, administration of both
B. breve DPC 6330 and B. breve NCIMB 702258 resulted in a
significantly lower proportion of Lachnospiraceae compared with
unsupplemented mice (p<0.05, Figure 2). Furthermore, Eubacteriaceae
tended to be less abundant in the caecum of mice supplemented with B.
breve DPC 6330 compared with both B. breve NCIMB 702258
supplemented mice and unsupplemented controls (3% vs. 12% vs. 13%;
p=0.06, Figure 2). Other observed differences at the family level included
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a tendency for an apparent enrichment in the Clostridiaceae population in
B. breve DPC 6330 supplemented mice (25%) compared with B. breve
NCIMB 702258 supplemented mice (12%) and unsupplemented mice
(18%, p=0.08, Figure 2). At the genus level, Eubacterium tended to be
lower following dietary supplementation with B. breve DPC 6330
compared with no supplementation and supplementation with B. breve
NCIMB 702258 (p=0.06, Figure 3).
PCoA generated using unweighted UNIFRAC distances demonstrated
that mice clustered into relatively distinct groups based on whether they
received B. breve DPC 6330, B. breve NCIMB 702258 or no
supplementation. Mice that received B. breve DPC 6330 (illustrated as
triangles, Figure 4) clustered closely together and showed a clear
separation from the unsupplemented mice (illustrated as squares, Figure
4) and B. breve NCIMB 702258 supplemented mice (illustrated as circles,
Figure 4). This suggests that supplementation with B. breve DPC 6330
had a greater effect on the gut microbiota than supplementation with B.
breve NCIMB 702258.
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Discussion
This study demonstrates that the response of fatty acid metabolism to
administration of bifidobacteria is strain-dependent and furthermore
highlights the importance of strain-strain differences in modifying the gut
microbiota composition of the host. Administration of B. breve NCIMB
702258 increased visceral fat mass and weight gain in C57BL/6 mice,
whereas administration of B. breve DPC 6330 did not. In general,
beneficial effects have been attributed to Bifidobacterium in connection
with obesity and weight management and reports support the
preventative role of bifidobacteria in promoting fat mass development and
body weight gain (Cani et al., 2007, Collado et al., 2008, Kalliomäki et al.,
2008). However, some studies contradict the preventative role of
Bifidobacterium in body weight gain (Furet et al., 2010, Santacruz et al.,
2009) and question the role of specific Bifidobacterium species in obesity
and weight management (Santacruz et al., 2009). Since the
Bifidobacterium genus is complex, it is possible that certain bifidobacterial
species, or even strains, as observed in the present study, promote fat
mass storage and body weight more efficiently than others through
diverse regulatory roles in fat absorption and distribution. Notably, strains
of B. breve have previously been shown to improve weight gain in very
low birth weight infants (Kitajima et al., 1997). However, it must be
acknowledged that this study is limited to two strains of B. breve,
therefore further studies are required to draw conclusions about the role
of specific Bifidobacterium species and strains in fat/energy absorption
and their impact on weight gain in animal models of obesity and in
humans.
Previous studies have demonstrated that the gut microbiota affects the
composition and quality of fat in the host, as well as the quantity
(Velagapudi et al., 2010). We have demonstrated that manipulation of the
gut microbiota by administering a single metabolically active strain, B.
breve NCIMB 702258, to different animal species influenced the
composition of bioactive fatty acids in host liver and adipose tissue (Wall
- 342 -
et al., 2009). In the present study, we compared the impact of B. breve
NCIMB 702258 and B. breve DPC 6330 on fatty acid composition of
different host tissues in mice. We observed that administration of these B.
breve strains altered the fatty acid composition in distinct ways. While
administration of B. breve DPC 6330 had a greater influence on the fatty
acid composition of epididymal adipose tissue, with higher palmitic acid,
palmitoleic acid and DHA, administration of B. breve NCIMB 702258 had
a greater impact on the fatty acid composition of brain. Intriguingly, mice
that were supplemented with B. breve NCIMB 702258 demonstrated
significantly higher concentrations of ARA and DHA in brain compared
with both B. breve DPC 6330 fed mice and unsupplemented mice. This
observation of increased ARA and DHA in the brain of mice administered
with B. breve NCIMB 702258 is consistent with our previous findings
using a different model (Wall et al., 2010). ARA and DHA play important
roles in neurogenesis, neurotransmission, and protection against
oxidative stress (Innis, 2007, Maekawa et al., 2009) and their
concentrations in the brain influences cognitive processes such as
learning and memory (Henriksen et al., 2008, Yurko-Mauro et al., 2010).
The importance of these fatty acids in neurodevelopment has led to their
supplementation in infant formula (Efsa, 2009). The present study
supports our previous observations (Wall et al., 2010, Wall et al., 2009),
and findings by others (Kankaanpää et al., 2002, Kaplas et al., 2007), in
which manipulation of the gut microbiota alter the composition of fat in the
host. Interactions between fatty acids and members of the gut microbiota
might affect the biological roles of both and such interactions may
therefore result in physiological consequences for the host.
The mechanism by which these ingested strains mediate the changes in
fatty acid composition observed in the present study is uncertain and
remains to be elucidated. Possible explanations include modulations of
fat absorption processes in the small intestine and/or desaturase
activities involved in the metabolism of fatty acids to the longer chain
unsaturated derivatives caused either directly by the strains administered
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or by alterations in the gut microbiota. Interestingly, a previous study in
lactating goats demonstrated that administration of a Lactobacillus
plantarum strain resulted in changes in the faecal microbiota and
modulated the milk fatty acid composition with a higher content of
polyunsaturated fatty acids (Maragkoudakis et al., 2010). Furthermore, a
recent study reported that dietary supplementation of lactating women
with Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 in
combination with rapeseed oil resulted in higher gamma-linolenic acid of
breast milk, compared with fatty acid-supplementation alone (Hoppu et
al., 2012).
The present study demonstrated not only significant differences in the
composition of the gut microbiota between B. breve-fed mice and non-B.
breve-fed mice but also differences between mice fed different B. breve
strains. At the phylum level, the Firmicutes population tended to be less
abundant in the caecum of mice supplemented with B. breve DPC 6330
and B. breve NCIMB 702258 compared with unsupplemented mice. At
the family level, the proportions of Eubacteriaceae were reduced in the
animals receiving B. breve DPC 6330, but not in those receiving B. breve
NCIMB 702258, compared with unsupplemented controls. In addition,
administration of B. breve DPC 6330 lead to an apparent enrichment in
Clostridiaceae compared to the unsupplemented mice, whereas this
enrichment was absent in B. breve NCIMB 702258 supplemented mice.
Penicillium were found to be present in the B. breve NCIMB 702258
supplemented mice, however this genus is not regarded as typical
members of the gut microbiota, and factors contributing to their presence
in the gut as found in this instance require further investigation. PCoA
analysis demonstrated that mice administered with B. breve DPC 6330
had a more divergent clustering pattern and were separated from the
unsupplemented mice and from mice fed B. breve NCIMB 702258. This
suggests that supplementation of B. breve DPC 6330 has a greater
impact on the composition of the murine gut microbiota than
supplementation with B. breve NCIMB 702258. Our observations suggest
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that administration of a single strain can play a role in determining the
composition of gut bacterial populations in vivo and furthermore that
strain-strain differences are important factors with respect to modulation
of the gut microbial community. Although changing the intestinal
microbiota may be more difficult in free-living individuals compared to
laboratory models, it is important to perform extensive microbiota-related
studies on bifidobacteria-associated probiotics in human trials, especially
in groups where shifts in the composition have been observed due to the
state of physiology (i.e. obesity, diabetes etc), particularly since an
alteration of the gut microbiota at lower taxonomic levels is still likely to
have important functional consequences for the host. While it is
acknowledged that pyrosequencing of the 16S rRNA genes, as
undertaken in this study, did not provide quantitative population data, it
did yield an overview of the effects of administration of these strains on
the entire microbial population.
SCFAs (acetate, propionate, butyrate, iso-butyrate) are major products
from fermentation processes from gut microbiota of non-digestible
carbohydrates in the intestine. These fatty acids have recently attracted
significant interest because of their positive effect on human
gastrointestinal health and diseases including colon cancer,
gastrointestinal infections and inflammatory bowel disease (D'argenio et
al., 1996, Emenaker et al., 2001, Galvez et al., 2005, Topping and Clifton,
2001). SCFAs are also believed to be a driver of energy sparing and are
portrayed as a potential mechanism involved in the increase of fat mass
storage in microbiota-bearing mice (Turnbaugh et al., 2006). The
differences in stool SCFA concentrations between lean and obese people
have been considerable. The mean total SCFA concentration in faecal
samples of obese volunteers was shown to be more than 20% higher
compared with lean volunteers, with the highest increase observed for
propionate being 41% higher in obese volunteers (Schwiertz et al., 2010).
Administration of B. breve DPC 6330 and B. breve NCIMB 702258 led to
an increase in propionate in the caecum, being 37% higher in mice
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supplemented with B. breve DPC 6330 and 30% higher in mice
supplemented with B. breve NCIMB 702258 compared with
unsupplemented mice. Noteworthy, neither of these B. breve strains
produce propionate in vitro, suggesting that administration of these
strains may result in an increase of propionate-producing bacteria in the
GIT. Well-known propionate producers belong to the genera Bacteroides
spp., Prevotella spp., and Propionibacterium spp. (Hosseini et al., 2011,
Schwiertz et al., 2010). However, since many metabolic properties are
shared between lower microbial taxa, it is difficult to link the capacity of
producing specific SCFAs, such as propionate, to phylogenetic
information obtained in the present study (Zoetendal et al., 2008).
Increases in propionate in the B. breve-fed mice could also be due to
cross-feeding, in which one bacterial species metabolises the
fermentation products of another, thus producing a different end product,
a common cooperation in a complex microbial community. Indeed,
Bifidobacterium are known to produce lactate, ethanol and succinate
(Macfarlane and Macfarlane, 2003, Van Der Meulen et al., 2006), all of
which could be used as substrates for the production of propionate by
other bacteria such as Bacteroides spp., Propionibacterium spp. and
Clostridium propionicum in a sequential fermentation, thus increasing the
propionate concentration in the gut (Hosseini et al., 2011, Stams et al.,
1998).
In conclusion, our results demonstrate that the impact of bifidobacteria on
host fatty acid metabolism is dependent on the strain administered and
that strain-strain differences are important factors with respect to
modulation of the gut microbial community by ingested microorganisms.
Further studies are needed to draw conclusions about the role of specific
Bifidobacterium species and strains in obesity and weight management.
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Table 1 Body mass, fat mass, liver mass and liver triglyceride levels of
mice fed B. breve DPC 6330, B. breve NCIMB 702258 and
unsupplemented diet for 8 weeks
B. breve DPC
6330 fed mice
B. breve NCIMB
702258 fed
mice
Unsupplemented
mice
Initial weight (g)
Final weight (g)
Weight gain (%)
26.5 ± 0.6
31.7 ± 0.8
20.3 ± 4.5
26.7 ± 0.6
33.4 ± 0.7
25.1 ± 3.7
25.4 ± 0.5
30.6 ± 0.8
20.5 ± 3.1
Visceral fat mass (g) 1.51 ± 0.16A,B 1.71 ± 0.13A 1.20 ± 0.10B
Liver mass (g) 1.64 ± 0.05 1.55 ± 0.06 1.47 ± 0.05
Liver triglycerides (mg/g) 4.64 ± 0.73A 3.44 ± 0.29A,B 2.93 ± 0.14B
Visceral fat mass include epididymal, perirenal, and mesenteric fat pads.
Results are expressed as Means  SEM, n = 8 mice/group. Means not
sharing a common superscript letter are significantly different at p0.05
based on ANOVA followed by post hoc Tukey’s multiple comparison tests
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Table 2 Serum parameters in mice fed B. breve DPC 6330, B. breve
NCIMB 702258 and unsupplemented diet for 8 weeks
Serum parameter
B. breve DPC
6330 fed mice
B. breve NCIMB
702258 fed mice
Unsupplemented
mice
Triglycerides
(mg/dL)
78.1 ± 12.8 56.2 ± 11.8 61.3 ± 8.2
Glucose (mg/dL) 217.6 ± 17.6 186.0 ± 6.4 183.3 ± 2.8
Insulin (ng/mL) 1.4 ± 0.2 2.5 ± 0.8 1.7 ± 0.3
Leptin (ng/mL) 3.9 ± 0.8 5.2 ± 0.91 2.4 ± 0.71
Blood samples were collected after fasting. Results are expressed as
Means  SEM, n = 8 mice/group. No significant differences were
observed. 1p=0.06, based on ANOVA followed by post hoc Tukey’s
multiple comparison tests
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Table 3 SCFA concentrations (mol/g) of caecum content
SCFAs
B. breve DPC
6330 fed mice
B. breve NCIMB
702258 fed mice
Unsupplemented
mice
Acetate 48.05 ± 3.58 45.05 ± 2.73 40.71 ± 2.43
Propionate 9.80 ± 0.51A 9.28 ± 0.49A 7.14 ± 0.40B
Butyrate 18.24 ± 2.67 13.44 ± 1.45 13.71 ± 1.59
Iso-butyrate 0.80 ± 0.09A,B 0.88 ± 0.05A 0.67 ± 0.02B
Total acids 76.88 ± 6.39 68.65 ± 4.03 62.23 ± 4.14
Results are expressed as Means  SEM; B. breve DPC 6330 (n=8), B.
breve NCIMB 702258 (n=7), unsupplemented mice (n=8). Means not
sharing a common superscript letter are significantly different at p0.05
based on ANOVA followed by post hoc Tukey’s multiple comparison tests
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Table 4 Fatty acid profile in brain of mice fed B. breve DPC 6330, B.
breve NCIMB 702258 or unsupplemented diet for 8 weeks
FAME Brain
g/100g
FAME
B. breve DPC
6330
B. breve NCIMB
702258
Unsupplemented
mice
C14:0 3.66 ± 0.21A 1.36 ± 0.05B 1.90 ± 0.08C
C16:0 22.34 ± 0.80A 21.46 ± 0.18A 26.75 ± 0.45B
C16:1c9 0.69 ± 0.03A 0.72 ± 0.03A 0.90 ± 0.04B
C18:0 10.80 ± 0.18A 11.99 ± 0.15B 11.08 ± 0.16A
C18:1c9 9.83 ± 0.17A 10.48 ± 0.07B 10.22 ± 0.13A,B
C18:2n-6 0.49 ± 0.02A 0.58 ± 0.02B 0.49 ± 0.01A
C18:3n-3 ND ND ND
C18:3n-6 ND ND ND
C20:3n-6 0.33 ± 0.01A 0.37 ± 0.01A 0.27 ± 0.01B
C20:4n-6 5.70 ± 0.31A 6.55 ± 0.07B 5.27 ± 0.07A
C20:5n-3 ND ND ND
C22:5n-3 0.24 ± 0.04 0.21 ± 0.04 0.20 ± 0.09
C22:6n-3 17.22 ± 0.35A 18.58 ± 0.32B 17.19 ± 0.10A
Results are expressed as percentage of total identified fatty acids. Data are
Means  SEM g/100g FAME, n = 8 mice/group. Means not sharing a common
superscript letter are significantly different at p0.05 based on ANOVA followed
by post hoc Tukey’s multiple comparison tests. FAME = fatty acid methyl esters.
C14:0 myristic acid; C16:0 palmitic acid; C16:1c9 palmitoleic acid; C18:0 stearic
acid; C18:1c9 oleic acid; C18:2n-6 linoleic acid; C18:3n-3 linolenic acid; C18:3n-
6 -linolenic acid; C20:3n-6 dihomo--linolenic acid; C20:4n-6 arachidonic acid;
C20:5n-3 eicosapentaenoic acid; C22:5n-3 docosapentaenoic acid; C22:6n-3
docosahexaenoic acid. ND; not detected
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Table 5 Fatty acid profile in epididymal adipose tissue of mice fed with B.
breve DPC 6330, B. breve NCIMB 702258 or unsupplemented diet for 8
weeks
FAME
Epididymal
Adipose tissue
g/100g
FAME
B. breve DPC
6330
B. breve
NCIMB 702258
Unsupplemented
mice
C14:0 1.96 ± 0.24A 1.44 ± 0.27A,B 1.10 ± 0.15B
C16:0 15.19 ± 0.94A 12.78 ± 0.68A,B 10.68 ± 0.52B
C16:1c9 4.31 ± 0.39A 3.75 ± 0.53A,B 2.85 ± 0.12B
C18:0 2.04 ± 0.13 2.26 ± 0.12 2.31 ± 0.03
C18:1c9 28.71 ± 0.92A 32.22 ± 0.89B 33.47 ± 0.48B
C18:2n-6 33.57 ± 1.18 34.93 ± 1.13 36.66 ± 0.68
C18:3n-3 2.44 ± 0.16 2.42 ± 0.10 2.57 ± 0.10
C18:3n-6 0.16 ± 0.01 0.15 ± 0.01 0.17 ± 0.005
C20:3n-6 0.42 ± 0.02 0.42 ± 0.02 0.42 ± 0.01
C20:4n-6 0.77 ± 0.04 0.71 ± 0.05 0.72 ± 0.03
C20:5n-3 0.093 ± 0.01 0.072 ± 0.01 0.085 ± 0.01
C22:5n-3 0.29 ± 0.02 0.26 ± 0.03 0.25 ± 0.02
C22:6n-3 0.77 ± 0.04A 0.66 ± 0.05A,B 0.62 ± 0.05B
Results are expressed as percentage of total identified fatty acids. Data are
Means  SEM g/100g FAME, n = 8 mice/group. Means not sharing a common
superscript letter are significantly different at p0.05 based on ANOVA followed
by post hoc Tukey’s multiple comparison tests.
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Table 6 Fatty acid profile in liver of mice fed B. breve DPC 6330, B. breve
NCIMB 702258 or unsupplemented diet for 8 weeks
FAME Liver
g/100g
FAME
B. breve DPC
6330
B. breve
NCIMB 702258
Unsupplemented
mice
C14:0 0.65 ± 0.08 0.67 ± 0.03 0.67 ± 0.05
C16:0 31.87 ± 0.33 30.53 ± 0.66 30.37 ± 0.40
C16:1c9 2.81 ± 0.26 2.91 ± 0.24 2.60 ± 0.23
C18:0 9.32 ± 0.48 9.03 ± 0.30 9.61 ± 0.45
C18:1c9 13.48 ± 0.82 13.05 ± 0.92 10.85 ± 0.35
C18:2n-6 21.55 ± 0.56A 19.40 ± 0.84A,B 19.07 ± 0.31B
C18:3n-3 0.83 ± 0.05 0.71 ± 0.05 0.71 ± 0.03
C18:3n-6 0.30 ± 0.01 0.26 ± 0.02 0.28 ± 0.01
C20:3n-6 0.91 ± 0.05 0.96 ± 0.06 0.94 ± 0.02
C20:4n-6 7.07 ± 0.48 7.25 ± 0.24 7.81 ± 0.35
C20:5n-3 0.22 ± 0.01 0.22 ± 0.02 0.22 ± 0.01
C22:5n-3 0.38 ± 0.03 0.42 ± 0.03 0.41 ± 0.02
C22:6n-3 3.57 ± 0.27A 3.82 ± 0.12A,B 4.48 ± 0.16B
Results are expressed as percentage of total identified fatty acids. Data are
Means  SEM g/100g FAME, n = 8 mice/group. Means not sharing a common
superscript letter are significantly different at p0.05 based on ANOVA followed
by post hoc Tukey’s multiple comparison tests. FAME = fatty acid methyl esters.
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Figure 1 Phylum-level distributions of the microbial communities present
in the caecum content, expressed as percentage of total population of
assignable tags. B. breve DPC 6330 (n = 7), B. breve NCIMB 702258 (n
= 7), unsupplemented mice (n = 8). No significant differences were
observed
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Figure 2 Family-level taxonomic distributions of the microbial
communities in caecum content, expressed as percentage of total tags
assignable at family level. B. breve DPC 6330 (n = 7), B. breve NCIMB
702258 (n = 7), unsupplemented mice (n = 8). *p<0.05, determined by
Kruskal-Wallis test
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Figure 3 Genus-level taxonomic distributions of the microbial
communities present in the caecum content, expressed as percentage of
total tags assignable at genus level. B. breve DPC 6330 (n = 7), B. breve
NCIMB 702258 (n = 7), unsupplemented mice (n = 8). No significant
differences were observed
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Figure 4 Principle coordinate analysis using unweighted UniFrac
distances. B. breve DPC 6330 (n = 7), B. breve NCIMB 702258 (n = 7),
unsupplemented mice (n = 8)
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Appendix 1
Supplementary information
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Table S1 Species-richness, coverage, and diversity estimations for each
data set
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Figure S1 Rarefaction curves of samples sequenced by high-throughput
DNA sequencing. Rarefaction curves at 97% similarity indicated that the
total bacterial diversity present was well represented. Number of
operational taxonomic units (OTUs) identified as a function of the number
of sequence tags sampled
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Discussion
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The threat posed to human health by antibiotic resistance cannot be
overstated. Antibiotics are fundamental to our ability to treat common
bacterial infections and are also central to the success of surgical
procedures, chemotherapy and organ transplantation (Penders et al.,
2013). Intensive investigations into antibiotic resistance reservoirs are
underway, with the aim of minimising the further dissemination of
resistance genes, thereby enabling the continued application of the
remaining effective antibiotics. Given the complexity of the human gut
microbiota, as well as its exposure to antibiotics, there is every
opportunity for the gut microbiota to develop or acquire antibiotic
resistance. To fully appreciate the likelihood that gut microbes will
develop antibiotic resistance, one must first understand the effects
antibiotics have on gut bacteria. This topic was reviewed with respect to
infants in chapter 1 and was the focus of the first study described in this
thesis.
Our initial study was designed as a follow up to an existing study (Hussey
et al., 2011), in which infants treated with ampicillin and gentamicin were
shown to have significantly reduced bifidobacteria colonization and
species diversity. Unlike this previous DGGE-based study, our aim was to
take advantage of high-throughput 454-pyrosequencing, to identify the
effects of ampicillin and gentamicin treatment on the entire infant gut
microbiota. Research at the time suggested that antibiotics cause
significant alterations to infant gut microbiota (Bennet et al., 2002, Favier
et al., 2003, Mangin et al., 2010), though no sequencing-based studies
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had been carried out to investigate this phenomenon. Currently, due to
the length of the 16S rRNA amplicons generated, accurate assignment at
species level cannot be completed. Due to our interest in comparing our
results to those detected in the earlier study, regarding the effects of
these antibiotics on bifidobacteria species, we not only amplified and
sequenced the V4 region of the 16S rRNA gene, but also the rpoB gene,
which enabled us to determine which bifidobacteria species were present
(Kim et al., 2010).
The results of this study demonstrate the significant dominance of the
Proteobacteria, at the expense of members of the Actinobacteria (most
notably Bifidobacterium) following short-term antibiotic exposure. Though
only treated with antibiotics for between 2 and 9 days, the infant gut was
dramatically altered, with the effects still being observed 8 weeks after
treatment ceased. Thus, even short-term antibiotic treatment can cause
significant perturbations to the gut microbiota, which are slow to resolve.
While previous studies have demonstrated the resilience of the adult
human gut microbiota (De La Cochetiere et al., 2005), here we have
shown that for a period of at least 8 weeks after antibiotic therapy, the
infant gut microbiota remains altered. A concern when interpreting high-
throughput sequencing data is whether the results relate to changes in
absolute numbers or relative proportions of bacteria. As the sequences
represent proportions of sequencing reads assigned to a particular
phylum, family or genus, it is important to consider if the total bacteria
numbers have decreased. To address this, we conducted qPCR analysis
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on copies of the 16S rRNA gene/g faeces and noted no difference in total
bacteria numbers following antibiotic therapy and thus our results
represent actual increases/decreases in bacteria following antibiotic
therapy. Using the rpoB sequences, we noted that overall bifidobacteria
diversity was decreased 4 and 8 weeks after treatment, though some
species, namely B. longum, appeared more resistant to antibiotic therapy
compared to others.
While this study represents an important insight into the short-term effects
of antibiotic treatment as identified using high-throughput sequencing,
there is a need for longer follow up trials to determine the duration of the
dysbiosis in gut microbiota. It has been suggested that early life exposure
to antibiotics results in an increased risk of atopic disease, allergies and
obesity (Ajslev et al., 2011, Foliaki et al., 2009, Marra et al., 2009,
Trasande et al., 2012), and hence understanding the duration for which
the perturbations appear in the infant gut, compared to healthy controls,
is vital. Importantly, sequencing-based approaches to identify the bacteria
that are most affected following antibiotic treatment, such as those
presented here, afford the opportunity to develop approaches (such as
probiotic therapy) with the aim of minimising the negative effects on gut
microbiota during and after antibiotic exposure.
The findings from our initial infant study highlighted the ability of certain
bacteria populations to become dominant following antibiotic exposure.
Previous studies have also demonstrated such trends (Antonopoulos et
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al., 2009, Murphy et al., 2013). To investigate if the gut naturally harbours
antibiotic resistant populations, enabling such bacteria to become
dominant upon exposure to antibiotics, we conducted a study
investigating the presence of antibiotic resistance genes in the gut
microbiota of healthy adult males. Following on from the previous study,
aminoglycoside and β-lactam resistance genes were specifically targeted.
Using a PCR-based approach, we detected genes encoding enzymes for
the modification of aminoglycosides (including acetylation, adenylation
and phosphorylation enzymes) and β-lactamases. Thus, it was evident
that the human gut microbiota is a source of antibiotic resistance, which
supports previous findings generated using alternative approaches
(Cheng et al., 2012, Sommer et al., 2009). Our approach of using direct
PCR analysis on metagenomic DNA, without screening for resistant
isolates, is a rapid and cost-effective method that is suitable for initial
investigations of any environment for genes of interest. Though not
applied in our study, this initial PCR analysis can be combined with lab-
scale high-throughput sequencing platforms such as the Ion Personal
Genome Machine or Illumina MiSeq, to provide additional insights into
genes and their sources.
In the majority of cases the detected genes shared closest homology with
genes found in members of the Enterobacteriaceae family, which is
consistent with the findings of our infant study in which these bacteria
became dominant following exposure to aminoglycosides and β-lactams.
Given that many of the detected β-lactamase genes, including ESBLs
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such as blaCTX-M, are plasmid-encoded, the potential exists for these to
disseminate to commensals or to microbes transiently colonizing the gut.
Thus, there is a concern that the gut microbiota, most often studied for its
beneficial roles in health, could be contributing to antibiotic resistance. A
recent CDC report on antibiotic resistance in the USA noted that an
estimated 2 million people are infected with antibiotic resistant bacteria
annually, resulting in an estimated 23,000 deaths. Of these, they estimate
that 26,000 infections and 1,700 deaths are due to ESBL producing-
Enterobacteriaceae. Thus, understanding the sources and the spread of
such resistance genes is highly pertinent. Moreover, recognizing that
such resistant populations exist in the human gut can help us to predict
the effects of certain antibiotics on the gut microbiota and enable
strategies to be developed to minimise such effects.
In silico analysis is now routinely employed to identify potential sources of
genes of interest. Following our initial study, we were interested in
determining if a genetic mechanism of resistance could account for the
variations in the response of different bifidobacteria species to
aminoglycosides and β-lactams. Existing culture-based research
suggested that bifidobacteria are sensitive to β-lactams and resistant to
aminoglycosides (D'aimmo et al., 2007, Masco et al., 2006, Xiao et al.,
2010, Yazid et al., 2001). Resistance to the aminoglycosides amongst
Bifidobacterium has been accepted as being intrinsic and due to a lack of
a cytochrome-mediated mechanism (Bryan et al., 1979). However, such
resistance would not explain the differences observed in the gut of the
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aminoglycoside treated infants, whereby bifidobacteria species
responded differently to aminoglycoside treatment. Through the use of in
silico analysis, the widespread prevalence of putative aminoglycoside and
β-lactam resistance proteins in the Bifidobacterium genus was evident.
Notably, however, antimicrobial resistance assays failed to detect β-
lactam resistance amongst the representative bifidobacteria that were
tested, which contained in silico detected putative β-lactam resistance
proteins. Hence we concluded that these proteins have been mis-
annotated. As sequencing speed and efficiency increased, genome
annotation moved from the time-intensive manual approach, to
automated annotation. Several studies have highlighted the high
frequency of mis-annotation which is now occurring as a result (Schnoes
et al., 2009). The detection of such a prevalence of mis-annotated
sequences amongst bifidobacteria highlights the need for these
sequences to be correctly annotated to enable their true function to be
determined.
With respect to the aminoglycosides, all of the tested bifidobacteria which
contained putative aminoglycoside resistance proteins were found to be
resistant. Therefore, our aim was to determine if the resistance proteins
encode additional resistance, above intrinsic levels. Difficulties in the
genetic manipulation of bifidobacteria have greatly hampered research
into this genus (Sun et al., 2012). Recently, however, there have been
several publications demonstrating the successful manipulation of genes
in B. breve UCC2003 (Mazé et al., 2007, O' Connell Motherway et al.,
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2013, O' Connell Motherway et al., 2009) via an insertional inactivation
approach. Our aim was to use this novel approach to disrupt the 2 genes
present in B. breve UCC2003, which encode putative aminoglycoside
resistance proteins and to determine the effects on the resistance
phenotype. A decreased resistance to aminoglycosides was observed,
thereby demonstrating for the first time an enzymatic role in
aminoglycoside resistance in bifidobacteria. Based on this, differences in
aminoglycoside resistance genes present in various bifidobacteria could
account for their individual response to aminoglycoside exposure.
Moreover, bifidobacteria containing such resistance genes could be
investigated as potential probiotics for use during aminoglycoside
therapy, with the aim of minimising the effects of these antibiotics on gut
bifidobacteria populations. The use of molecular approaches, such as
those applied in this study, facilitate insights into the genetics of families
of bacteria such as Bifidobacterium, which until now have remained
somewhat elusive.
While high-throughput sequencing has significantly enhanced our ability
to gain comprehensive insights into gut microbiota, metagenomic
libraries/banks have also become an increasingly popular and valuable
approach with respect to capturing and expressing genes from bacteria in
complex environments. Initially this approach was used to investigate the
soil as a source of novel genes (Torres-Cortés et al., 2011), providing
considerable insights which culture-based approaches could not. Since
these initial soil-based studies, metagenomic banks have been used to
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investigate antibiotic resistance genes present in diverse environments
from gull faeces to the gut microbiota of honey bees and humans (Martiny
et al., 2011, Sommer et al., 2009, Tian et al., 2012). However, there have
been very few studies in which the infant gut microbiota has been
examined using metagenomic library-based approaches, with just 2
published when our study was conducted (De Vries et al., 2011, Moore et
al., 2013). The first study demonstrated the transfer of antibiotic
resistance genes from mother to infant (De Vries et al., 2011), while the
second demonstrated that the infant gut contained bacteria expressing
resistance genes to all major families of antibiotics (Moore et al., 2013).
Our aim was to determine if aminoglycoside and β-lactam resistance
genes are present in 6 month old infants with no antibiotic exposure. By 6
months of age, infants have been exposed to bacteria potentially
containing resistance genes from maternal, environmental and dietary
sources. This study thus provides insight into the development of the
infant resistome devoid of antibiotic exposure.
The results clearly demonstrate that by 6 months of age, an infant
resistome has already established. Use of a high-throughput robotic
approach allowed us to screen our entire library to rapidly detect
ampicillin and gentamicin resistant isolates. The resistance genes
detected shared closest homology with genes present in bacteria from
the Firmicutes and Proteobacteria phyla. However, we also detected
genes sharing homology with those found in more obscure sources,
including uncultured soil bacterium. These results highlight the
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considerable insight that metagenomic libraries can provide with respect
to resistance genes and the human gut. It should also be noted that while
our focus was on aminoglycoside and β-lactam resistance, the
metagenomic bank could be screened for resistance to all known families
of antibiotics and indeed for any other phenotype of interest for which a
culture-based, high-throughput screen exists, or can be developed. Thus,
once created, metagenomic banks become an invaluable resource for
future studies. Furthermore, it is evident that through investigations using
metagenomic libraries, insights into previously unexplored resistance
reservoirs can be gained.
While the primary focus of this thesis was antibiotics, antibiotic resistance
and gut microbiota, we also performed studies on related topics regarding
gut microbiota repopulation and manipulation. Short bowel syndrome
(SBS) is a condition characterized by a significant reduction in the length
of the bowel. While it can be congenital, in the majority of cases it occurs
in infants as a result of the surgical removal of a large portion of the
bowel, most often due to necrotizing enterocolitis. Culture-based research
has consistently stated that short bowel syndrome results in increased
faecal levels of Lactobacillus (Joly et al., 2010, Kaneko et al., 1997).
Bowel resection results in reduced colon length, increased oxygen
content, altered pH and altered nutrient availability. All of these factors
make it highly probable that the gut microbiota will also be significantly
altered. A comprehensive understanding of the gut microbiota present in
infants with SBS could help explain the associated health effects
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including diarrhoea, weight loss and increased immunological
inflammation (Sukhotnik et al., 2002). Our study took advantage of a
recently developed piglet model of infants with SBS (Pereira-Fantini et al.,
2011). The advantages of a piglet model lie not only in their physiological
and immunological similarities to humans, but also in the fact that due to
their lifecycle, you can study the human equivalent of infancy in a 2 week
period.
Our study demonstrated increased Acidaminococcus, Fusobacterium and
Veillonellaceae and decreased Ruminococcaceae at 2 and 6 weeks after
surgery relative to controls. The detection of high levels of Veillonellaceae
6 weeks after resection is interesting and could relate to their particularly
successful utilization of carbohydrates, the levels of which are increased
in infants with SBS. Interestingly, contrary to existing research, significant
changes in Lactobacillus levels in the SBS piglets were not detected in
our study. Our results may differ from published research, as our
approach enables the detection of changes to the entire gut microbiota,
which culture-based approaches cannot achieve. Reductions in bacterial
diversity were associated with increased inflammation 6 weeks post-
surgery, with increased levels of pro-inflammatory cytokines IL-1β, IL-8,
IL-18 and TNF-α. This study also investigated the effects of minor surgery
on gut microbiota. While minor surgery was associated with some
changes in gut microbiota, these were minor compared to the dramatic
dysbiosis observed in the SBS piglets. We were conscious of the
implications of the use of antibiotics in this trial, given their effects on the
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gut microbiota. However, all piglets, including the controls, received the
same treatment and the results clearly indicate that the effects of
antibiotics could not account for the changes that were only observed in
the SBS piglets. Furthermore, as antibiotic treatment occurs in infants
with SBS, our results provide a true representation of the combined
effects of surgery and antibiotic exposure, on the gut microbiota of infants
with SBS. It has been suggested that the remaining portion of the colon
adapts rapidly following resection. However, while this may be true of the
physiological adaptations, significant changes to the gut microbiota 6
weeks post-operative were observed in this study, indicating prolonged
dysbiosis in this condition.
While this thesis has demonstrated the significant dysbiosis that results in
the gut as a result of antibiotics and surgery, we were also interested in
investigating ways via which the gut might be repopulated. The human
appendix has recently been suggested as a source of commensals
capable of recolonizing the gut following e.g. antibiotic or diarrhoeal
perturbations (Randal Bollinger et al., 2007). Such a theory is supported
by the observations that individuals with ulcerative colitis or proctitis who
underwent appendectomy exhibited a significant improvement in
symptoms, potentially due to the lack of bacterial stimulation of the
immune system in the absence of the appendix (Bolin et al., 2009).
Despite the renewed interest in the human appendix, a paucity of
research identifying the microbiota it contains existed. Our aim was to
conduct the first study applying high-throughput sequencing to investigate
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the microbiota of the human appendix. Seven appendices were studied
and the results highlighted not only the inter-individual differences
between the samples but also the diverse and complex microbiota
present in the human appendix. It was found that Bacteroidetes,
Proteobacteria and Fusobacteria were commonly detected though the
Firmicutes were the dominant phylum. At family level, Lachnospiraceae,
Enterobacteriaceae and Streptococcaceae were noted frequently. It was
also interesting that we detected certain bacteria including Gemella and
Deinococcus-thermus that are not usually associated with the gut
microbiota. In one individual where the faecal microbiota was sequenced
and compared to the microbiota of their appendix, it was interesting to
note the higher microbial diversity present in the appendix compared to
faeces. Overall our study provides the first comprehensive insight into the
microbiota of an organ often regarded as an evolutionary vestige.
Considering our results and the location of the appendix, it is highly
probable that the appendix plays a role in host health, one which has yet
to be fully elucidated.
Finally, with ever increasing interest in, and consumer demand for,
probiotics, knowledge regarding the effects of different potential probiotic
strains on the gut microbiota is vital. The effects of probiotics on the infant
gut microbiota have been described in the literature review in chapter 1 of
this thesis. One of the fundamental requirements for a probiotic bacterial
strain is its ability to enable an increase in beneficial microbes, without
increasing potential pathogens. Thus studies investigating the effects of
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different strains of probiotics on gut microbiota are of increased
importance. In this final study, 2 CLA-producing probiotic strains of B.
breve (NCIMB 702258 and DPC 6330) were administered to mice and
the effects on fatty acid metabolism, fat deposition and gut microbiota
were studied. The high-throughput sequencing results demonstrate the
strain-specific effects of these 2 probiotic strains on gut microbiota
composition, which may relate to fatty acid metabolism. The insights
provided by this study into the effects of different strains on gut microbiota
demonstrates the need to carefully consider not just which probiotic
species, but which strain, to use. As regulations surrounding probiotic use
heightens, data regarding specific strains and their effects on host
metabolism and gut microbiota will become increasingly important.
The area of molecular microbiology has been revolutionized over the past
decade with high-throughput sequencing and molecular techniques that
facilitate the creation of metagenomic banks, enabling unprecedented
insights into the true microbial complexity of environments, not least the
human gut. This thesis presents an insight into the harmful effects of
antibiotics on the gut microbiota and the resistant bacterial populations
inhabiting the human gut. These results act as a stark reminder of the
ubiquitous nature of resistance genes that may be present in the infant
gut from birth and can remain with us for life.
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